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Abstract 
Kaposi’s sarcoma-associated herpesvirus (KSHV) is an oncogenic human virus 
associated with a number of malignancies, including Kaposi’s sarcoma. Similar to all 
herpesviruses, KSHV establishes either latent or lytic infections in host cells. The latent 
stage involves minimal viral gene expression, enabling the virus to remain dormant, 
maintaining genome integrity and enabling viral persistence. Conversely, lytic 
replication is characterised by the expression of a highly regulated and coordinated 
cascade of viral gene expression, ultimately resulting in the production of new mature, 
infectious virions. Importantly, lytic replication is necessary for the development and 
spread of Kaposi’s sarcoma. 
State of the art high throughput, high resolution “omics” approaches, such as mass 
spectrometry-based quantitative proteomics and next generation sequencing-based 
transcriptomics, are rapidly becoming the techniques of choice for discovering novel 
biological phenomena due, in part, to their sensitivity and the ability to repeatedly ask 
new questions of an existing dataset. 
Herein, three high throughput, high resolution approaches, namely SILAC-based 
quantitative proteomics, miRNA sequencing and mRNA sequencing are employed in an 
attempt to identify and characterise novel interactions between KSHV and the host 
cell.  
Utilising quantitative proteomics, the essential host cell splicing factor Prp19 is 
identified as a novel interacting partner of the lytic KSHV ORF57 protein in subnuclear 
bodies. This interaction, surprisingly, does not contribute to viral mRNA maturation, 
but instead has implications for the cellular DNA damage response, appearing to limit 
the effectiveness of this important pathway, possibly to reduce any negative effects on 
viral replication. 
Proteomic analyses also highlighted a link between KSHV lytic replication and host 
miRNA biogenesis pathways. Through the application of miRNA sequencing, two host 
miRNAs, namely miR-151a-5p and miR-365a-3p, were found to be dysregulated during 
KSHV infection. Importantly, neither of these miRNAs appear to represent a host 
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antiviral response. Instead, cellular target mRNAs are identified for miR-365a-3p, 
through the use of mRNA sequencing. These targets, termed DOCK5 and PRUNE2 are 
rapidly degraded during KSHV lytic replication via the viral-mediated upregulation of 
miR-365a-3p expression. Subsequent analysis of DOCK5 function during lytic 
replication suggests this interaction may promote viral egress. 
The data presented herein sheds light on previously unidentified mechanisms 
employed by KSHV to hijack the host cell, and may aid in the development of novel 
therapeutics against this important pathogen.  
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1 Introduction 
1.1 Herpesviridae 
1.1.1 Classification of herpesviruses 
The Herpesvirales are an order of enveloped viruses roughly ~200 nm in diameter with 
large double stranded DNA genomes between 125 and 240 kb in length (Davison, 
2007b). Herpesviruses are known to infect a wide range of animal hosts, and they have 
been classified according to their architectural and morphological properties (Davison 
et al., 2009). There are three distinct families within the Herpesvirales order: 
Herpesviridae, which infect mammals, birds and reptiles, Alloherpesviridae, pathogens 
of fish and amphibians, and Malacoherpesviridae, which consist of just two bivalve 
viruses (Davison et al., 2009; Davison et al., 2005; Savin et al., 2010). The Herpesviridae 
family was further divided in 1979, resulting in three subfamilies: the alpha-, beta- and 
gammaherpesvirinae (Matthews, 1979). Whilst the classifications of these three 
subfamilies were initially based on infectious properties, such as the temporal length 
of the lytic cycle and infection of specific tissue types, the distinctions have since been 
further strengthened due to developments in genome sequencing (Roizmann et al., 
1992; Davison, 2010). Figure 1.1 shows the evolutionary relationship between the 
Herpesviridae in the form of a phylogenetic tree. 
1.1.1.1 Alphaherpesvirinae 
The alphaherpesviruses exhibit a broad host range, a short lytic cycle and spread 
rapidly in cell culture (Roizmann et al., 1992). Latent alphaherpesvirus infections are 
usually established in neuronal cells, particularly sensory ganglia. Lytic 
alphaherpesvirus infection usually affects epidermal cells and leads to the destruction 
of the infected cell. This class contains five genera, including Varicellovirus, which 
contains the human herpesvirus varicella zoster virus (VZV), and Simplexvirus, which 
contains the human herpesviruses herpes simplex virus type 1 and 2 (HSV-1/2). The 
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class also contains a number of important animal herpesviruses including suid 
herpesvirus 1 (SuHV-1), a porcine pathogen that causes pseudorabies, gallid 
herpesvirus 2 (GaHV-2), the aetiological agent of Marek’s disease in chicken, and 
bovine herpesvirus 1 (BoHV-1), known to cause a number of diseases in cattle (Chang, 
1984). Furthermore, cercopithecine herpesvirus 1 (CeHV-1), an infectious agent of 
macaque monkeys, which may cause zoonotic infections in human hosts (Huff and 
Barry, 2003; Tischer and Osterrieder, 2010). 
 
 
Figure 1.1: Phylogenetic tree of Herpesviridae. 
Phylogenetic tree showing the evolutionary relationship between members of the Herpesviridae. KSHV 
(HHV-8) is highlighted by a red box. Adapted from (Gao and Qi, 2007).  
1.1.1.2 Betaherpesvirinae 
Defining characteristics of betaherpesviruses include a long lytic cycle, restricted host 
range and slow proliferation in cell culture (Roizmann et al., 1992). Furthermore, 
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infected cells typically exhibit a distinctive enlargement of the cell, known as 
cytomegaly.  Latent betaherpesvirus infections usually persist in lymphoreticular cells, 
secretory glands and kidneys. This class consists of four genera, including 
Cytomegalovirus, which contains human cytomegalovirus (HCMV), Roseolovirus, 
containing human herpesviruses 6A, 6B and 7 (HHV6A/6B/7), Muromegalovirus, 
containing two murine herpesviruses and Proboscivirus, consisting of four animal 
herpesviruses.  
1.1.1.3 Gammaherpesvirinae 
Gammaherpesviruses have a narrow host range and a variable lytic cycle (Roizmann et 
al., 1992). Latent infection usually affects lymphoid tissue, with different viruses 
normally exhibiting T- or B-lymphocyte specificity. Some lytic gammaherpesvirus 
infections can take place in epithelial cells and fibroblasts. This class contains four 
genera including Lymphocryptovirus, containing the human herpesvirus Epstein-Barr 
virus (EBV) and Rhadinovirus, containing Kaposi’s sarcoma-associated herpesvirus. 
These are the only two human herpesviruses in the gammaherpesvirus class, and also 
the only known oncogenic human herpesviruses (Davison, 2010). The remainder of the 
gammaherpesviruses comprise the Macavirus and Percavirus genera. Interestingly, the 
murine gammaherpesvirus MHV-68 (MuHV-4) has been observed to cause zoonotic 
infection in human hosts (Hricová and Mistríková, 2007). 
1.1.2 Virion architecture 
The Herpesvirales were originally classified together according to their unique 
morphology. All herpesvirus genomes consist of a single large, linear double stranded 
DNA molecule, which is contained within an icosahedral capsid (Fig. 1.2). The capsid 
itself is assembled from 162 capsomeres and is around 125-130 nm in diameter when 
fully formed (Davison, 2007b). In the mature virion, one capsomere is replaced by the 
portal vertex, which is vital for both the packaging and release of the viral genome 
(White et al., 2003; Cardone et al., 2007; Rochat et al., 2011). Surrounding the capsid is 
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an amorphous layer of multiple proteins, known as the tegument. The tegument 
consists of at least 16 different viral and cellular proteins that are required for proper 
envelopment (Mettenleiter, 2004). Many tegument proteins are also involved in other 
processes upon entry of the virus into a host cell, including capsid transport, immune 
system evasion, activation of the lytic cycle and activation of the host shutoff response 
(Kelly et al., 2009; Penkert and Kalejta, 2011). A lipid envelope forms the final layer of 
the virion, and holds a number of viral membrane proteins that enable host cell 
binding and fusion with the membrane (Mettenleiter et al., 2009). A full herpesvirus 
virion ranges from 120-300 nm in diameter, mainly due to differences in the 
composition of the tegument (Roizmann et al., 1992). 
 
Figure 1.2: Mature Herpesvirus virion architecture. 
Cartoon shows a schematic of a HSV-1 virion. A mature herpesvirus virion consists of a large, linear, 
double stranded DNA genome packaged within an icosahedral capsid. An amorphous layer of proteins 
known as the tegument sits between the capsid and a lipid envelope studded with envelope proteins. 
Adapted from Viral structures and antibodies (Abcam®). 
1.1.3 Genomic structure 
Herpesvirus genomes consist of linear, double stranded DNA, comprising 125 – 291 
kbp in length, encoding between 70 and 200 genes (McGeoch et al., 2006). The ends of 
the genome contain unpaired nucleotides that are neither covalently closed or linked 
to proteins. Herpesviruses exhibit considerable differences in their nucleotide 
sequences, even between different strains of the same species. Most of the genome 
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content is made up of unique sequences, the vast majority of which is coding, however 
there are non-coding, repeated sequence elements in most of the different genomes, 
which can account for up to 30% of the total genome (Davison, 2007a). These repeat 
sequences can be situated at the ends of the genome as well as intragenomically, 
allowing for six different configurations of herpesvirus genome (Fig. 1.3). Interestingly, 
these genome configurations do not correlate with evolutionary relations between 
different herpesviruses, and viruses within each class may differ in their genome 
configuration (Davison, 2007a).  
 
Figure 1.3: Herpesvirus genome configurations. 
Schematic representations of the six different genome configurations found within the Herpesvirales. 
Lines represent unique regions and boxes represent various types of repeat sequence. Arrowheads 
indicate the orientation of the repeated element. TR - terminal repeat; IR – internal repeat; UL – unique 
long region; US – unique short region. Adapted from (Domingo et al., 2008). 
The divergence of the Herpesvirales into Allo-, Malaco- and Herpesviridae is estimated 
to have occurred between 180 and 400 million years ago (Davison, 2007b). Due to this, 
there is very little conservation between genes of the different classes. Indeed, only 
three genes can be clearly identified across all members of the Herpesvirales 
(McGeoch et al., 2006). Between the Herpesviridae, gene conservation is more 
apparent, and these viruses have retained a common set of 43 core genes, including 
those encoding the structural proteins, as well as essential genes for viral replication 
(Davison, 2007a). Important non-coding regions, such as those involved in genome 
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packaging and the origin of lytic replication are also conserved. Many herpesviruses 
also encode homologues of cellular genes. These genes, which regulate processes such 
as immune evasion and apoptosis, are less common in the alphaherpesvirinae, 
suggesting they are non-essential for successful viral replication during the shorter lytic 
cycle (Davison, 2007a). Many herpesviruses also produce non-coding transcripts such 
as microRNAs and untranslated latency associated RNAs (Tang et al., 2011; Lei et al., 
2010; Guo et al., 2014; Cazalla et al., 2010; da Silva and Jones, 2013; Amen and 
Griffiths, 2011). 
1.1.4 Life cycle 
The herpesvirus life cycle begins upon contact between a mature, infectious virion and 
the surface of a host cell. The conserved glycoproteins gB, gH and gL, among other 
non-conserved envelope proteins studded in the viral envelope, contact and bind to 
cellular receptors, such as the proteoglycan heparan sulphate, which is bound by HSV-
1 and KSHV (Akhtar and Shukla, 2009). Some of these receptors are utilised in order to 
concentrate virions on the cell surface, whilst others are used to facilitate membrane 
fusion, allowing viral ingress (Spear and Longnecker, 2003). In contrast, some members 
of the Herpesvirales do not enter the cell by membrane fusion, but by endocytosis, 
followed by acidification of the endosomal compartment leading to de-envelopment 
(Tortora et al., 2013). Similarly, some cell types are not permissive to membrane fusion 
and also require entry by endocytosis. Following de-envelopment, tegument proteins 
are released into the cytoplasm and begin influencing cellular processes such as capsid 
movement and nuclear import, host cell shutoff and immune evasion (Kelly et al., 
2009). The capsid is also released and begins to traffic towards the nucleus via the 
microtubule network (Mabit et al., 2002; Naranatt et al., 2005). Upon reaching the 
nuclear membrane, the capsid releases its genome through the nuclear pore complex 
(Shahin, 2006; Rode et al., 2011; Labokha and Fassati, 2013). At this point, the viral 
DNA forms a circularised extrachromosomal episome. Here the virus can enter one of 
its two life cycle phases; latency or lytic replication (Mabit et al., 2002). 
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1.1.4.1 Latency 
A characteristic of all herpesviruses is the ability to establish and maintain latent viral 
reservoirs for the lifetime of the host (Werner et al., 1978; Kaschka-Dierich et al., 
1982). During this latent phase no mature viral progeny are produced. As different 
herpesviruses establish latency in different cell types, latent processes differ between 
viruses. HSV-1/2 and VZV establish latency in neuronal cells which do not undergo 
mitosis (Cohrs and Gilden, 2001). In contrast, both KSHV and EBV establish latent 
infections in B cells undergoing cell division, and therefore the genome is replicated by 
the host replication machinery, and maintained by a limited subset of latency 
associated genes (Lieberman et al., 2007; Damania and Pipas, 2009). Herpesviruses 
also encode a number of latency associated transcripts involved in immune evasion 
and lytic cycle regulation (Wang et al., 2005; Cliffe et al., 2009; Chentoufi et al., 2011). 
Indeed, some herpesviruses, such as KSHV and HSV-1, encode viral miRNAs in order to 
inhibit the expression of immediate early or lytic switch genes (Umbach et al., 2008; 
Qin et al., 2012). This repression can be overcome, however, and all herpesviruses may 
reactivate and undergo the lytic cycle upon an appropriate cellular stimulus (Penkert 
and Kalejta, 2011). 
1.1.4.2 Lytic replication 
The lytic cycle consists of a coordinated temporal cascade of gene expression, 
encompassing immediate early, delayed early and late genes (Arvin, 2007). The 
immediate early stage culminates in the production of viral-encoded factors which 
control the temporal gene cascade, as well as cellular gene expression. The delayed 
early stage results in the production of all proteins required for viral DNA replication, 
which occurs in specialised replication compartments localised around the nuclear 
periphery (Quinlan et al., 1984). Following viral DNA synthesis, late genes are 
expressed, giving rise to the structural components required for capsid assembly and 
packaging of viral DNA. The assembled capsid then exits the nucleus, gaining an 
envelope by passing through the inner nuclear membrane into the perinuclear space 
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(Granzow et al., 2001). Upon fusion with the outer nuclear membrane, the capsid is 
de-enveloped. Tegument proteins are acquired in the cytoplasm through a series of 
protein-protein interactions (Mettenleiter et al., 2009). The virus is then re-enveloped, 
forming mature viral progeny, via fusion with the membranes of a cytoplasmic 
organelle, the identity of which is currently debated; the prime candidates including 
endosomal compartments, endocytic tubules or the more commonly accepted Trans-
Golgi network (Mocarski Jr., 2007; Mettenleiter et al., 2009; Hollinshead et al., 2012; 
Johns et al., 2014 p. 6). Mature viral progeny are finally released by exocytosis. 
 
Figure 1.4: Herpesvirus lytic replication. 
An infectious herpesvirus virion binds to the cytoplasmic membrane of a potential host cell, and is 
internalised by membrane fusion. The de-enveloped capsid is transported to the nuclear membrane and 
releases the viral genome into the host cell nucleus through a nuclear pore. A coordinated temporal 
gene cascade begins, culminating in the replication of viral DNA and the formation of a viral capsid 
around newly synthesised DNA. The capsid then exits the nucleus and gains an envelope through fusion 
with the membranes of a cellular organelle, believed to be the Trans-Golgi network. The mature virion is 
finally released from the host cell vie exocytosis. Image adapted from (Paludan et al., 2011). 
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1.1.5 Gammaherpesvirinae 
The gammaherpesvirinae is comprised of four genera: Lymphocryptovirus, 
Rhadinovirus, Macavirus and Percavirus (Davison et al., 2009). Primary infection occurs 
in B- or T-lymphocytes, where a latent reservoir is established. An initial round of lytic 
infection then takes place in these lymphocytes before the shed viral progeny are able 
to disseminate and infect epithelial cells or fibroblasts for subsequent rounds of 
replication (Longnecker and Neipel, 2007; Odumade et al., 2011). The 
gammaherpesvirinae exhibit highly conserved genomes, particularly within a central 
region containing four gene blocks, separated by unique open reading frames (ORFs) 
(Pedro Simas and Efstathiou, 1998; Longnecker and Neipel, 2007). A variable number 
of terminal repeat sequences reside at either end of the central region. 
Gammaherpesvirinae establish latency in dividing cells, and therefore have evolved 
mechanisms to ensure genome maintenance and efficient persistence in daughter cells 
(Cohrs and Gilden, 2001). This is accomplished through tethering of several copies of 
the viral episome to host mitotic chromosomes (Cotter and Robertson, 1999). Latent 
genes expressed by gammaherpesviruses also serve to suppress apoptosis, increase 
host cell survival, enhance progression of the cell cycle and subvert the immune 
response (Speck and Ganem, 2010). To date, EBV and KSHV are the only human 
herpesviruses currently known to cause cancer in infected hosts, and both are 
associated with multiple malignancies (Damania and Pipas, 2009). 
1.1.5.1 Epstein Barr Virus 
Epstein-Barr virus was discovered in primary cells from Burkitt’s lymphoma tissue over 
50 years ago, making it the first oncogenic human virus to be discovered (Epstein et al., 
1964; Henle et al., 1967). Since then, EBV has been implicated in a range of other 
malignancies, including a number of B-cell associated lymphomas and carcinomas 
arising from epithelial infection (Damania, 2004). Over 90% of the global population 
are believed to be seropositive for EBV, the vast majority of infections occurring during 
childhood or adolescence with infected individuals remaining asymptomatic (Damania 
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and Pipas, 2009). Primary infection in adults, by contrast, often leads to mononucleosis 
and hyperproliferation of B cells. This typically manifests as fatigue and flu-like 
symptoms, lasting several weeks. The virus is spread by oral transmission, infecting the 
mucosa of the upper respiratory tract.  
EBV usually establishes latency in B-lymphocytes and persists for the life of the host, 
with low levels of mature virus being found in the saliva (Longnecker and Neipel, 
2007). Latently infected B-cells typically exhibit immortalisation, and lead to the 
generation of lymphoblastoid cell lines. T-cells and NK-cells are also susceptible to EBV 
infection, and although this is rare, this type of infection carries a much greater risk of 
the associated lymphomas (Jones et al., 1988). In general, a very limited number of 
those infected with EBV will develop the more serious malignancies associated with 
the virus; Burkitt’s lymphoma, Hodgkin’s lymphoma, immunosuppression associated 
lymphomas, Nasopharyngeal carcinoma and gastric carcinoma (Damania and Pipas, 
2009; Levine et al., 1971; Pathmanathan et al., 1995). Often incidences of EBV 
associated malignancies exhibit distinct associations with geographical and ethnic 
groups, suggesting an important role for environmental factors in disease progression 
(Yu and Yuan, 2002). 
At least four distinct latency gene expression profiles exist for EBV, known as type I, II, 
III and 0 (Young and Rickinson, 2004; Young et al., 2007). The latency I profile 
comprises the expression of the fewest genes, consisting of the episome maintenance 
and immune evasion related protein, EBNA1; a non-translated RNA implicated in 
reducing apoptosis, EBER; and the BART transcript, encoding up to 20 viral miRNAs, 
some of which have also been implicated in apoptosis avoidance. Latency I is 
commonly identified in Burkitt’s Lymphoma tissue. Latency II consists of the expression 
of all genes expressed during Latency I, plus two transmembrane proteins, LMP1 and 
LMP2A/B, which act as constitutively active growth factors. Latency II is associated 
with nasopharyngeal carcinoma and Hodgkin’s lymphoma. Latency III further expands 
on the Latency II gene repertoire, with the expression of 5 additional nuclear proteins, 
all associated with increased cell growth and survival, as well as transcriptional 
regulation. These genes are EBNA2, EBNA3A/B/C and EBNALP. Latency III is only 
associated with immunocompromised patients, typically those exhibiting post-
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transplant lymphoma. It is not surprising, given the functions of the latency associated 
genes, that all EBV-associated diseases are associated with latency. A fourth latency 
profile also exists, termed Latency 0 in which no transcripts are produced. This profile 
is observed in resting memory B cells, which house the latent reservoir in 
immunocompetent individuals. It is believed that the Latency III profile is required for 
host colonisation during primary infection, in order to drive proliferation and 
differentiation of B-cells (Fig. 1.5). In immunocompetent individuals, the virus is then 
thought to downregulate its own gene expression as latency becomes established and 
infected cells begin to exhibit phenotypes more closely associated with memory B-cells 
(Bollard et al., 2012). 
 
Figure 1.5: EBV primary infection and latency profiles. 
EBV spreads via oral transmission and infects B-cells in the mucosa of the upper respiratory tract. The 
Latency III profile is established in order to facilitate host colonisation and gain access to the memory B-
cell pool. Latency I or 0 is then established, with minimal need for viral maintenance or the expression of 
associated genes. EBV – Epstein-Barr virus; HL – Hodgkin’s lymphoma; LMP – latent membrane protein; 
NHL – Non-Hodgkin’s lymphoma. Taken from (Bollard et al., 2012) 
1.1.5.2 Kaposi’s Sarcoma-associated Herpesvirus 
Kaposi’s sarcoma (KS) is a tumour of endothelial cell origin, first described by Moritz 
Kaposi in 1872 (Kaposi, 1872). Over a century later in 1994, herpesvirus DNA was first 
isolated from KS tissue, following a surge in KS incidence associated with the AIDS 
epidemic (Chang et al., 1994). This virus was named Kaposi’s sarcoma-associated 
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herpesvirus, and represents the second and most recent oncogenic human herpesvirus 
to be discovered. The viral genome ranges from 165-170 kb in size, containing a core of 
140 kb between 25-30 kb GC rich terminal repeats (Russo et al., 1996). KSHV encodes a 
large number of conserved herpesvirus genes, as well as 15 open reading frames that 
are specific to its own species, termed K1-15. The virus also encodes 18 mature viral 
miRNAs, as well as a large polyadenylated nuclear RNA (PAN), widely believed to be 
non-coding, although a recent high resolution genomics and proteomics study contests 
this, suggesting that PAN may encode three small peptides of unknown function (Qin 
et al., 2012; Song et al., 2002; Chang et al., 2002; Arias et al., 2014). 
 
Figure 1.6: Map of open reading frames and miRNAs in the KSHV genome. 
Latent KSHV genes are shown in white, immediate early lytic genes are shown in grey, early lytic genes 
are shown in light blue, late lytic genes are shown in dark blue, KSHV encoded pre-miRNAs are displayed 
as green arrowheads. Adapted from (Coscoy, 2007) following updates to gene expression classifications 
described in (Arias et al., 2014). 
The seroprevalence of KSHV is much lower than EBV, with roughly 10% of the 
European, American and Asian population testing positive for the virus, compared to 
50% in sub-Saharan Africa (Uldrick and Whitby, 2011). In accordance, KS is one of the 
most common malignancies in this region, displaying a significant association with 
AIDS, causing significant mortality. 
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Figure 1.7: Global KSHV seroprevalence. 
KSHV seroprevalence in European, Asian and American populations is typically below 10%, compared to 
between 20-30% in the Mediterranean and over 50% in sub-Saharan Africa. Taken from (Mesri et al., 
2010) 
1.1.5.3 KSHV-associated diseases 
Following the identification of a close link between KSHV and AIDS-associated KS, KSHV 
has also been implicated in all other forms of KS, as well as Multicentric Castleman’s 
disease and primary effusion lymphoma (Damania and Pipas, 2009).  
Kaposi’s sarcoma manifests as a dark red/brown skin lesion. The colour is produced 
due to the formation of blood-filled channels, caused by the disorganisation of the 
microvascular system near infected cells (Dictor and Andersson, 1988). There are four 
different classifications of KS; classical, endemic, AIDS-related and iatrogenic 
(Dourmishev et al., 2003). Classical KS is classified as a benign tumour typically 
presenting at the extremities and predominantly observed in elderly males of 
Mediterranean and Jewish descent (Boshoff and Weiss, 2001). Patients of classical KS 
often live with the disease for several years, commonly dying from other causes. The 
endemic form of KS is mainly identified in Eastern and Central Africa. It is a much more 
aggressive disease than classical KS, and patients, typically children or males in their 
thirties, usually die from this malignancy (Ziegler and Katongole-Mbidde, 1996). 
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Unsurprisingly, AIDS-related KS incidence increased dramatically with the AIDS 
pandemic in 1989 (Beral et al., 1990). KS is the most common neoplasm in AIDS 
patients, and exhibits a very high mortality rate (Parkin et al., 2008). AIDS-related KS 
initially manifests on the upper torso before rapidly and aggressively spreading to the 
inner organs (Ganem, 2010). Coinfection of HIV and KSHV contributes to the increased 
aggression of this form of the disease, primarily due to the well characterised 
immunosuppression of HIV+ individuals, but also due to more subtle direct and 
indirect mechanisms occurring in coinfected individuals (Varthakavi et al., 1999; 
Mercader et al., 2000). Iatrogenic KS is found in immunosuppressed patients that are 
not infected with HIV, such as those who have recently received a solid organ 
transplant. This form of KS correlates with incidence rate in the geographical area, 
accounting for as high as 80% of transplant related malignancies in areas of high KSHV 
prevalence (Qunibi et al., 1998; Duman et al., 2002). 
Multicentric Castleman’s disease is a rare condition in which lymphoid tissue becomes 
hyperproliferative (Polizzotto et al., 2013). This phenotype can spread to other organs 
as the disease progresses. Interleukin 6 is often observed to be upregulated in MCD, 
and is believed to be a major contributing factor to this condition (Yoshizaki et al., 
1989). This may also explain the relation between KSHV and MCD, as KSHV encodes a 
viral homologue of the Interleukin 6 gene, known as vIL-6. HIV coinfection correlates 
strongly with KSHV involvement in MCD, with 100% of HIV-positive MCD patients 
exhibiting KSHV infection, compared to 40% for HIV-negative MCD (Soulier et al., 
1995).  
Primary effusion lymphoma is also rare and highly associated with HIV/KSHV 
coinfection (Chen et al., 2007; Cesarman et al., 1995). This disease is characterised by 
the invasion of transformed, proliferating B cells into body cavities. Survival rates are 
extremely low, with a median of 6 months following positive diagnosis and, to date, 
there is no effective therapy against this malignancy (Y.-B. Chen et al., 2007). KSHV is 
necessary for the onset of PEL, and PEL-derived cells are commonly used in order to 
study KSHV replication cycles in a laboratory setting (Damania and Pipas, 2009).  
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1.1.5.4 Life cycle 
Upon contact with a potential host cell, KSHV envelope proteins bind to receptors on 
the cell surface, such as heparan sulphate, which is bound by the viral glycoproteins 
K8.1, gB, gH and ORF4 (Chakraborty et al., 2012). In addition, KSHV uses integrins α3β1 
and αVβ3 as well as EphrinA2 for internalisation. The viral envelope proteins, gB, gH 
and gL, then facilitate fusion of the viral and host membranes, and the virus travels 
towards the nuclear membrane, depositing its genome in the host cell nucleus through 
a nuclear pore. Primary infection is subsequently resolved via a cytotoxic T-cell 
response, however, the virus persists in the host following primary infection, by 
establishing a latent reservoir in B-cells (Robey et al., 2010; Ganem, 2007). 
Latency is associated with the expression of a limited gene repertoire including three 
major latency associated transcripts, the latency associated nuclear antigen (LANA), 
vFLIP and v-cyclin D, as well as all 18 mature viral miRNAs (Sun et al., 1999; Fakhari and 
Dittmer, 2002; Schulz and Chang, 2007; Qin et al., 2012). LANA acts to maintain and 
replicate the viral episome, a necessary process as KSHV establishes latency in dividing 
cells (Hu et al., 2002; Ballestas and Kaye, 2011). Furthermore, LANA acts as a regulator 
of viral and cellular transcription, and has also been implicated in modulating the host 
cell cycle and apoptosis via interactions with p53 and Rb (Garber et al., 2002; Direkze 
and Laman, 2004; Verma et al., 2004; An, 2004; Moore, 2007; Verma et al., 2007; Chen 
et al., 2010; Cai et al., 2013). vFLIP also functions to prevent apoptosis, through the 
inhibition of cellular caspases and an interaction with NFκB (Keller et al., 2000; 
Guasparri, 2004). v cyclin D interacts with and phosphorylates Rb in order to 
dysregulate the host cell cycle (Li et al., 1997; Verschuren, 2004). Although the latency 
associated expression profile of KSHV affects similar cellular processes to EBV, latency 
alone is not sufficient to cause any KSHV-associated malignancies (Grundhoff and 
Ganem, 2004).  
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1.1.5.5 Lytic reactivation 
Latent virus is able to reactivate lytic replication upon the application of a relevant 
external stimulus, including HIF-1α accumulation, a typical effect of hypoxia (Cai et al., 
2006). Indeed, exposure of a commonly studied KSHV positive, latently infected B-cell 
line to low oxygen conditions is sufficient to induce lytic reactivation, and this may 
explain the tendency for classical KS to affect the extremities (Davis, 2001). In addition, 
both B-cell differentiation and immune response factors have also been implicated in 
the induction of the KSHV lytic cycle (Johnson et al., 2005; Yu et al., 2007; Kati et al., 
2013). Reactivation begins with expression of a viral transcription factor termed RTA, 
which acts as the lytic switch, driving the expression of a coordinated temporal lytic 
gene cascade (Lukac et al., 1998; Sun et al., 1998; Gradoville et al., 2000)). Indeed, the 
expression of this protein alone is sufficient to drive lytic reactivation, and numerous 
triggers can drive initial RTA expression, after which RTA is able to promote its own 
expression through a positive feedback loop (Bottero et al., 2009). RTA binds to a 
conserved sequence element, present in multiple viral gene promoter regions, known 
as the RTA response element (RRE) (Wen et al., 2009). Despite this, the RRE is not 
essential for RTA-mediated gene expression, and RTA also indirectly drives the 
expression of genes lacking this element, such as ORF57 (Liang, 2002; Chang et al., 
2005). This is enhanced through the recruitment of other cellular transcription factors, 
such as RBP-Jκ, C/EBPα and AP-1 (Wang et al., 2003; Wang et al., 2004). RTA facilitates 
the recruitment of RNA polymerase II to target IE genes, driving their expression and 
thus beginning the lytic stage of the viral life cycle (Gwack et al., 2003). A highly co-
ordinated gene cascade follows, culminating in the production of mature, infectious 
virions as described in Section 1.1.4.2. Prior to egress, the nuclear egress complex, 
composed of ORF67 and ORF69 facilitate the export of assembled capsids from the 
nucleus by remodelling the host nuclear membrane into transport vesicles (Luitweiler 
et al., 2013). Following this process, it is widely believed that, similar to other 
herpresviruses, KSHV utilises dynein motors to traverse the microtubule network in 
order to traffic assembled capsids towards the cell membrane (Lyman & Enquist, 
2009).  
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1.2 Virus – host cell interactions  
Obligate intracellular parasites such as viruses, by definition, are unable to produce 
adequate means for their own replication outside of a host. Therefore, all viruses 
interact with host cell factors in order to facilitate their own replication. Since the first 
virus, Tobacco mosaic virus, was discovered in 1892 by Dmitry Ivanovsky, there have 
been countless publications describing different interactions between viruses and their 
host cells. Increasing understanding of these interactions has allowed humankind to 
overcome some of the greatest health challenges faced. Smallpox is widely regarded as 
the best example, with this DNA virus responsible for the most deaths worldwide of an 
infectious agent (Smith and McFadden, 2002). There have also been many molecular 
mechanisms identified by virological studies that have greatly enhanced our collective 
understanding and potential in fields that are not directly associated with the study of 
parasites. Indeed, the interaction between Simian vacuolating virus 40 (SV40) and p53, 
has been essential in increasing the collective understanding of cancer, DNA damage, 
apoptosis and the cell cycle (Lane and Crawford, 1979; Linzer and Levine, 1979; 
Vousden and Prives, 2009). Furthermore, different viruses were also crucial in first 
identifying and describing mechanisms of mRNA splicing (Chow et al., 1977; Berget et 
al., 1977), capping (Muthukrishnan et al., 1975; Wei and Moss, 1975) and 
polyadenylation (Edmonds et al., 1971), in vitro DNA replication (Challberg and Kelly, 
1979; Ikeda et al., 1980; Benoist and Chambon, 1981), transcription promoter 
sequences (Banerji et al., 1981; Fromm and Berg, 1983), transcription factors (Fromm 
and Berg, 1983; Payvar et al., 1983; Dynan and Tjian, 1983) and gene silencing (Fire et 
al., 1998; Brigneti, 1998). These discoveries represent just a fraction of the important 
work undertaken in the field of virology, and much of modern science would not be 
possible without prior knowledge of these processes. Clearly, viruses are great 
teachers and represent both a major health risk that must be overcome, as well as a 
powerful tool for the elucidation of biological phenomena. 
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1.2.1 mRNA maturation and virus infection 
mRNA plays a central role in the gene expression of any organism, and therefore, cells 
have evolved complex mechanisms to ensure quality control and regulation. mRNAs 
undergo numerous important processing steps prior to their initial translation, and 
each of these steps is associated with checkpoints to ensure each mRNA produced is 
free of error. Intracellular pathogens, therefore, are faced with an important challenge 
of subverting these host checkpoints in order to efficiently facilitate the expression of 
their own genes.  
1.2.1.1 mRNA biogenesis 
The biogenesis of an mRNA begins with the transcription of a pre-mRNA from a coding 
genomic sequence. Large numbers of transcription factors associate with promoter 
sequences to mediate the expression of a gene, ultimately culminating in the 
recruitment of RNA polymerase II (RNA pol. II) to the site, producing an initial 
transcript complementary to the DNA sequence (Kornberg, 2001). The carboxy-
terminal domain (CTD) of RNA pol. II then facilitates the processing of these 
transcripts, in a highly coordinated pathway involving the capping, splicing and 
polyadenylation of the mRNA (Zorio, 2004).  
Capping of an mRNA involves the addition of a methylated guanine nucleotide to the 5’ 
end of the mRNA with an unusual inverted 5’ to 5’ triphosphate bond (Shatkin, 1976). 
Capping occurs during transcription once the nascent transcript has achieved a length 
of between 20 and 40 nucleotides (Coppola et al., 1983; Moteki and Price, 2002). The 
heptameric repeat of the RNA pol. II CTD is phosphorylated at serine 5, leading to the 
dissociation of various transcription factors and the recruitment and activation of the 
capping machinery (Trigon et al., 1998; Cho et al., 2001). There are three important 
enzymes involved in the capping process, RNA triphosphatase, RNA 
guanylyltransferase and RNA-(guanine-7) methyltransferase, which act in succession 
(Mizumoto and Kaziro, 1987). Following cap formation, serine 5 of the CTD heptad 
repeat is dephosphorylated and the capping enzyme complex dissociates from RNA 
20 
 
pol. II and the transcript (Komarnitsky et al., 2000; Schroeder et al., 2000). Capping is 
important for mRNA stability, preventing the action of 5’ exonuclease enzymes as well 
as forming an important binding site for mature mRNA circularisation following 
maturation (Wells et al., 1998). In addition, the cap is necessary for efficient splicing, 
nuclear export and translation of transcripts (Lewis et al., 1995). 
Splicing involves the removal of intronic sequences from the nascent transcript. Nearly 
all eukaryotic genes contain introns, with an average of 9 introns per transcript, and 
many genes can be alternatively spliced in order to produce different protein products 
(Lander et al., 2001). Splicing also occurs during transcription elongation, with the 
phosphorylation of serine 2 of the RNA pol. II CTD by the kinase, P-TEFb (Garriga and 
Graña, 2004). Splicing requires interactions between five U snRNPs, U1, U2, U4, U5 and 
U6, as well as a large protein complex called the spliceosome, comprising as many as 
200 different proteins, which can associate with the complex at different stages of the 
reaction (Jurica and Moore, 2003). As different introns and their splice junctions can be 
distant from each other, splicing components are recruited to different areas of the 
transcript at different times, however, the reaction begins with the recognition and 
binding of a GU element at the 5’ splice junction by U1 and the binding of  the U2 
auxiliary factor (U2AF1) to the 3’ splice junction (Sanford, 2004). U2 is subsequently 
recruited to an adenosine residue in the intron branch point, and assembly of a trimer 
of U4-U6-U5 shortly follows. These components then rearrange themselves to form 
the catalytic form of the spliceosome complex, which removes the intron sequence in 
a protein-assisted manner. The 5’ GU of the removed intron is then ligated to the A 
residue in the branch point through 2 transesterification reactions catalyzed by U6 and 
U2, forming an intron lariat which is subsequently degraded (Reed and Maniatis, 
1985). The exon junction complex (EJC) is deposited at these splice sites, and remains 
bound to the spliced transcript to promote important interactions during mRNA 
nuclear export (Le Hir, 2001; Masuda et al., 2005; Cheng et al., 2006). 
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Figure 1.8: The mRNA splicing reaction. 
mRNA splicing begins with the recognition of a GU element by U1 at the 5’ splice junction, and an AG 
element by U2AF1 and U2 at the 3’ splice junction. The U4-U6-U5 complex is subsequently recruited to 
form a catalytic complex which removes the intron and forms a lariat via two transesterification 
reactions. The spliced exons are ligated together, whilst the intron lariat is subsequently degraded. 
Taken from (Lodish, 2000). 
Polyadenylation is the final stage of mRNA processing, and begins with the recognition 
of an AAUAAA motif, which represents the cleavage site, within 30 nucleotides of the 
3’ end of the transcript (Proudfoot, 1991). The cleavage and polyadenylation specificity 
factor (CPSF) complex, comprising CPSF-160, CPSF-100, CPSF-73 and CPSF-30, binds to 
the cleavage motif, and recruits both cleavage stimulation factor (CstF) and 
polyadenylate polymerase (PAP) to the pre-mRNA (Manley, 1995). Again, the RNA pol. 
II CTD is instrumental in this process, associating with both CPSF and CstF to increase 
polyadenylation efficiency (McCracken et al., 1997). The transcript is cleaved prior to 
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transcription termination, via an endonucleolytic attack by cleavage factor 1 and 2 
(CF1/2) (Gilmartin and Nevins, 1989). Following cleavage, PAP begins to add adenosine 
residues to the 3’ end of the RNA (Manley, 1995). Polyadenylate binding protein 2 
(PABP2) binds to the newly formed poly(A) tail and increases the affinity between PAP 
and the transcript through the formation of a quaternary complex involving CPSF, 
PABP2, PAP and the RNA (Wahle et al., 1993; Bienroth et al., 1993). The 
polyadenylation reaction proceeds until the tail is ~250 nucleotides long, at which 
point PAP becomes too distant from CPSF and the interaction breaks down, preventing 
any further polyadenylation, as such this interaction determines the maximum poly(A) 
tail length. Polyadenylation promotes nuclear export as it is an important signal for the 
formation of an export-competent mRNP, and it also promotes translation via 
interactions with eukaryotic initiation factor 4G (eIF4G), as well as several other 
proteins that mediate translation (Vassalli et al., 1989; Huang and Carmichael, 1996; 
McKendrick et al., 2001). 
Finally, nuclear export of the fully processed mRNA is also required prior to translation. 
This begins with the formation of an export-competent messenger ribonucleoprotein 
(mRNP) complex, containing various heterogeneous nuclear RNPs (hnRNPs) and the 
mRNA (Carmody and Wente, 2009). The ATP dependent RNA-helicase UAP56 is 
believed to play a major role in the formation of this complex, firstly during its 
recruitment to the mRNA via an interaction with the spliceosome, promoting its 
assembly during mRNA splicing (Zhou et al., 2000). UAP56 then recruits the export 
adaptor Aly, followed shortly by the recruitment and formation of the full transcription 
and export (TREX) complex. An interaction between Aly and cap binding protein 80 
(CBP80) determines the localisation of the TREX complex at the 5’ end of the mRNA 
(Cheng et al., 2006; Chi et al., 2013). Aly and another TREX component, Thoc5, then 
recruit the export receptor Nxf1, alongside its cofactor Nxt1, which are able to interact 
with certain FG-nucleoporins found in the nuclear pore complex (NPC) (Katahira et al., 
2009). This interaction promotes the translocation of the mRNP through the nuclear 
pore, in a highly controlled and regulated manner.     
23 
 
1.2.1.2 Viral interactions with cellular mRNA processing machinery 
The highly regulated and ordered processes that occur during mRNA processing 
represent a significant challenge for viruses to overcome. Many viruses exploit 
different components and mechanisms involved in all stages of the mRNA processing 
pathway. A common way that viruses exploit the host cell is through the acquisition of 
5’ m7G caps for viral transcripts, therefore preventing the identification of uncapped 
nascent viral mRNAs as “non-self” by the host cell, which may lead to their degradation 
(Decroly et al., 2011). Viruses facilitate cap acquisition in different ways, using both 
conventional and unconventional capping mechanisms. For example, most DNA viruses 
utilise the cellular RNA polymerase II enzyme for the transcription of viral mRNAs, 
thereby feeding the viral transcripts into the cellular mRNA processing pathway at the 
earliest stage. Alternatively, some viruses, such as the Orthomyxovirus, influenza A 
virus (IAV), encode proteins, such as the PA and PB2 subunits of the viral 
heterotrimeric polymerase, that “snatch” caps and short 5’ regions from cellular 
mRNAs via an endonucleolytic attack, subsequently using these hijacked transcripts to 
prime viral mRNA synthesis (Plotch et al., 1981; Guilligay et al., 2014). Alternatively, 
many single stranded RNA viruses encode their own capping enzymes and cofactors in 
order to synthesise their own capped transcripts. Vesicular stomatitis virus (VSV), for 
example, encodes the L protein, which adds GDP, rather than GMP, to the 5’ end of 
VSV encoded transcripts, acting in the same manner as a canonical cap (Abraham et 
al., 1975).  
The splicing reaction is an important part of mRNA processing, with strong links to 
mRNA export, whilst also representing an important cellular checkpoint to ensure 
mRNA quality control. Many viruses encode introns in their genes despite the fitness 
cost associated with a larger genome, demonstrating the importance of the cellular 
splicing checkpoint (Holmes, 2010). Some viruses have developed alternative splicing 
mechanisms in order to benefit further from their introns, for example, human 
immunodeficiency virus 1 (HIV-1) encodes a single primary transcript that gives rise to 
over 40 different mRNA species (Stoltzfus and Madsen, 2006). This 9 kb transcript 
serves as both the viral genome and mRNA, and so HIV-1 carefully regulates and 
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controls alternative splicing mechanisms. The virus encodes multiple non-canonical 
splice sites over the length of the polycistronic transcript, which are recognised and 
processed with different efficiencies by the host spliceosome (O’Reilly et al., 1995; 
Staffa and Cochrane, 1994). During early stages of infection, five 3’ splice junctions 
near the centre of the transcript are used to produce the partially and fully spliced Tat, 
Rev and Nef mRNAs (Purcell and Martin, 1993). As Rev protein accumulates, it binds to 
the Rev response element (RRE) present in the transcript and mediates the nuclear 
export of the viral singly spliced (4 kb) and unspliced genomic RNAs. The use of 
suboptimal splice sites is further regulated by viral sequences, known as exonic splicing 
enhancers (ESE) and exonic/intronic splicing silencers (ESS/ISS), which interact with 
various cellular factors such as hnRNPs and SR proteins to modulate splice site usage 
(Caputi and Zahler, 2002; Jacquenet et al., 2001; Zahler et al., 2004). Alternative 
splicing is also important for IAV replication, as IAV expresses two polycistronic 
transcripts; NS and M (Dubois et al., 2014). Similarly to HIV-1, IAV uses suboptimal 
splice sites, however it regulates the use of different sites of NS using intronic 
sequences that are believed to inhibit spliceosome activity by folding into secondary 
structures (Chua et al., 2013; Dubois et al., 2014). Alternative splicing of M uses a 
different mechanism, with two 5’ splice sites located within close proximity on the 
transcript. It has been suggested that the viral polymerase is able to promote the use 
of the proximal, rather than the distal splice site, producing more M2 mRNA (Shih et 
al., 1995; Tsai et al., 2013). In addition, M mRNAs all use the same 3’ splice site, which 
is located within an ESE that binds the SR protein, SF2, to promote M2 production, 
suggesting a mechanism similar to that used by HIV-1 (Shih and Krug, 1996). 
Viruses must also overcome the cellular mRNA checkpoint of polyadenylation, if they 
are to disguise their transcripts as “self” so as not to be detected by the host. IAV, 
which, as previously described, has mechanisms to cap and splice its mRNA, also has a 
mechanism to polyadenylate them, thereby completing the process of disguising its 
transcripts. IAV uses a host independent mechanism to transcribe polyadenylated 
mRNA from the virion RNA (vRNA), in which a poly(U) tract in the genome is encoded 
in close proximity to a base-paired region of a pan-handle structure (Plotch and Krug, 
1977; Desselberger et al., 1980). It has been suggested that the viral RNA polymerase 
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is unable to navigate this genomic region, and therefore “slips” on to the poly(U) run, 
and transcribes this as a poly(A) tail (Hsu et al., 1987; Pritlove et al., 1998). VSV also 
produces polyadenylated transcripts, albeit by a different mechanism. VSV genes occur 
upstream of a consensus 5’ – AUACU7 – 3’ intercistronic sequence, which acts as both a 
non-canonical polyadenylation signal, causing “stuttering” of the viral RNA polymerase 
at the U7 residues, as well as a transcriptional stop site (Schubert et al., 1980). In 
addition, this sequence has been shown to be necessary for the transcription of 
monocistronic transcripts from the VSV genome (Hwang et al., 1998). 
The mechanisms employed by KSHV to overcome the host cell mRNA quality control 
checkpoints are particularly interesting. KSHV encodes many intronless mRNAs which, 
therefore, do not undergo splicing. Splicing is closely linked with mRNA export, and so 
to overcome this potential problem, the KSHV encoded ORF57 protein directly binds 
and recruits Aly or another TREX export adaptor, UIF, to these transcripts (Malik et al., 
2004; Jackson et al., 2011). Through this interaction, ORF57 is able to recruit the entire 
TREX complex to KSHV intronless mRNAs, forming export-competent RNPs. 
Interestingly, the viral mRNAs are then trafficked through the nucleolus, and disruption 
of nucleoli or nucleolar localisation signals within the ORF57 protein drastically reduce 
KSHV mRNA nuclear export (Boyne and Whitehouse, 2009; Boyne and Whitehouse, 
2006). Furthermore, TREX components also colocalise with ORF57 is the nucleolus. The 
reason for this process is not yet understood, however this mechanism may avoid the 
host cell shutoff process, caused by the KSHV-encoded shutoff and exonuclease (SOX) 
protein. SOX interacts with multiple components of the polyadenylation machinery, 
including PAP2 and PABP1, inducing the hyperadenylation of cellular transcripts 
resulting in their increased turnover (Lee and Glaunsinger, 2009; Covarrubias et al., 
2011). Interestingly, KSHV promotes polyadenylation of the viral mRNAs using two 
canonical polyadenylation sites at the 3’ end of many of its genes, however the viral 
mRNAs are not hyperadenylated like their cellular counterparts (Majerciak et al., 
2013). It is therefore likely that this nucleolar localisation prevents SOX activity on viral 
mRNAs. Following nucleolar trafficking, viral mRNAs are exported through the nuclear 
pore complex, via an interaction with Nxf1, which is bridged by Aly (Fig. 1.9) (Boyne et 
al., 2008). 
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Figure 1.9: ORF57 mediated TREX recruitment, nucleolar trafficking and nuclear export of viral mRNA. 
ORF57 directly recruits Aly/UIF to intronless viral transcripts, leading to the subsequent recruitment of 
the full TREX complex. ORF57 then mediates the trafficking of the viral transcript through the nucleolus. 
Finally, Aly bridges an interaction between the viral mRNA and the export receptor, Nxf1, which 
facilitates the transit of the transcript through the nuclear pore via an interaction with FG-nucleoporins. 
Adapted from (Schumann et al., 2013).  
1.2.2 The DNA damage response, apoptosis and virus infection  
Genome integrity is vital for the correct regulation and production of new biological 
material. DNA is repeatedly exposed to insults and stresses that, if not adequately 
repaired, could lead to the formation of cancerous tissue (Branzei and Foiani, 2008). To 
combat this, multicellular organisms have evolved a series of defence mechanisms 
designed to quickly identify various forms DNA damage and then mediate DNA repair 
(Smith et al., 2010). Alternatively, if the damage cannot be rectified, affected cells are 
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forced into a programmed cell death pathway known as apoptosis, in order to 
preserve genome integrity (Roos and Kaina, 2006). Many of the cellular factors that 
contribute to the DNA damage response and trigger DNA repair or apoptosis are highly 
conserved between multicellular organisms, demonstrating their importance (Aravind, 
1999).  
1.2.2.1 DNA damage 
The genome of any organism is constantly under attack from many different sources, 
and there are many different forms of DNA damage (Fig. 1.10) (Helleday et al., 2014). 
The most common type of DNA damage is caused by the spontaneous breaking of the 
N-glycosidic bond between the pentose-phosphate DNA scaffold and the nucleobase, 
leading to an abasic (apurinic or apyrimidinic) site (Krokan et al., 1997). This is a 
common phenomenon, believed to occur up to 104 times per cell per day, and is 
rectified by the activity of AP endonuclease enzymes, which cleave the DNA strand to 
remove the affected position (Loeb and Preston, 1986; Wilson et al., 1997). The newly 
formed single strand break is subsequently repaired, usually by the short patch base 
excision repair pathway (Helleday et al., 2014). Deamination, the removal of an amine 
group, is a similar spontaneous reaction most commonly associated with the 
conversion of cytosine to uracil by hydrolysis, forming a GU mismatch (Krokan et al., 
2002). Uracil is subsequently removed by Uracil-DNA glycosylase, which promotes 
glycosidic bond cleavage using a “pinch-push-pull” mechanism. Other mismatches can 
also occur spontaneously by insertion, deletion or misincorporation, rather than by a 
chemical reaction affecting correctly matched bases. All mismatches are repaired by 
the mismatch repair (MMR) machinery, which is able to distinguish the newly 
synthesised daughter strand, which is likely to contain any mismatches, from the 
parental strand by a mechanism which is not yet fully understood (Jiricny, 2013).  
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Figure 1.10: Common forms of DNA damage. 
Many forms of DNA damage exist including abasic (apurinic or apyrimidinic) sites, deamination, 
mismatches, pyrimidine dimers, intercalating agents, interstrand crosslinks, bulky adducts, single strand 
breaks and double strand breaks. The thick grey bars represent a DNA double helix, dashed grey lines 
represent base complementarity. Adapted from (Helleday et al., 2014). 
In contrast, many forms of DNA damage are induced by exogenous sources, and it has 
long been known that exposure to certain chemicals or energy sources dramatically 
increases the risk of cancer development (Poirier, 2012). Pyrimidine dimers, a form of 
bulky adduct, occur during excitation of two pyrimidines by UV light, resulting in C=C 
double bonds between the residues (Goodsell, 2001). This type of molecular lesion is 
most commonly repaired by the nucleotide excision repair (NER) pathway, which 
removes a short strand of DNA containing the adduct (Marteijn et al., 2014). The 
missing strand is subsequently replaced and ligated by DNA polymerase and DNA 
ligase. Other bulky adducts are also repaired in this manner.  
Interstrand crosslinks can be formed by both exogenous and endogenous sources, and 
frequently cause stalled replication forks (Clauson et al., 2013). As interstrand 
crosslinks affect both strands, the aforementioned simple repair pathways do not 
suffice, and instead a more complicated repair pathway known as homologous 
recombination takes place (Fig. 1.11). Homologous recombination at interstrand 
crosslink associated stalled replication forks begins with cleavage of one of the strands 
to form a one sided double strand break (Li and Heyer, 2008). A second cleavage event 
occurs on the other strand at the other side of the interstrand crosslink. This allows the 
affected area to “flip out”, and translesion synthesis is then able to bypass this area, 
generating a new strand. The double strand break is subsequently resolved by invasion 
of one strand into the area containing the “flipped out” lesion, displacing the newly 
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generated strand. The lesion is again bypassed by translesion synthesis. The replication 
fork is restored with the generation of the final strand and the formation of a Holliday 
junction, which can be resolved by a number of mechanisms, usually with the junction 
being cleaved in different patterns by different enzymes (Rass et al., 2010). 
 
Figure 1.11: Homologous recombination repair at interstrand crosslink associated stalled replication 
forks. 
Schematic showing the steps in interstrand crosslink associated stalled replication fork resolution by 
homologous recombination. 1. Interstrand crosslink formation; 2. Stalled replication fork formation; 3. 
Generation of a one sided double strand break; 4. Cleavage of affected strand near lesion; 5. “Flipping 
out” of lesion and translesion synthesis; 6. Strand invasion and translesion synthesis; 7. Restoration of 
replication fork past lesion; 8. Translesion synthesis and Holliday junction formation. Taken from (Li and 
Heyer, 2008). 
Various alterations to the described method of homologous recombination can occur 
depending on the type of replication stress or DSB formed. However, HR cannot always 
be used to rectify damage, as it is only applicable during certain stages of the cell cycle 
(Branzei and Foiani, 2008). Similarly, sometimes translesion synthesis cannot occur as 
there is a loss of sequence data on both strands of the DNA, and a sister chromosome 
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may not have been generated for use as a template. In these scenarios, a process 
known as non-homologous end joining (NHEJ) takes over. NHEJ always resolves double 
strand breaks, although if a single strand break is generated that cannot be rectified by 
HR, the unbroken strand may be cleaved before the subsequent DSB is repaired by 
NHEJ. NHEJ acts to ligate two ends found at a DSB together with two ends of another 
DSB (Davis and Chen, 2013). Usually there are short homologous overlaps found at the 
broken ends, and in these scenarios NHEJ normally leads to the correct repair of the 
DSB. Occasionally, however, DSBs will generate flush ends, with no guiding 
homologous sequence. In this scenario, NHEJ will ligate the broken ends with any 
other broken ends the NHEJ machinery comes into contact with, and this often results 
in the generation of aberrant sequences. Indeed, this process often leads to well 
documented chromosome translocations at specific sites, as chromosomes occupy 
defined territories in the nucleus, and certain areas of each chromosome are highly 
prone to DSBs (Roukos and Misteli, 2014). Furthermore, although many chromosome 
translocations are well tolerated and do not produce an altered phenotype, some 
translocations can lead to alterations to gene function, occasionally generating 
oncogenes if a strong promoter from one gene is translocated upstream of another 
minimally expressed gene. This effect is frequently observed in the case of 
“Philadelphia chromosome” formation, a well characterised and recurring 
chromosome translocation between chromosome 9 and chromosome 22 that is 
associated with chronic myelogenous leukaemia (Fig. 1.12) (Koretzky, 2007; Kosior et 
al., 2011). Both the breakpoint cluster region (BCR) of chromosome 22 and the Abl1 
gene on chromosome 9 are highly prone to the generation of DSBs, and these two 
regions are often ligated together by NHEJ, forming the oncogenic BCR-Abl1 fusion 
gene that acts as a constitutively active tyrosine kinase. 
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Figure 1.12: Philadelphia chromosome formation via a translocation between chromosome 9 and 
chromosome 22. 
Schematic showing the formation of a Philadelphia chromosome. Double strand breaks occur on 
chromosome 9 and chromosome 22. Subsequent erroneous NHEJ forms t 9;22 and the Philadelphia 
chromosome, generating a fusion gene between Abl1 and BCR. Yellow and red lines represent the 
promoter regions for Abl1 and BCR respectively, orange block represents Abl1 gene. Adapted from 
(Kosior et al., 2011). 
The cellular DNA damage response profile is highly complex, and many proteins have 
been identified as signal transducers, responding to various forms of genotoxic stress 
and facilitating the expression of large numbers of genes which contribute to the 
repair or apoptosis pathways (Yang et al., 2003). What is less clear, however, is how 
damaged DNA is first detected and how specific signalling cascades are triggered. 
Recent research suggest roles for a small subset of protein kinases in this function. In 
particular, three kinases known as ataxia-telangectasia mutated (ATM), ATM- and Rad3 
related (ATR) and DNA-dependent protein kinase catalytic subunit (DNA-PKcs) have 
major roles in sensing DNA damage and initiating the subsequent DDR protein kinase 
cascade (Yang, 2003). These kinases have been demonstrated to respond to specific 
forms of genotoxic stress, and each appear to be responsible for the activation of 
different pathways. Interestingly, however, there appears to be a degree of crosstalk 
between the three different pathways, and each kinase has been shown, in certain 
conditions, to phosphorylate targets of the other pathways. 
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1.2.2.2 The ATM-Chk2 DNA damage response pathway 
ATM is a Serine/Threonine (Ser/Thr) protein kinase, first discovered as a mutated gene 
associated with the genomic instability syndrome ataxia-telangiectasia, a disease 
characterised by a defect in the response to DSBs (Shiloh and Ziv, 2013). It is not 
surprising, therefore, that the primary role of ATM and its associated protein kinase 
cascade is to signal the presence of DSBs and bring about their repair.  
The MRE11-RAD50-NBS1 (MRN) complex is believed to be one of the first complexes 
to be recruited to DSBs, acting as a physical scaffold to keep the two ends of the DSB in 
close proximity (Uziel, 2003; Shiloh and Ziv, 2013). The MRN complex also acts as an 
initial sensor of DNA damage, and its localisation to DSBs is required for the activation 
and recruitment of ATM to DSBs (Fig. 1.13). The biophysical mechanism of ATM 
recruitment and activation is not fully understood, however, an interaction between 
ATM and Nijmegen breakage syndrome protein 1 (NBS1), strengthened by breast 
cancer type 1 susceptibility protein (BRCA1) and tumour suppressor p53-binding 
protein 1 (53BP1), as well as Lys63-linked ubiquitylation of NBS1 by S-phase kinase-
associated protein 2 (SKP2), is crucial to this process. ATM is found as a homodimer in 
its inactive form, but quickly dissociates into active monomers, which are recruited to 
sites of DSBs following their induction. Upon its recruitment, ATM forms a “turret” 
structure with other DSB associated proteins, and begins to function as a kinase of 
nearby proteins. One of the first phosphorylation events following DSB localisation is 
its auto-phosphorylation at Ser1981, which aids in the retention of active ATM at DSBs. 
ATM also phosphorylates components of the MRN complex, which is believed to both 
activate a number of subsequent ATM signalling cascades and act as a positive 
feedback loop to generate a sustained effort to repair the detected DSB (Shiloh and 
Ziv, 2013). 
Other members of the turret structure also function in a similar manner to MRN 
complex components, such as mediator of DNA damage checkpoint protein 1 (MDC1) 
(Mochan et al., 2003). MDC1 associates with DSBs through an interaction with the well 
characterised marker of DNA damage, phosphorylated histone H2A.X (γH2A.X). Upon 
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ATM recruitment, ATM binds and phosphorylates MDC1, in another feedback loop, 
stabilising the protein turret and promoting a sustained effort to rectify the DSB. 
Moreover, ATM also phosphorylates additional H2A.X residues and interacts with a 
number of proteins associated with histone ubiquitylation, further amplifying the DNA 
damage markers associated with the DSB. 
Downstream of the DSB-related protein turret assembly, ATM activation culminates in 
the phosphorylation of several other protein kinases, including a cofactor of the 
aforementioned DNA damage sensor, DNA-PK, demonstrating one of the ways in 
which the three major DDR pathways exhibit crosstalk (B.P.C. Chen et al., 2007). In 
addition, ATM phosphorylates RAC-alpha serine/threonine-protein kinase (AKT) (Xu et 
al., 2012), homeodomain-interacting protein kinase 2 (HIPK2) (Hofmann et al., 2013) 
and checkpoint kinase 2 (Chk2) (Smith et al., 2010), as well as a number of other, less 
well characterised protein kinases. Chk2 is particularly interesting, as this protein 
kinase is frequently defective in a range of cancers, and phosphorylates other well 
characterised and important cell stress associated proteins, such as cellular tumour 
antigen p53 (p53), BRCA1, transcription factor E2F-1 (E2F-1), M-phase inducer 
phosphatase 1 (Cdc25A) and M-phase inducer phosphatase 3 (Cdc25C) (Bartek et al., 
2001). ATM phosphorylates Chk2 at T68, and this modification is detected by the FHA 
domain of other Chk2 molecules (Ahn et al., 2002). The two molecules then transiently 
form dimers, and the inactive form is autophosphorylated by the active form, 
culminating in the full activation of the Chk2 pool. Through its interaction with p53, 
Chk2 is then able to enhance DNA repair, initiate cell cycle blockade and, in extreme 
cases, force the cell into apoptosis (Shiloh and Ziv, 2013). 
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Figure 1.13: The ATM protein kinase DNA damage signalling and repair pathway. 
Following the induction of a DSB, the MRN complex forms a scaffold structure holding the two broken 
ends in close proximity. MDC1 associates with the DSB site, binding to γH2A.X moieties. ATM is recruited 
to the DSB site through interactions with NBS1 and MDC1, as well as numerous other nearby proteins. 
ATM phosphorylates itself, as well as NBS1, MDC1 and additional H2A.X residues. Eventually ATM 
phosphorylates Chk2, leading to DNA repair, cell cycle block or apoptosis. Green circles - H2A.X; red 
circles - γH2A.X; yellow circles labelled “p” – phosphate; lightning bolt – source of DNA damage; 
horizontal black lines – DNA. 
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1.2.2.3 The ATR-Chk1 DNA damage response pathway 
ATR is a protein kinase with sequence homology to members of the PIKK family, similar 
to ATM (Cimprich and Cortez, 2008). In contrast to ATM, ATR is typically associated 
with the repair of DNA single strand breaks (SSBs). 
Sites of DNA SSBs generally leave a stretch of single stranded DNA, which is rapidly 
coated with multiple copies of replication protein A (RPA) (Zou, 2007; Smith et al., 
2010). RPA subsequently becomes hyperphosphorylated and is detected by a member 
of the mRNA splicing machinery, known as pre-mRNA processing factor 19 (Prp19), 
which has only recently been demonstrated to play a role in the DNA damage 
response, along with a number of other mRNA splicing associated proteins (Maréchal 
et al., 2014). Prp19 associates with RPA at sites of SSBs, and facilitates the recruitment 
of ATR to these sites, through an interaction with the ATR cofactor ATR interacting 
protein (ATRIP). Similarly to ATM, ATR is believed to require autophosphorylation for 
its activation, however it also relies heavily on the actions of two other proteins; DNA 
topoisomerase-2 binding protein 1 (TopBP1) and Claspin (Liu et al., 2011; Smith et al., 
2010). TopBP1 is recruited to sites of SSBs through an interaction with a protein 
“clamp” structure made up of the DNA repair protein RAD9 (RAD9), cell cycle 
checkpoint protein RAD1 (RAD1) and checkpoint protein HUS1 (HUS1), and is able to 
stimulate ATR activity through an unknown mechanism. Claspin is phosphorylated by 
ATR, and then subsequently acts as a scaffold, binding Chk1 and recruiting it to the SSB 
site in order to facilitate its phosphorylation and activation by ATR. ATR 
phosphorylates Chk1 at several sites including S317 and S345. Chk1 is subsequently 
believed to dissociate from Claspin and phosphorylates multiple targets including 
Cdc25A, Cdc25C, Wee1-like protein kinase (Wee1), breast cancer type 2 susceptibility 
protein (BRCA2) and DNA repair protein Rad51 homolog 1 (Rad51). Similarly to Chk2, 
activated Chk1 is able to bring about DNA repair, cell cycle arrest or apoptosis, 
depending on the situation, through further kinase signalling cascades. ATR is also able 
to phosphorylate p53 at S15 and S37 (Menon and Povirk, 2014). 
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1.2.2.4 The DNA-PK DNA damage response pathway 
DNA-PK is a complex consisting of a catalytic subunit termed DNA-PKcs, and a targeting 
subunit, composed of a heterodimer of Ku70 and Ku80 (Gottlieb and Jackson, 1993). 
Similarly to both ATM and ATR, DNA-PKcs is a member of the PIKK family of Ser/Thr 
protein kinases, which acts in response to the detection of genomic instability 
(Durocher and Jackson, 2001). The DNA-PK associated DDR pathway typically 
culminates in NHEJ. 
The Ku70-Ku80 heterodimer has a high affinity for DNA and forms a ring-like structure 
which is able to slide over the broken end of a DNA molecule containing a DSB (Fig. 
1.14). It binds to the DNA backbone, rather than the bases, and so binding occurs in a 
sequence independent manner (Rivera-Calzada et al., 2007). Once bound, the 
heterodimer acts as a scaffold for the recruitment of NHEJ associated proteins. The 
first protein to be recruited is the catalytic subunit of DNA-PK; DNA-PKcs. Binding of 
DNA-PKcs to the Ku70-Ku80 heterodimer drives the movement of the heterodimeric 
ring further along the DNA strand, and this in turn activates DNA-PKcs kinase function 
(Yoo, 1999). DNA-PKcs forms a scaffold structure that holds the broken ends of the 
DSB in close proximity, similar to the MRN complex in the ATM pathway. DNA-PKcs 
phosphorylates a multitude of NHEJ associated proteins, including Ku70, Ku80, DNA 
repair protein XRCC4 (XRCC4), DNA ligase IV and Non-homologous end-joining factor 1 
(XLF) (Davis and Chen, 2013). Interestingly, however, none of these phosphorylation 
events are necessary for canonical NHEJ. Phosphorylation of the NHEJ protein Werner 
by DNA-PKcs, however, does appear to increase the efficiency of DSB repair 
(Kusumoto-Matsuo et al., 2014). DNA-PKcs is also able to phosphorylate p53 and 
H2A.X, but this is not specific to this pathway, as both phosphorylation events are also 
observed in the ATM-Chk2 and ATR-Chk1 pathways (Lakin and Jackson, 1999; 
Podhorecka et al., 2010). As such, the mechanism for DNA-PK dependent NHEJ is not 
fully understood, but DNA-PK binding at DSBs is able to inhibit the activities of ATM-
Chk2 and ATR-Chk1 pathway proteins at these sites (Davis and Chen, 2013). 
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Figure 1.14: DNA-PK associated non-homologous end joining. 
Following the induction of a double strand break, the Ku70-Ku80 heterodimer ring slides over the 
broken ends of the DNA and then bind and activate DNA-PKcs. This catalytic subunit then 
phosphorylates a number of non-homologous end joining associated proteins, including DNA ligase IV, 
XRCC4 and XLF, and the DSB is repaired by NHEJ. Taken from (Joaquin and Fernandez-Capetillo, 2012). 
1.2.2.5 Viral activation of the DNA damage response 
Many viruses initiate a DNA damage response during infection. Incoming or replicating 
viral DNA often features abnormal structures that are recognised by components of 
the DDR, often leading to the suppression of viral gene expression (Everett, 2006; 
Luftig, 2014). The phenomenon is not specific to DNA viruses, and integration of 
retroviral genomes can also trigger the DDR. These processes are common amongst 
many different classes of viruses, however, a large number of viruses also have further 
potential to cause a host DDR, through other common viral processes, such as cell 
cycle modulation or host transcriptional regulation. Activation of a host cell DDR 
through these means is widely regarded as being an unintentional side effect of 
general virus infection, which must be overcome by the virus.  
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Detection of foreign DNA is not the only way the DDR machinery can be activated 
during virus infection. During lytic replication, many DNA viruses express proteins that 
are able to modulate the cell cycle, as these viruses often infect dormant cells and 
must stimulate the generation of cellular factors that are crucial for viral replication. 
For example, the SV40 T-antigen, adenovirus E1A and the human papillomavirus (HPV) 
E7 proteins all inhibit the interaction between the cellular tumour suppressor gene Rb 
and the E2F transcription factor (DeCaprio et al., 1988; Ikeda and Nevins, 1993; 
Münger et al., 1989). Rb normally blocks the transactivation domain of E2F in order to 
silence E2F target genes and repress the G1/S transition (Giacinti and Giordano, 2006). 
By inhibiting this interaction, SV40, adenovirus and HPV force the cell into S phase, 
however, a side effect of this process is abnormally high E2F levels, which promote 
hyperproliferation, leading to an abundance of replication fork collapses and 
associated genome instability. The high levels of damage subsequently trigger the 
activation of the DDR machinery during early virus infection, as a side effect of cell 
cycle modulation (Luftig, 2014). 
Detection of foreign DNA or abnormal structures, along with the induction of 
replicative stress through modulation of the cell cycle both represent ways in which a 
virus can trigger the DDR as a side effect of other viral replication processes. However, 
many viral proteins directly interact with DDR components in order to promote the 
viral life cycle (Fig. 1.15). For example, both the HPV E7 protein and the murine 
gammaherpesvirus 68 (MHV-68) M2 protein are able to bind directly to ATR and force 
the activation of a number of ATR targets (Moody and Laimins, 2009; Liang et al., 
2006). Conversely, some viruses interact with the DDR components in order to subvert 
the response. Human T lymphotropic virus type 1 (HTLV-1) encodes an oncoprotein 
called Tax, which inhibits the interaction between ATM and chromatin, allowing 
infected cells to progress into S phase despite potentially large amounts of DNA 
damage (Chandhasin et al., 2008). Furthermore, Tax forms small foci of DDR 
components in HTLV-1 infected cells. MDC1, BRCA1, γH2A.X, Chk2 and activated DNA-
PK are all recruited to these foci, and through this mechanism it is hypothesised that 
Tax sequesters these proteins away from sites of viral DNA replication, allowing 
replication to proceed uninhibited (Belgnaoui et al., 2010). 
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Figure 1.15: Viral protein interactions with DNA damage repair factors. 
Many viral proteins interact with components of the ATR, ATM and DNA-PK DDR pathways. Ad5 – 
adenovirus 5; Ad12 – adenovirus 12; HCV – hepatitis C virus; HBV – hepatitis B virus; JCPyV – JC 
polyomavirus. Taken from (Luftig, 2014). 
Herpesviruses, in particular, interact with components of the DDR in multiple ways. 
Firstly, herpesvirus infections are associated with an activation of the DDR, at least in 
part due to the detection of incoming viral DNA, leading to the repression of the viral 
genomes at nuclear domain 10 (ND10) bodies (Everett et al., 2006; Glass and Everett, 
2013). HSV-1 overcomes this host cell response via expression of the viral protein ICP0, 
which is able to mediate the degradation of the core ND10 protein, PML, thereby 
dispersing any ND10 bodies associated with the viral genome (Everett et al., 2006). 
Despite this, herpesviruses also hijack the DDR machinery to promote lytic replication. 
Indeed, a well conserved family of proteins exist in all of the Herpesviridae, known as 
conserved herpesviral protein kinases (CHPKs) that are vital for viral replication and 
spread (Gershburg and Pagano, 2008). The BGLF4 kinase encoded by EBV promotes 
the switch between the latent and lytic phases via the activation of the histone 
acetyltransferase, TIP60 (Li et al., 2011). The histone acetyltransferase function of 
TIP60 has also been implicated in events during the ATM and DNA-PK DDR signalling 
pathways, as well as transcriptional activation of p53 (Squatrito et al., 2006). 
Unsurprisingly, activation of TIP60 by BGLF4 coincides with a DDR in EBV infected cells 
(Li et al., 2011). Although the full mechanisms are not understood, it appears that an 
activated DNA damage response is necessary for the replication of many herpesviruses 
(Xie and Scully, 2007; E et al., 2011; Hollingworth et al., 2015).  
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1.2.3 Viral and cellular microRNAs 
Regulation of gene expression represents a fundamental area of biological studies. 
There are many dynamics in the expression of a gene, working on multiple levels. For 
instance, at the DNA level there are factors such as promoter and enhancer sequences. 
At the mRNA level, turnover rates of transcripts, mRNA processing and nonsense 
mediated decay can affect the expression of a gene. Considering proteins, 
transcription factor availability and binding, protein turnover rate, and even factors 
such as protein-protein interactions can affect the expression of whole subsets of 
genes. The discovery of miRNAs in 1993 revealed another player in the gene 
expression and regulation field. Since then, thousands of miRNAs have been identified 
and characterised, and the vast majority are able to regulate multiple genes at the 
mRNA stage.   
1.2.3.1 miRNA biogenesis and function 
The biogenesis of a miRNA begins with the transcription of a long primary transcript 
known as a pri-miRNA (Lee et al., 2002). Pri-miRNAs exist in a number of genomic 
contexts, most commonly being located in intronic sequences of other, longer 
transcripts, however they can also be found in exons. The pri-miRNA is released from 
the longer transcripts by the ribonuclease Drosha and its cofactor DGCR8, which form 
a complex known as Microprocessor (Denli et al., 2004). Upon complex formation, 
Drosha cleaves a 60-110 nucleotide region out of the pri-miRNA ~11 bp away from the 
basal junction, where the ssRNA becomes dsRNA, which is ~22 bp away from the apical 
junction at the terminal loop (Fig. 1.16) (Zeng et al., 2005; Han, 2004). This cleaved 
product is known as a pre-miRNA, and forms a tertiary structure generally consisting of 
a stem loop with a number of other loops residing down the length of the stem at the 
sites of non-complementary bases (Ha and Kim, 2014). The pre-miRNA is subsequently 
exported into the cytoplasm via the nuclear pore by a protein complex consisting of 
Exportin-5 and Ran-GTP (Bohnsack et al., 2004; Yi et al., 2003). Once in the cytoplasm, 
the complex dissociates following GTP hydrolysis, releasing the pre-miRNA, which is 
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subsequently cleaved in the cytoplasm, just after the terminal loop, by the 
endonuclease Dicer (Fig. 1.16) (Bohnsack et al., 2004; Yang and Lai, 2011). Dicer binds 
at a 2 nucleotide 3’ overhang, previously generated during Drosha cleavage of the pri-
miRNA, and cleaves the pre-miRNA 22 nucleotides away from the 5’ end of the 
molecule (Park et al., 2011). This produces a ~22 nucleotide double stranded RNA, 
known as a miRNA:miRNA* duplex. One of these strands is typically more prevalent or 
biologically active than the other, and is distinguished as the miRNA, whilst the less 
active strand is referred to as miRNA* (Chiang et al., 2010; Ha and Kim, 2014). 
 
Figure 1.16: Sites of pri-miRNA and pre-miRNA cleavage. 
Pri-miRNAs are cleaved ~11bp from the basal junction and ~22nt from the apical junction by the 
ribonuclease Drosha, generating a pre-miRNA. Pre-miRNAs are subsequently cleaved near the terminal 
loop by Dicer, generating a miRNA:miRNA* duplex.  Adapted from (Ha and Kim, 2014). 
The Dicer-generated miRNA:miRNA* duplex is bound by an Argonaute (AGO) protein, 
forming the RNA-induced silencing complex (RISC). RISC activation is thought to be 
completed via the dissociation of the duplex, either by passenger strand cleavage or 
through a more complex process guided by mismatches in the dsRNA (Kawamata and 
Tomari, 2010). Often, both strands of the duplex can be recruited to functional RISC 
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complexes, and strand selection involves sensing of RNA stability, with more unstable 
5’ ends generally indicating the guide strand, or miRNA (Khvorova et al., 2003). The 
active RISC then acts to degrade or repress transcription of a subset of mRNAs 
containing complementary sequences to the miRNA, usually found within the 3’ UTR of 
target mRNAs (Fig. 1.17) (Lewis et al., 2005). There is also evidence of miRNA binding 
at the 5’ UTR or coding regions of mRNAs, which again leads to inhibitory effects on 
gene expression, ultimately reducing protein synthesis (Tay et al., 2008; Lytle et al., 
2007). One important factor guiding miRNA activity is the complementarity between 
the mRNA target region and the miRNA “seed” sequence, located between positions 2 
and 8 (Lewis et al., 2003; Brennecke et al., 2005). However, recent evidence suggests 
this may be an oversimplified model, as nucleotide alterations at various positions of 
the seed region of miHDS1 have been demonstrated to produce similar mRNA 
silencing as the unmodified miRNA (Monteys et al., 2014). Therefore, more recent 
models suggest that ~60% of the gene regulation controlled by a given miRNA is due to 
perfect seed sequence binding (Zisoulis et al., 2010).   
Interestingly, the view that miRNAs generally inhibit protein synthesis of target genes 
has recently been challenged with the discovery that some miRNAs are able to 
increase protein output. This has been demonstrated to occur through a number of 
mechanisms, including de-repression of mRNAs by interfering with repressor protein-
target mRNA binding, or through the recruitment of protein complexes to AU rich 
regions (Vasudevan et al., 2007; Eiring et al., 2010). Clearly, despite large amounts of 
work into their function, there are still many dynamics in the regulation of miRNA gene 
silencing that are not fully understood. 
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Figure 1.17: miRNA biogenesis, RISC complex formation and RISC-mediated degradation or repression 
of target mRNAs. 
Pri-miRNAs are transcribed by RNA polymerase II and cleaved into pre-miRNAs by Drosha and DGCR8 in 
the nucleus. Pre-miRNAs are then exported into the cytoplasm by Exportin-5 and Ran-GTP, where they 
are cleaved into miRNA:miRNA* duplexes by Dicer. A guide strand is then selected by Argonaute, 
forming a functional RISC complex, which binds target mRNAs at complementary sites in the 3’ UTR, 
mediating degradation or translational repression of the target mRNA. Adapted from (Ling et al., 2013). 
1.2.3.2 Viral miRNAs 
It is generally believed that RNAi evolved as a defense mechanism against harmful 
genetic species, such as viruses. However, if this model is correct, viruses have been 
able to subvert this defense, and have hijacked miRNAs for their own purposes. 
miRNAs represent important tools for viruses, as they can modulate host cell function 
whilst being less detectable than foreign proteins by the host immune system. Over 
the last decade, more than 500 viral miRNAs have been discovered (miRbase.org; July 
2015) and, interestingly, nearly half of these miRNAs are encoded by members of the 
Herpesvirales (Fig. 1.18). Epstein-Barr virus was the first human virus demonstrated to 
encode miRNAs, 5 of which were initially identified in the BHRF1 and BART genomic 
regions (Pfeffer et al., 2004). An additional 39 EBV miRNAs have subsequently been 
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identified, and show varying levels of expression in different EBV infected cell lines and 
latency profiles (Pratt et al., 2009). These miRNAs have been demonstrated to regulate 
numerous viral and cellular mRNAs, and modulate the host cell immune response and 
apoptosis pathways in order to maximise viral replication (Barth et al., 2011). For 
example, miR-BART5 targets the host cell Bcl-2-binding component 3 (BBC3) mRNA, 
whilst other BART miRNAs target the pro-apoptotic Bim transcript (Choy et al., 2008; 
Marquitz et al., 2011). Indeed, it appears that most characterised viral miRNAs play 
roles in the persistence of the virus within the host cell, regulating host or viral genes 
and limiting the effectiveness of the host immune response, in order to expand the 
longevity of infected cells. This, therefore, explains the high numbers of viral miRNAs 
found within herpesviruses, all of which exhibit a latent phase and persistence in the 
infected host. 
 
Figure 1.18: Herpesvirus-encoded pre-miRNAs and their positions within the viral genomes. 
Schematic showing the position of pre-miRNAs within the genomes of the Herpesviridae. Pre-miRNAs 
may produce more than one mature miRNA. Taken from (Skalsky and Cullen, 2010).   
KSHV encodes at least 18 mature viral miRNAs, all of which are expressed during 
latency and encoded within the latency-associated region (KLAR) of the genome (Qin 
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et al., 2012). Of these, KSHV encodes at least two miRNA orthologs of a cellular 
miRNAs, miR-K12-11 and miR-K10a, analogs of miR-155 and miR-142-3p respectively, 
and has retained both the complete seed sequences as well as many of the mRNA 
targets are thought to be cellular transcripts (Gottwein et al., 2007; Gottwein et al., 
2011). Overexpression of miR-155, as with many cellular miRNAs, has been implicated 
in cancer formation, affecting a number of processes including haematopoiesis and 
tumorigenesis (Faraoni et al., 2009). The KSHV ortholog has been demonstrated to 
affect these processes in similar ways, highlighting one of the ways latently infected 
cells contribute to KSHV associated pathogenesis (Gottwein et al., 2007; Ganem, 2010; 
Qin et al., 2012). KSHV also encodes a number of miRNAs which do not appear to have 
cellular counterparts, and therefore may target non-cellular genes. For example, both 
miR-K12-9-5p and miR-K12-7-5p inhibit reactivation of the lytic cycle by repressing 
expression of the viral RTA transcript (Bellare and Ganem, 2009; Lin et al., 2011). Other 
KSHV miRNAs target distinct subsets of cellular genes, also showing limited relation to 
host miRNAs, such as miR-K12-1-5p, which represses the IκBα transcript, repressing 
activation of the NFκB pathway, which also drives lytic reactivation (Lei, Bai, et al., 
2010). 
1.2.3.3 Viral dysregulation of cellular miRNAs 
In addition to encoding their own miRNAs, many viruses are also able to alter the 
expression or function of host miRNAs for pro-viral processes. Often, these 
interactions occur during viral latency to evade the host immune response, similarly to 
a number of previously described examples of viral encoded miRNAs. For example, 
during latency III, the EBV latent membrane protein 1 (LMP1) stimulates upregulation 
of both miR-146a and miR-29b during B cell infection (Cameron et al., 2008; 
Anastasiadou et al., 2010). miR-146a subsequently targets at least two members of the 
toll-like receptor (TLR) signalling pathway, TNF receptor-associated factor 6 (TRAF6) 
and interleukin-1 receptor-associated kinase 1 (IRAK1), limiting the host innate 
immune response (Cameron et al., 2008; Xiao and Rajewsky, 2009). Meanwhile, miR-
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29b targets T-cell leukaemia gene 1 (TCL1) to modulate cell survival and proliferation 
(Anastasiadou et al., 2010). 
Interestingly, a number of RNA viruses have also evolved mechanisms of promoting 
viral replication by utilising host miRNAs. The RNA genomes of enteroviruses lack a cap 
structure and therefore depend on internal ribosome entry sites for their translation 
(Thompson and Sarnow, 2003). During enterovirus infection, miR-141 expression is 
strongly upregulated, as this miRNA targets the eukaryotic translation initiation factor 
4E (eIF4E), a protein which promotes the translation of capped RNAs. This limits the 
cells ability to translate its own mRNAs, ultimately contributing to a host shutoff 
response and allowing the enterovirus genome to be replicated much more efficiently 
(Ho et al., 2011). Hepatitis C virus also utilises host miRNAs for processes associated 
with the viral RNA genome. HCV infects hepatocytes which express the liver specific 
miR-122, and HCV is able to interact with miR-122 in a number of unique ways. It was 
first discovered that miR-122 acts as a shield for the viral genome, binding to the 5’ 
UTR and protecting it from the actions of exonuclease enzymes, such as Xrn1 (Jopling 
et al., 2005; Y. Li et al., 2013). It was subsequently demonstrated that through this 
mechanism, HCV also acts as a miRNA sponge to de-repress a number of miR-122 
target mRNAs (Fig. 1.19) (Luna et al., 2015). The effects of the dysregulation of miR-
122 target genes has not been further examined, however, it is believed that miR-122 
acts as a tumour suppressor, necessary for long term liver homeostasis. By interrupting 
this function, it is likely that HCV promotes its own replication while also increasing its 
oncogenic potential.  
KSHV has also been shown to dysregulate the expression of host miRNAs, causing 
increased oncogenic potential. Expression of the miR-221-222 cluster is downregulated 
by LANA and Kaposin B during KSHV latent infection, while miR-31 levels are increased 
by K15 via its SH2-binding motif (Wu et al., 2011; Tsai et al., 2009). Downregulation of 
miR-221 and miR-222 is predicted to cause an increase in their target mRNAs, namely 
protein-C ETS-1 and -2 (ETS1/ETS2), both enhancers of endothelial cell migration. 
Downregulation of the known miR-31 target, Protocadherin Fat 4 (FAT4), also 
contributes to this phenotype, and it is believed that this process enhances the 
oncogenic potential of KSHV by spreading malignant KS progenitor cells. Furthermore, 
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the KSHV-encoded viral FLICE inhibitory protein (vFLIP) interacts with NFκB, and this 
interaction promotes the upregulation of miR-146a, which, in turn, targets mRNAs 
encoding the C-X-C chemokine receptor type 4 (CXCR4) (Punj et al., 2010). The 
associated downregulation of CXCR4 is associated with release of KSHV infected 
endothelial progenitor cells into the circulation, which is also believed to increase the 
potential for KS development and spread.  
 
Figure 1.19: Recruitment of miR-122 to HCV genomes causes de-repression of miR-122 targets. 
Schematic showing the functions of miR-122 in normal vs HCV infected hepatocytes. In uninfected 
hepatocytes, miR-122 binds to target mRNAs, causing mRNA repression. In HCV infected cells, miR-122 
is recruited to the 5’ UTR of the HCV RNA genome, and is therefore sequestered away from cellular 
target mRNAs, causing their de-repression. Taken from (Luna et al., 2015). 
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1.3 Omics approaches 
Over decades of studies into biology at a molecular level, countless interactions 
between different biological materials have been described, and chief amongst these 
materials are those that, together, form the central dogma of molecular biology; DNA, 
RNA and protein. Despite the extraordinary amount of work undertaken during this 
time, it appears there are still millions of undiscovered and uncharacterised 
interactions occurring in each and every cell. However, with the invention of new 
scientific technologies comes the promise of greater and greater understanding, and 
nowhere is this more apparent than in the recent developments in “omic” approaches. 
Genome sequencing represents the most widely cited aspect of these developments, 
and has reduced the average time required to sequence a sample to just a few hours 
(Greninger et al., 2015). Compare this to the effort undertaken by Ray Wu to produce 
the first published sequence data in 1972 using a location-specific primer extension 
technique and it becomes apparent that the power of modern sequencers cannot be 
overstated (Wu, 1972). Furthermore, the cost of sequencing continues to decrease, to 
the point where now laboratories all over the world routinely sequence samples. 
Similarly, advances in high throughput, high resolution proteomics and transcriptomics 
have greatly aided investigative potential, and their power continues to increase with 
novel experimental designs, even without the invention of new hardware. Indeed, the 
large datasets produced by these technologies are now frequently published and 
shared in online databases, allowing large scale biological association studies to be 
undertaken without access to a laboratory, just a computer and a hypothesis.  
1.3.1 Proteomics 
Early attempts to analyse the cellular proteome began in 1970, with the advent of 
polyacrylamide gel electrophoresis (PAGE) (Laemmli, 1970). This technique is still 
commonly used in laboratories around the world for the separation of proteins as an 
important part of the Western blotting protocol. PAGE has numerous limitations, 
however, and it is often difficult to detect individual proteins in a complex mixture, 
requiring successful antibody binding which can prove problematic. Despite a number 
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of improvements to the initial PAGE technique in both detection limits and sample 
separation, its power is still limited, mainly due to the complexity of the samples being 
analysed (O’Farrell, 1975)(Klose and Kobalz, 1995; Görg et al., 2004; Patton, 2002). 
Fortunately, subsequent developments in proteomics now allow protein samples to be 
further characterised by mass spectrometry (MS).  
Mass spectrometry can be used to identify and quantify the protein composition of 
protein samples of differing complexities, however samples can be separated using 
PAGE or liquid chromatography (LC) in order to reduce highly complex mixtures into 
more manageable samples for better detection rates and subsequent analysis (Owen 
et al., 2014). Other methods may also be used to reduce sample complexity, such as 
subcellular fractionation. Despite this, MS-based proteomics will generally only achieve 
coverage of ~10% of the proteome, while quantifying even less (Michalski et al., 2011). 
Although this still represents an important step forward in the power of proteomics, 
improving this coverage rate remains an important technical challenge. Following any 
separation protocol, proteins are digested into peptides, typically using trypsin, before 
being separated further by LC. Either electrospray ionization (ESI) or matrix-assisted 
laser desorption/ionization (MALDI) is then used to charge the peptides, before they 
are analysed by tandem MS/MS. In the first round of MS, known as MS1, the mass to 
charge ratio (m/z) of the ionized peptides in the sample are measured, generating a 
precursor ion spectrum. Individual peptide populations are subsequently taken 
forward for collision induced dissociation (CID), prior to the second round of MS, MS2, 
which again measures the m/z generates a final CID spectrum via detection of the 
peptide fragments produced (Fig. 1.20). These spectra are then compared to 
theoretical databases in order to assign protein identification to the samples, and their 
peak intensities are used to quantify these proteins (Washburn et al., 2001; Yates et 
al., 1995). This technique is usually applied to multiple samples simultaneously to 
compare protein composition across multiple conditions. Samples can be 
differentiated using a number of peptide tagging protocols, such as stable isotope 
labelling with amino acids in cell culture (SILAC) or with the addition of pre-made 
isotopic tags, such as tandem mass tags (TMT), isobaric tags for relative and absolute 
quantification (iTRAQ) or isotope-coded affinity tags (ICAT)(Ong et al., 2002; Wiese et 
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al., 2007; Shiio and Aebersold, 2006; Gygi et al., 1999). Alternatively, label free 
approaches have also been recently developed in order to overcome some limitations 
of the tagging procedures (Griffin et al., 2010; Wong and Cagney, 2010). 
 
Figure 1.20: Separation of protein samples by PAGE/LC and identification and quantification by 
MS/MS. 
Complex protein samples are separated by 1D or 2D PAGE or LC. Separated samples are then digested 
into peptides and subjected to LC coupled to ESI. Ionized peptides are then subjected to MS1, 
generating a precursor ion spectrum that is used for peptide quantification. Peptides are then identified 
using CID and a second round of MS. The CID spectrum generated by this procedure is compared to a 
theoretical database in order to assign a protein identity to the analysed peptides. Adapted from (Owen 
et al., 2014). 
1.3.1.1 SILAC 
SILAC makes use of the different stable (non-radioactive) isotopes of carbon (C12 and 
C13) and nitrogen (N14 and N15) to create amino acids of different masses (Ong et al., 
2002). By growing cells in the presence of differentially weighted amino acids, these 
residues are incorporated into all proteins synthesised by that cell. This normally 
requires several days of growth due to differential protein turnover rates, and 6 to 8 
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cell doublings are usually recommended when analysing cell culture systems by SILAC, 
normally generating over 90% isotopic incorporation. Interestingly, SILAC has also been 
demonstrated to be effective when using simple organisms such as D. melanogaster or 
C. elegans, and this technique has even been applied to mice using diets containing 
specific labelled amino acids (Krijgsveld et al., 2003; Krüger et al., 2008). Most 
commonly arginine and lysine are labelled, as these residues are cleaved at the C-
terminus by trypsin, which is typically used to generate peptide fragments from the 
proteins for analysis (Ong and Mann, 2007). This means that all peptides generated will 
contain one labelled amino acid, excluding the C terminal peptide, allowing maximum 
sample differentiation. Following labelling, cells/organisms are subjected to the 
treatment being investigated, for example, virus infection, and protein samples are 
harvested. Samples are then normalised and mixed at equal ratios before being 
subjected to LC-MS/MS. As the amino acids incorporated into the different samples 
have different masses, they are easily detected and differentiated during analysis by 
MS. 
SILAC has a number of advantages over other MS-based proteomics techniques, as 
samples are mixed into one pooled sample which is then processed at once, reducing 
errors arising from differential handling of samples. In addition, as tagging occurs 
during protein synthesis, the vast majority of proteins in the final sample are labelled, 
reducing biases that may be introduced during tagging reactions using pre-made tags. 
However, SILAC can only be used to analyse live material, due to the requirement for 
incorporation of isotopically labelled amino acids into the proteins at the point of 
synthesis. Furthermore, certain cell lines may not be compatible with SILAC, due to cell 
sensitivity to changes in medium composition. 
1.3.1.2 TMT/iTRAQ/ICAT 
Isotopic tags have been used in MS-based quantitative proteomics since 1999, with the 
advent of ICAT (Gygi et al., 1999). Tags are created with variable masses, but otherwise 
identical physical properties, and make use of the ability to covalently link additional 
52 
 
material to one end of a peptide sequence. TMT, iTRAQ and ICAT tags differ in their 
composition, but work in the same manner.  
ICAT tags comprise a biotin molecule for streptavidin-mediated peptide purification, a 
linker group containing different stable isotopes for differential masses between tags, 
and a reactive iodoacetyl group which can be covalently linked to free thiols on 
cysteine residues. This introduces a heavy bias for peptides containing cysteine 
residues, however, a variation on the ICAT method has been developed in order to 
overcome this limitation, in which isotopic tags are bound to free amino groups of any 
amino acid, therefore improving coverage (Schmidt et al., 2005). 
TMT and iTRAQ tags differ from ICAT tags in that they are all of the same mass 
(Thompson et al., 2003; Ross et al., 2004). This is achieved through the use of variable 
mass reporter groups, containing different isotopes, at one end of the tag, with 
variable mass carbonyl balance groups in the middle of the tag to normalise the 
weight. A reactive group makes up the rest of the tag. An advantage of using these 
tags over ICAT tags is that the identical masses allow the proteins to behave in exactly 
the same way during separation by LC and the first round of MS. Differential 
quantification of peptides between samples is achieved during MS2, when the tags are 
cleaved from the peptide during CID, generating different peaks on the CID spectrum 
relative to the amounts present in each sample. TMT and iTRAQ allow the 
simultaneous analysis of up to 8 different protein samples, a significant increase over 
other methods.  
MS-based proteomics using isotopic tags carries the advantage that any sample 
containing protein can be used, as the tags are added following protein synthesis. 
1.3.1.3 Label free proteomics 
Due to various issues with labelling of protein samples prior to analysis by MS, two 
label free proteomics techniques have recently been developed. The first of these 
approaches makes use of spectral counting, based on the principle that more 
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concentrated peptides will take longer to elute into the ionisation chamber following 
LC, and therefore more fragment-ion spectra will be acquired from highly 
concentrated peptides than less concentrated peptides (Liu et al., 2004; Ryu et al., 
2008). This technique has been modified in recent years to include analysis of peptide 
count and physical properties, protein length and fragment-ion intensity, in an attempt 
to reduce sample to sample variation that was previously associated with the 
technique (Griffin et al., 2010). This technique is controversial, however, as it relies on 
simple counting of the acquired spectra rather than any tangible physical 
measurements. 
The second approach is less controversial, and utilises the measurement of 
chromatographic peak areas of peptide precursor ions, as each peptide of a particular 
m/z ratio generates a mono-isotopic mass peak in the acquired spectra. The retention 
time of this mass peak has been demonstrated to directly correlate with peptide 
abundance in a linear fashion over a wide range, allowing protein abundances to be 
directly calculated from this measurement (Bondarenko et al., 2002; Chelius and 
Bondarenko, 2002). Label free proteomics are associated with greater proteome 
coverage, however there are also issues associated with the quantification accuracy 
and reproducibility using these methods (Megger et al., 2013). 
1.3.2 Transcriptomics 
The first attempt to profile a mammalian transcriptome was undertaken in 1991 by a 
large group at the NIH, led by Craig Venter. Using cDNA clones to generate expressed 
sequence tags (ESTs), this group was able to sequence 609 different genes, 337 of 
which were newly identified (Adams et al., 1991). However, the success of this 
technique was relatively short lived due to the announcement of microarray 
technology in subsequent years (Schena et al., 1995). Using picomoles of 
complementary probes spotted on a small chip, it was possible to quantify the 
expression of thousands of genes or other expressed sequences simultaneously and 
with minimal effort. Microarrays represented a leap forward in the power of 
transcriptomics, and were widely used for the following decade, prior to the 
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development of next generation sequencing platforms that are more commonly used 
today. Modern sequencing technologies again make use of ESTs, and eliminate the 
false positive signals that were associated with microarrays due to non-specific 
binding, whilst also not requiring prior knowledge of the sequences to be examined, 
allowing the identification of novel sequence expression. Furthermore, next 
generation sequencing introduces less bias for specific sequences, and allows the 
processing of large numbers of samples simultaneously by tagging different samples 
with a unique sequence code. 
1.3.2.1 mRNA sequencing 
The most commonly investigated transcripts are mRNAs, due to their central role in 
gene expression and regulation. The first investigation into mRNA expression using 
next generation sequencing was published in 2006, making use of Roche 454 
sequencing technology (Bainbridge et al., 2006). This approach utilised the sequencing-
by-synthesis principle of the previously developed Sanger sequencing, where 
nucleotide incorporation could be detected due to the release of pyrophosphate. This 
pyrophosphate is first converted into ATP by ATP sulfurylase, and then used as a 
substrate for a chemiluminescent enzyme such as luciferase, which emits a detectable 
light signal. Single cDNA fragments were bound to beads, which were then individually 
settled into wells on a slide where a DNA synthesis reaction could begin using these 
fragments as a template. By sequentially flowing pools of individual bases over these 
samples, the incorporation of specific bases could be recorded for large numbers of 
different sequences simultaneously. This approach demonstrated the potential of next 
generation sequencing technologies, however it was limited in its power and struggled 
to compete with microarrays.  
Short read technology was first described in three separate studies published in 2008, 
using approaches developed by Solexa (Mortazavi et al., 2008; Sultan et al., 2008; 
Wilhelm et al., 2008). Different adaptor sequences are added to both ends of cDNA 
fragments, and one end of the molecule is stuck to a flow cell at a random position, 
while the other uses a complementary sequence, also positioned at various locations 
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on the flow cell, as a primer for the sequencing reaction. These adaptor sequences also 
contain unique sequence codes to allow multiple samples to be sequenced on the 
same flow cell while still allowing differentiation during the analysis stage. During the 
sequencing-by-synthesis reaction, clusters are generated from a single cDNA at any 
position on the flow cell, ultimately generating ~1 million copies (Fig. 1.21). This 
method also makes use of light emission following nucleotide incorporation, however 
nucleotides do not need to be applied sequentially, as each contains a fluorescent 
label specific to that base. The newly incorporated nucleotide contains a 3’-OH 
chemical blocking element, that prevents further synthesis, meaning that each 
nucleotide incorporation is a single event. After each incorporation, this block is 
removed by chemical treatment, allowing the next incorporation to take place. This 
process repeats for a user-defined period, usually between 25 and 35 times. Poor 
quality sequences are removed and sequenced fragments can then be analysed.  
Solexa/Illumina sequencing allows much higher throughput than 454 sequencing as, all 
four bases are incorporated on different fragments during one flow cycle, and the 
fragments sequenced are much shorter. Short read sequencing has also been 
demonstrated to give much better coverage than 454 sequencing (Li et al., 2014 p. 
454). There are now multiple competitors to the Solexa/Illumina platform, achieving 
short read sequencing through modified mechanisms and each providing different 
advantages. In addition, 454 sequencing is still useful in certain experimental contexts, 
for instance, short read sequencing may fail to differentiate between different closely 
related species or strains of microorganism due to perfect homology over short 
stretches of the genomes (Luo et al., 2012). 
Next generation sequencing of mRNA is now widely used in various scientific studies. 
Interestingly, however, it has been revealed that mRNA abundance does not always 
directly correlate with expression at the protein level, and so analyses of gene 
expression should be carefully considered and validated in a wet laboratory setting 
(Evans et al., 2012). Nevertheless, combining mRNA sequencing with other high 
throughput omics technologies can produce interesting results and begin to answer 
questions that no individual approach can achieve. For instance proteomics informed 
by transcriptomics allows novel protein discovery using reference transcriptomes. This 
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is particularly useful when attempting to characterise genes of poorly annotated 
genomes or of multiple species simultaneously (Evans et al., 2012). Transcriptomics 
has also been used in combination with both metabolomics and lipidomics to 
characterise metabolites and gene expression influencing lipogenesis (Batushansky et 
al., 2014; Caesar et al., 2010).  
1.3.2.2 Small RNA sequencing 
In recent years, transcriptomics has become increasingly useful in the investigation of 
small, noncoding RNAs, such as miRNAs, PIWI interacting RNAs (piRNAs) and small 
nucleolar RNAs (snoRNAs), as modified library preparation protocols have been 
developed to allow the specific sequencing of small RNAs. Small RNA sequencing was 
first described in two studies published in 2006, using pyrosequencing technology 
(Rajagopalan et al., 2006; Ruby et al., 2006). In the first of these investigations, 
340,114 unique small RNA sequences were found in Arabidopsis thaliana, most of 
which had high similarity to siRNA sequences found in other organisms, as indicated by 
their presence in intergenic regions and their ~22 nt length (Rajagopalan et al., 2006). 
In addition, 38 confirmed novel A. thaliana miRNAs were discovered, with many more 
candidate miRNAs also observed. In the second study, a set of novel nematode specific 
small RNAs known as 21U-RNAs were discovered in Caenorhabditis elegans, as well as 
18 novel miRNAs and numerous uncharacterised siRNAs (Ruby et al., 2006). More 
recently, the development of short read sequencing platforms with higher throughput 
has aided the discovery of ever increasing numbers of small RNAs and small RNA 
classifications. It is important to note, however, that small RNA sequencing is unable to 
provide absolute expression data, and this is believed to be due to biases during 
sample preparation or during the sequencing reaction (Kawaji and Hayashizaki, 2008; 
Linsen et al., 2009). 
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Figure 1.21: Mechanism of Solexa/Illumina short read sequencing platforms. 
i. cDNA samples are generated and different adaptor sequences are bound at both ends of each cDNA. 
ii. Adaptor ligated cDNAs are then randomly attached to the surface of a flow cell, which presents 
numerous complementary adaptor sequences. iii. The unbound adaptor associates with its 
complementary sequence on the flow cell, and the bound adaptor acts as a primer for DNA synthesis 
across the newly formed bridge. iv. Following full strand synthesis, the double stranded DNA product is 
denatured. v. Sequencing begins by flowing primers, labelled bases and DNA polymerase across the flow 
cell. vi. The identity of the first base is recorded and the block and fluorophore are removed from the 
base. vii. This process is repeated until the full fragment sequence has been recorded. Adapted from 
(Mardis, 2008). 
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1.4 Thesis aims 
Previous work in the Whitehouse laboratory and many other laboratories around the 
world has shown that high throughput, high resolution “omics” techniques can 
uncover novel interactions between viruses and the host cell. Proteomics and 
mRNA/miRNA sequencing based transcriptomics have all been used to great effect 
individually, and especially when used in combination with each other. 
The initial aim of this thesis was to use a combination of subcellular fractionation and 
SILAC based proteomics to uncover novel interactions between KSHV and host cell 
proteins, occurring in subnuclear organelles. Chapter 3 identifies a novel interaction 
between KSHV ORF57 and the cellular mRNA processing/DNA damage factor, Prp19. 
Interestingly, this interaction does not appear to directly contribute to the previously 
observed interactions between KSHV proteins and the mRNA processing pathway. 
Instead, ORF57 limits the effectiveness of the ATR-Chk1 driven DNA damage response 
pathway, colocalising with numerous proteins involved in this pathway, including 
Prp19, at probable sites of DNA damage, ultimately preventing downstream pathway 
activation via an unknown mechanism. 
Chapter 4 investigates host miRNA dysregulation during KSHV lytic replication using 
miRNA sequencing. 19 differentially expressed miRNAs are detected at different times 
post lytic reactivation in KSHV-infected cells. Upregulation of miR-151a-5p and miR-
365a-3p occurs in multiple KSHV infected cell lines, at different times during lytic 
replication, but does not appear to reflect a host driven response against the virus, as 
neither viral RNA or protein production are targeted by either of these miRNAs. 
Instead, it seems more likely that the virus promotes the upregulation of these miRNAs 
for pro-viral mechanisms, as inhibition of miRNA activity, particularly that of miR-365a-
3p, corresponds with a block in a viral process prior to viral egress. 
Finally, chapter 5 described the identification of host mRNAs targeted by the 
upregulated miR-365a-3p late in the KSHV lytic cycle. Utilising a combination of mRNA 
sequencing and open source host miRNA target prediction software, numerous cellular 
transcripts were identified as potential targets of miR-151a-5p or miR-365a-3p and 
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observed to decrease in abundance over the course of KSHV lytic replication. 
Transcripts of both DOCK5 and PRUNE2, predicted miR-365a-3p targets, are observed 
to be stabilised at 18 hours into KSHV lytic replication in the presence of a miR-365a-3p 
inhibitor. The overexpression of DOCK5 is subsequently investigated, ultimately 
demonstrating a similar effect as miR-365a-3p inhibition on a viral process following 
DNA replication but prior to viral egress. 
In summary, these findings shed light on multiple cellular pathways exploited by KSHV 
during lytic replication. The increased understanding of these interactions may present 
novel drug targets for the prevention of KSHV associated malignancies, as well as other 
herpesviruses. In addition, research into oncogenic pathogens may concomitantly help 
in the understanding of mechanisms associated with other cancers. Moreover, the 
datasets generated by the three high throughput, high resolution technologies used in 
this thesis will become an invaluable resource for future investigations into 
interactions between KSHV and the host cell. 
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2 Materials and methods 
2.1  Materials 
2.1.1 Chemicals 
Unless stated otherwise, chemicals were obtained from Sigma Aldrich®, Invitrogen™, 
VWR International Inc., or Merck Chemicals Ltd.  Sterilisation was achieved by 
autoclaving (121oc, 30 minutes, 15 psi) or sterile filtration (0.22 µm filters, Millipore). 
2.1.2 Enzymes 
Enzymes were obtained as indicated in Table 2.1. 
Table 2.1: List of enzymes and suppliers. 
Enzyme Supplier 
Taq DNA Polymerase Invitrogen™ 
RNase A Fermentas 
DNase I Invitrogen™ 
Protoscript II Reverse Transcriptase Invitrogen™ 
2.1.3 Antibodies 
Specific antibodies were obtained from sources indicated in Table 2.2. Secondary Goat 
antibodies specifically targeting Mouse or Rabbit primary antibodies, conjugated with 
Horse Radish Peroxidase for immunoblotting were obtained from DAKO. Secondary 
Rabbit antibody specifically targeting Sheep primary antibody, conjugated with Horse 
Radish Peroxidase for immunoblotting was obtained from Santa Cruz Biotech®. 
Secondary antibodies for immunofluorescence microscopy conjugated to Alexa488, 
Alexa546 and Alexa633 were obtained from Invitrogen™. 
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Table 2.2: List of antibodies and suppliers. 
Target Catalogue # Species Supplier 
B23 sc-47725 Mouse Santa Cruz Biotech® 
C23 sc-55486 Mouse Santa Cruz Biotech® 
CDC5L A301-682A Rabbit Bethyl Laboratories, Inc. 
ORF57 sc-135746 Mouse Santa Cruz Biotech® 
p53 (phos.S15) #9284P Rabbit Cell Signaling Technology, Inc. 
GFP 632381 Mouse Clontech Laboratories, Inc. 
HA H9658 Mouse Sigma-Aldrich® 
SC-35 S4045 Mouse Sigma-Aldrich® 
GAPDH ab8245 Mouse Abam® 
LaminB1 ab16048 Rabbit Abcam® 
Prp19 A300-101A Rabbit Bethyl Laboratories, Inc. 
Minor Capsid Protein F110P Sheep 2B Scientific Ltd. 
RPA p34 R1280 Mouse Sigma-Aldrich® 
RPA (phos.T21) ab109394 Rabbit Abcam® 
ATRIP A300-095A Rabbit Bethyl Laboratories, Inc. 
Nup414 ab24609 Mouse Abcam® 
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2.1.4 Oligonucleotides 
Oligonucleotides were purchased from IDT, Universal Probe Library Probe 21 was 
purchased from Roche. Oligonucleotides used in this work are listed in Table 2.3.  
Table 2.3: List of primer names and sequences. 
Primer name Sequence (5’-3’) 
GAPDH Fw AGGGTCATCATCTCTGCCCCCTC 
GAPDH Rv TGTGGTCATGAGTCCTTCCACGAT 
K8 Fw CCACCAAGAGGACCACACATTC 
K8 Rv CACACAAAGTCTGGCATGGTTCTC 
ORF47 Fw CGCGGTCGTTCGAAGATTGGG 
ORF47 Rv CGAGTCTGACTTCCGCTAACA 
ORF57 Fw GCCATAATCAAGCGTACTGG 
ORF57 Rv GCAGACAAATATTGCGGTGT 
ABI3 Fw GCATATGGAGAAGGTGGCCC 
ABI3 Rv GGTAGGTTCTCTGGGGCGAT 
5s rRNA Fw TACGGCCATACCACCCTGAA 
5s rRNA Rv GCGGTCTCCCATCCAAGTAC 
18s rRNA Fw GTAACCCGTTGAACCCCATT 
18s rRNA Rv CCATCCAATCGGTAGTAGCG 
DSP Fw GCTGGCAAAGGTAAGAAACCAC 
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DSP Rv TGCATGGATATCTCCTTGATGGTG 
FAM9C Fw GGACAGTCCGTGAGGGGGAG 
FAM9C Rv CTCGCTGATTGGTCGGCCC 
SPINK2 Fw GTTACTGGCGGTTCCCCAGAG 
SPINK2 Rv CTGAGAGCAGTTTGGCGTTCTAT 
HSPA8 Fw GCTGGTGGGAGAAGTAGGCT 
HSPA8 Rv ACAATGCTCTGAAGGGCAACT 
SLC15A4 Fw GCGCCGACCAGGTTAAAGAT 
SLC15A4 Rv GGCAATGCCACCTAACGACA 
HOXA3 Fw CAGCTCATGAAACGGTCTGCG 
HOXA3 Rv AGGGGTTTGACACCCGTGA 
ZNF512 Fw TCTTCCAGACTCGGTGCTGT 
ZNF512 Rv CAGTGCAAAGGCGGGTAACA 
DOCK5 Fw ATCGGCTATCACCATTTCACGG 
DOCK5 Rv AACGATGGGGAGCTTAGGGT 
PRUNE2 Fw GACAACCGGCTTTGGAGGAC 
PRUNE2 Rv CCTCCGTGAGAAATGACTCTCC 
FMN2 Fw ACAGGCTCGAGGATGCTGAA 
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FMN2 Rv TCAACAACTTCCTTCTGGACAGC 
SGK1 Fw ACGGTGAAAACTGAGGCTGC 
SGK1 Rv TCAGACCCATCCTCCTCTGC 
vIL-6 Fw GGCATCTGCAAGGGTATTCT 
vIL-6 Rv AAATCCTATTAACCCGCAGTGAT 
IL-6 Fw TCTGCGCAGCTTTAAGGAGT 
IL-6 Rv GACCAGAAGAAGGAATGCCCA 
ORF74 Fw ATATGAGCGGATATGACTACTCTGG 
ORF74 Rv TCATCTCACACACGCTCACTT 
PAN Fw TTTTCCAGTGTAAGCAAGTCGATTT 
PAN Rv TGTTCTTACACGACTTTGAAACTTCTG 
K12 Fw AACAGACAAACGAGTGGTGGTATC 
K12 Rv CAGTTCATGTCCCGGATGTG 
hsa-miR-151a-5p RT Stem Loop GTTGGCTCTGGTGCAGGGTCCGAGGTATTCGCACCAGAG
CCAACACTAGA 
hsa-miR-151a-5p Fw GTGTGGAGTGTGACAATGG 
Universal Reverse GTGCAGGGTCCGAGGT 
hsa-miR-365a-3p RT Stem Loop GTTGGCTCTGGTGCAGGGTCCGAGGTATTCGCACCAGAG
CCAACATAAGG 
66 
 
hsa-miR-365a-3p Fw GTTGGGTAATGCCCCTAAAAAT 
Universal Probe Library Probe 21 TGGCTCTG 
2.1.5 Mammalian cell culture reagents 
Tissue culture media, FCS, Glutamate and Lipofectamine® 2000 were purchased from 
Invitrogen®. SILAC labelling media and FCS were obtained from Dundee Cell Products. 
2.1.6 Plasmid constructs 
pPRP19-HA expressing PRP19 as a HA fusion protein and pPRP19-Myc expressing 
PRP19 as a Myc fusion protein were kindly provided by Dr. Marko Noerenberg 
(Whitehouse Laboratory). 
pORF57-EGFP expressing ORF57 as an EGFP fusion protein, pEGFP-N1 and  pORF47 
expression constructs were kindly provided by Dr. Brian Jackson (Whitehouse 
Laboratory). 
pDOCK5-GFP expressing DOCK5 as a GFP fusion protein was kindly provided by Dr. 
Matthew Sanders (Wayne State University). 
2.1.7 siRNAs and miRIDIAN miRNA Hairpin Inhibitors 
All siRNAs and miRIDIANs were purchased from Dharmacon (GE Life Sciences). siRNAs 
and miRIDIANs used in this work are listed in Table 2.4. 
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Table 2.4: List of siRNAs and miRIDIAN microRNA inhibitors. 
siRNA/miRIDIAN Catalogue # 
CDC5L M-011237-00-0005 
Prp19 M-004688-02-0005 
hsa-mir-151a-5p IH-301086-02-0002 
hsa-mir-365a-3p IH-300666-05-0002 
2.2  Methods 
2.2.1 Mammalian cell culture 
2.2.1.1 Routine maintenance 
Cells were grown in a humidified atmosphere with 5% CO2. HEK 293T, 293T rKSHV.219 
and iSLK.219 cells were cultured in DMEM high glucose supplemented with 10% heat 
inactivated FCS. Prior to use, FCS was heat inactivated for 30 minutes at 50oC. HEK 
293T and 293T rKSHV.219 cells were usually split 1:20 every 3 days. HEK 293 derived 
cells were split by “shake off” method and an aliquot diluted into fresh media. KSHV 
lytic cycle was induced in 293T rKSHV.219 cells by supplementing media with 3 mM 
sodium butyrate and 20 ng/ml TPA (12-O-tetradecanoylphorbol-13-acetate). TREx 
BCBL1-Rta cells were cultured in RPMI1640 supplemented with 10% heat inactivated 
FCS. TREx BCBL1-Rta cells are grown as a suspension culture and were diluted into 
fresh media for passaging. KSHV lytic cycle was induced in TREx BCBL1-Rta cells by 
supplementing media with 2 µg/ml doxycycline hyclate. 
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2.2.1.2 Transient transfection 
Cells were transfected using Lipofectamine® 2000, according to manufacturer’s 
recommendation. In short, 100 µl Opti-MEM was mixed with 3 µl Lipofectamine 2000 
and 100 µl Opti-MEM was mixed with 1 µg plasmid DNA per 35mm dish (10 cm2) for 15 
minutes. The solutions were then combined for 15 minutes, after which they were 
pipetted into the 35mm dish containing cells to be transfected, and mixed by gentle 
agitation. Transfection media was replaced 4 hours post transfection. Experiments 
were conducted 24 hours post transfection unless otherwise stated. 
2.2.1.3 Long term storage of mammalian cells 
Approximately 2 x 106 cells were harvested before reaching confluency, washed in PBS 
and resuspended in freeze down media (10% DMSO, 20% FCS, 70% DMEM). Cells were 
frozen in cryotube vials inside a 5100 Cryo 1oC freezing container (NALGENE®) at -80oc 
overnight, before being transferred to liquid nitrogen for long term storage. 
2.2.1.4 Immunofluorescence confocal microscopy analysis 
HEK 293Tor 293T rKSHV.219 cells were grown on poly-L-lysine coated coverslips for 24 
hours before transfection. Transfections were performed as described in Section 
2.2.1.2. Cells were fixed for 15 minutes with 4% paraformaldehyde in PBS. Cells were 
then washed three times with PBS, permeabilised with 1% Triton X-100 in PBS, washed 
three times with PBS, blocked with 10% BSA in PBS and incubated with primary 
antibodies diluted 1:100 in 10% BSA in PBS for 1 hour at 37oc. Cells were then washed 
five times in PBS and then incubated with secondary antibodies conjugated with 
fluorophores diluted 1:500 in 10% BSA in PBS for 1 hour at 37oc. Cells were mounted 
on to slides with VectaShield mounting media containing DAPI (Vector). Images were 
taken with an Upright Zeiss LSM 510 (Carl Zeiss Ltd, Welwyn Garden City; UK) and 
analysed with Zen 2011 image browser. 
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2.2.1.5 siRNA/miRIDIAN transfection 
Cells were transfected using Lipofectamine 2000, according to manufacturer’s 
recommendation, with the following modifications: a 100 nM final concentration 
siRNA/miRIDIAN was used, and transfection was performed whilst cells were 30-50% 
confluent. Transfection media was replaced 4 hours post transfection. Cells were then 
transfected again 24 hours post initial transfection. Transfection media was replaced 4 
hours post transfection. Experiments were conducted 48 hours post second 
transfection unless otherwise stated. 
2.2.2 Protein analysis 
2.2.2.1 SDS-Polyacrylamide gel electrophoresis 
Protein samples were separated by migration through a Sodium dodecyl sulphate 
polyacrylamide gel. Protein samples were mixed 1:1 in 2 x Laemmli loading buffer (50 
mM Tris-HCl [pH 6.8], 2% [w/v] SDS, 20% [v/v] Glycerol, 50 µg/ml bromophenol blue, 
10 mM DTT) and subsequently incubated at 95oC for 5 minutes. Typically, 10% 
polyacrylamide gels were cast containing 10% (v/v) Acrylamide/bis-acrylamide 37:5:1 
(Severn Biotech Ltd.), 375 mM Tris-HCl (pH 8.8), 0.1% (w/v) SDS, 0.1% (w/v) APS, 0.1% 
(v/v) TEMED, overlaid with 5% stacking gels containing 5% (v/v) Acrylamide/bis-
acrylamide 37:5:1, 125 mM Tris-HCl (pH 6.8), 0.1% (w/v) SDS, 0.1% (w/v) APS, 0.1% 
(v/v) TEMED. Gels were placed in 1x Tris-Glycine buffer (5 mM Tris, 250mM Glycine, 
0.1% [w/v] SDS) and protein samples were separated by electrophoresis at 180 V until 
sufficient separation was achieved. Following electrophoresis, gels were either used 
for immunoblotting, silver stain or Coomassie stain analysis. 
2.2.2.2 Immunoblot analysis 
Protein samples were separated by SDS-PAGE and blotted onto Hybond™-C 
(Amersham – GE Healthcare). Blots were blocked with 3% non-fat Marvel milk in TBS-T 
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(150 mM NaCl, 50 mM Tris-HCl [pH 7.5], 1% Tween 20) for 1 hour and incubated with 
primary antibodies diluted 1:500-1:10,000 in 3% non-fat Marvel milk TBS-T for 1 hour 
at room temperature. Blots were washed five times in TBS-T for 10 minutes and 
incubated with HRP conjugated secondary antibodies diluted 1:500 in 3% non-fat 
Marvel milk TBS-T for 1 hour at room temperature. Blots were then washed five times 
in TBS-T for 10 minutes, and then incubated with EZ-ECL substrate (Geneflow) and 
visualised on Hyperfilm® ECL (Amersham). 
2.2.2.3 Coomassie staining of SDS-Polyacrylamide gels 
Following SDS-PAGE separation, proteins were visualised by incubating the 
polyacrylamide gel in Coomassie staining solution (30% [v/v] methanol, 10% [v/v] 
acetic acid, 0.2% [w/v] Coomassie blue G) for 30 minutes. Stained gels were then 
incubated in destaining solution (25% [v/v] methanol, 10% [v/v] acetic acid) until a 
sufficient signal to background ratio was achieved. 
2.2.2.4 Silver staining of SDS-Polyacrylamide gels 
Following SDS-PAGE separation, proteins were visualised by fixing the polyacrylamide 
gel in buffer A (50% [v/v] ethanol, 10% [v/v] acetic acid) for 30 minutes and then 
incubating the fixed gel in buffer B (5% [v/v] ethanol, 1% [v/v] acetic acid for 15 
minutes. Gel was then washed three times in dH2O and incubated in buffer C (0.02% 
[w/v] Na2S2O3) for 2 minutes. Gels were then washed 3 x in dH2O and incubated in 
buffer D (0.2% [w/v] AgNO3, 0.075% [v/v] formaldehyde) for 20 minutes in the absence 
of light. Gels were then washed three times in dH2O before being developed in buffer E 
(6% [w/v] Na2CO3, 0.05% Formaldehyde, 0.0004% [w/v] Na2S2O3). When bands were 
sufficiently visible, developing was stopped by the addition of buffer F (5% [v/v] acetic 
acid). 
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2.2.2.5 Preparation of subnuclear fractions for SILAC analysis 
TREx BCBL1-Rta cells were grown in either light media (DMEM-14, Dundee Cell 
Products) or media containing the heavy isotopes of arginine and lysine (DMEM-16, 
Dundee Cell Products) supplemented with 10% SILAC dialysed FCS (DS1003, Dundee 
Cell Products) for 5 passages prior to experiments to ensure complete labelling of 
proteins. Roughly 2 x 108 cells per condition were used as starting material. Cells 
grown in heavy media were induced for KSHV lytic cycle by the addition of doxycycline 
(2 µg/ml) for 8, 16 or 24 hours prior to fractionation. Cells grown in light media were 
not induced for KSHV lytic cycle, and served as a latent KSHV control. Cellular 
fractionation was performed according to a protocol published by the Lamond 
laboratory (Lam et al., 2010), with minor modifications of the removal of MgCl2 in 
buffers S2 and S3, as well as increased sonication cycles as described below. Cells were 
pelleted by centrifugation and washed with PBS, then pelleted and resuspended in 5ml 
ice cold swelling buffer (buffer A: 10 mM HEPES, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM 
DTT, 1 x Complete Protease Inhibitor cocktail) and incubated for 20 minutes on ice. All 
steps from this point were carried out on ice and samples examined under a light 
microscope after each step. Cells were lysed by 25 strokes with a Dounce homogeniser 
using a tight pestle. Lysate was clarified by centrifugation at 230 x g at 4oC for 5 
minutes. Supernatant was retained as the cytoplasmic fraction for subsequent 
immunoblot and silver stain analysis. The nuclear pellet was resuspended in 3ml buffer 
S1 (0.25 mM Sucrose, 1 x Complete Protease Inhibitor cocktail, 1.5 mM MgCl2) and 
layered over buffer S2 (0.35 mM Sucrose, 1 x Complete Protease Inhibitor cocktail) 
prior to centrifugation at 1,400 x g at 4oC. The pellet was resuspended in buffer S2 and 
sonicated for 25 cycles with a Soniprep 150 (MSE) at an amplitude of 10 µm for 10 
seconds with 10 seconds pause to prevent overheating of the sample. In addition, 
samples were returned to ice for 5 minutes after every 5 cycles to prevent 
overheating. The sonicated samples were layered over a cushion of buffer S3 (0.88 mM 
Sucrose, 1 x Complete Protease Inhibitor cocktail) and subnuclear fractions were 
pelleted by centrifugation at 2,800 x g for 10 minutes at 4oC. The pellet was further 
enriched by resuspension in buffer S2 and a second centrifugation through a cushion 
of buffer S3.  Fractions were aliquoted to prevent repeated freeze-thaw cycles and 
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stored at -80oC. Successful fractionation was confirmed by SDS-PAGE and subsequent 
silver stain or immunoblot using antibodies specific to cytoplasmic, nucleoplasmic and 
nucleolar marker proteins. 
2.2.2.6 GFP-Trap® immunoprecipitation assays 
GFP and GFP fusion ORF57 proteins were expressed by transient transfection in HEK 
293T cells, as described in Section 2.2.1.2. 24 hours post transfection cells were 
washed in PBS and lysed by resuspension in ice cold modified RIPA buffer (150 mM 
NaCl, 50 mM Tris-HCl [pH 7.5], 1% NP-40 Alternative) for 20 minutes on ice with 
frequent gentle agitation. Lysates were clarified by centrifugation at 12,000 x g at 4oC 
for 10 minutes and pellets were discarded. An aliquot of the supernatant was retained 
and mixed 1:1 with 2 x Laemmli loading buffer as an input sample. The supernatant 
was precleared by incubation with 20 µl bab20 blank beads (Chromotek, GmbH) which 
were washed three times before use in PBS, prior to use, for 1 hour at 4oc with gentle 
agitation. Beads were then removed by centrifugation at 12,000 x g for 5 minutes at 
4oC. The supernatant was then incubated with 1 x RNase A (Fermentas) and 20 µl GFP-
TRAP beads (Chromotek, GmbH) which were washed three times in PBS, prior to use, 
for 1 hour at 4oC with gentle agitation. Beads were pelleted by centrifugation at 500 x 
g for 10 minutes at 4oC and washed 3 x in PBS and once in modified RIPA buffer. 
Pelleted beads were then mixed with 50 µl Laemmli loading buffer. Resuspended 
beads and associated proteins, as well as input samples were analysed by SDS-PAGE 
and immunoblotting as described in Sections 2.2.2.1 and 2.2.2.2. 
2.2.3 RNA analysis 
2.2.3.1 RNA isolation 
1 x 106 cells were washed once with PBS before RNA isolation was performed using 
TRIzol (Invitrogen™) reagent according to manufacturer’s instructions. In short, 500 µl 
TRIzol was added to the cell pellets and incubated for 5 minutes at room temperature. 
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100 µl chloroform was then added to the samples and vortexed. Phase separation was 
achieved by centrifugation at 4oC for 15 minutes at 12,000 x g. The upper aqueous 
phase was then removed and mixed with 250 µl isopropanol to precipitate RNA, which 
was pelleted by centrifugation at 4oC for 10 minutes at 12,000 x g. Pelleted RNA was 
washed with 75% ethanol and allowed to air dry, before being solubilised in 50 µl 
nuclease free water (Sigma-Aldrich®). 
2.2.3.2 Preparation of miRNA sequencing library 
Changes in abundance of cellular miRNAs were analysed using miRNA sequencing. 
KSHV lytic replication was induced in 1 x 107 TREx BCBL1-Rta cells with for 8 or 18 
hours, or left uninduced (latent KSHV control) prior to RNA isolation (as described in 
Section 2.2.3.1). Total RNA was then treated with DNA-free (Ambion™), run on an 
Agilent Technologies 2100 Bioanalyzer to calculate a RIN number for each sample and 
5 µg of total RNA from each sample was used to generate miRNA sequencing libraries 
using NEBNext Multiplex Small RNA Library Prep Set for Illumina (New England Biolabs, 
Inc.) according to manufacturer’s instructions. In short, 3’ SR adaptors were ligated 
onto RNA molecules present in the samples using T4 RNA Ligase 1 before excess 3’ SR 
adaptors were hybridised to SR RT primer to prevent adaptor-dimer formation. 5’ SR 
adaptors were then ligated on to the RNA molecules present in the samples and 
adaptor ligated RNAs were reverse transcribed using an adaptor specific primer. PCR 
amplification was then performed for 12 cycles using LongAmp Taq polymerase with 
an SR primer, as well as a different index primer for each sample to ensure that 
samples could be differentiated after sequencing. Samples were checked using an 
Agilent Bioanalyzer to assess whether adaptor-dimers (represented by a 127 bp peak) 
or excess primers (represented by a 70-80 bp peak) were present in the sample. 
AMPure XP beads were then used to specifically select and purify small RNAs from the 
samples. Final libraries were analysed using an Agilent Technologies 2100 Bioanalyzer 
to assess the purity of adaptor ligated small RNAs (represented by a 150 bp peak). 
Small RNA libraries were subsequently sequenced using a HiSeq (Illumina, Inc.) 
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sequencing platform. Reads were aligned to known Homo sapiens miRNA sequences 
and read counts were normalised using SeqEM and edgeR bioinformatic algorithms. 
2.2.3.3 Preparation of mRNA sequencing library 
Changes in abundance of cellular mRNAs were analysed using mRNA sequencing. 1 x 
107 TREx BCBL1-Rta cells were induced for KSHV lytic cycle with doxycycline hyclate (2 
µg/ml) for 8 or 18 hours, or left uninduced (latent KSHV control) prior to RNA isolation 
using Trizol reagent as described in Section 2.2.3.1. Total RNA was then treated with 
DNA free (Ambion), run on an Agilent Technologies 2100 Bioanalyzer to calculate a RIN 
number for each sample and 2 µg of total RNA from each sample was used to generate 
mRNA sequencing libraries using an Illumina TruSeq Stranded mRNA Sample Prep Kit 
(Illumina) according to manufacturer’s instructions. In short, polyadenylated mRNAs 
were purified from total RNA samples with poly-T oligomers conjugated to magnetic 
beads during 2 rounds of purification. mRNAs were then fragmented and first strand 
cDNA was synthesised by SuperScript II Reverse transcriptase (using random 
hexamers). Actinomycin D was added to prevent spurious DNA dependent DNA 
synthesis, while allowing RNA dependent synthesis to occur, improving strand 
specificity. Blunt ended cDNA was then generated with the synthesis of the second 
strand using dUTP in place of dTTP in order to quench the second strand during 
amplification, as the polymerase does not incorporate past this nucleotide. A single 
Adenine residue was then ligated to the 3’ ends of the blunt ended cDNA molecules to 
prevent them ligating together during adaptor ligation. 3’ adaptors containing multiple 
index sequences for each sample were then ligated on to the cDNA molecules using a 
single Thymine overhang. 5’ adaptors were also ligated during this step. 15 cycles of 
PCR were then performed to specifically enrich the DNA fragments ligated to adaptors 
at both ends, by using primers specific to the adaptors. Libraries were then analysed 
using an Agilent Technologies 2100 Bioanalyzer to assess the purity of adaptor ligated 
cDNAs generated from mRNAs in the original sample (represented by a peak at 
approximately 260 bp). Libraries were sequenced using a HiSeq (Illumina, Inc.) 
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sequencing platform. Reads were aligned to the Homo sapiens genome using the 
Burrows-Wheeler Transform method.   
2.2.3.4 Reverse transcription 
1 x 106 cells were washed once with PBS before RNA isolation was performed using 
TRIzol reagent as described in Section 2.2.3.1. For this, total RNA was then treated with 
DNA-free™ (Ambion®) according to the manufacturer’s instructions. In short, 16 µl 
RNA sample was mixed with 1 µl DNase I and 2 µl reaction buffer and incubated at 
37oC for 30 minutes. The reaction was then stopped using the supplied stop beads at 
room temperature for 2 minutes before the sample was separated by centrifugation at 
10,000 x g for 2 minutes and 20 µl supernatant was removed. 250 ng (measured by 
NanoDrop ND-1000 [NanoDrop Technologies] spectrophotometer) of this RNA was 
reverse transcribed with Protoscript II Reverse Transcriptase (Invitrogen™) according 
to the manufacturer’s instructions. In short, 10 µl RNA (0.5 µg total amount) was mixed 
with 1 µl oligo-dT primer and 1 µl 10mM dNTP mix and incubated at 65oC for 5 
minutes, then placed on ice. A reaction mixture consisting of 4 µl reaction buffer, 2 µl 
DTT, 1 µl RNase OUT (Invitrogen ™) and 1 µl Protoscript II reverse transcriptase was 
then added to each sample, mixed and incubated at 42oC for 50 minutes. The reaction 
was then stopped by incubating at 70oC for 15 minutes. Changes in transcript 
abundance of either endogenous mRNAs or transfected constructs were analysed 
using qPCR.  
2.2.3.5 ORF57 mRNA export activity assay 
Export assays were performed as described previously (Boyne et al., 2008). HEK 293T 
cells were transfected without DNA (mock) or with a Prp19-HA expression construct as 
described in Section 2.2.1.2. Alternatively, cells were transfected with scramble siRNA 
(control), Prp19 specific siRNA or CDC5L siRNA or cotransfected with a mixture of both 
Prp19 and CDC5L specific siRNAs as described in Section 2.2.1.5. HEK 293T cells were 
then cotransfected with 1 µg ORF47 expression construct and 1 µg ORF57-EGFP or 
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EGFP-N1 expression constructs per 35mm dish (10 cm2). 24 hours post transfection 
cells were washed in PBS and incubated in 1% Triton X-100 in PBS supplemented with 
40 U/ml RNaseOUT (Invitrogen™) for 10 minutes on ice. Fractions were separated by 
centrifugation at 500 x g for 5 minutes at 4oC. RNA extraction was then performed on 
both cytoplasmic and nuclear fractions as described in Section 2.2.3.1. RT and qPCR 
were performed as described in Sections 2.2.3.4 and 2.2.4.1, using primers specific to 
GAPDH and ORF47. 
2.2.3.6 Splicing assay 
293T rKSHV.219 cells were transfected with plasmid DNA as described in Section 
2.2.1.2 or with siRNA as described in Section 2.2.1.5. 24 hours following transfection, 
cells were washed in PBS and pelleted by centrifugation. The pellet was resuspended 
in TRIzol reagent and total RNA was extracted as described in Section 2.2.3.1. Total 
RNA was then DNase treated and reverse transcribed as described in section 2.2.3.4. 
PCR was then performed using Taq DNA Polymerase (Invitrogen™) according to 
manufacturer’s instructions using primers flanking the inner exons of KSHV K8, as well 
as primers specific to GAPDH. PCR products were mixed 1:10 with 10x loading dye 
(0.25% (w/v) Orange G, 30% (v/v) glycerol) and were separated by size using horizontal 
gel electrophoresis in a gel containing 1% Agarose in 1 x TBE buffer (90 mM Tris-base, 2 
mM EDTA, 80 mM boric acid) prestained with 0.5 µg/ml ethidium bromide. Gel 
electrophoresis was performed at 100 V until sufficient separation was achieved.  
Invitrogen™ 1Kb Plus DNA Ladder was used to estimate product size. DNA bands were 
visualised in a GeneGenius bio-imaging system (Syngene) under ultra-violet light.  
2.2.3.7 miRNA stem loop based qRT-PCR 
Changes in abundance of either endogenous cellular miRNAs were analysed using 
Stem Loop based qRT-PCR. 1 x 106 cells were washed once with PBS before RNA 
isolation was performed as described in Section 2.2.3.1. Total RNA was then treated 
with DNase as described in Section 2.2.3.4 and 10 ng RNA was reverse transcribed 
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using miRNA specific Stem Loop RT primers and TaqMan MicroRNA Reverse 
Transcription Kit (Applied Biosystems) according to the manufacturer’s instructions. 
Briefly, 3 µl 5 x stem loop RT primer was added to each 5 µl RNA sample and incubated 
at 85oC for 5 minutes, followed by 60oC for 5 minutes, then placed on ice. 7 µl reaction 
mix consisting of 0.15 µl 100 mM dNTP mix, 1 µl MultiScribe™ Reverse Transcriptase, 
1.5 µl 10 x reverse transcription buffer, 0.19 µl (final concentration of 20 U/µl) RNase 
inhibitor and 4.16 µl nuclease free water was then added to each sample. The reaction 
was incubated at 16oC for 30 minutes, followed by 42oC for 30 minutes, and was then 
stopped by incubation at 85oC for 5 minutes. qPCR was then performed using 2 ng 
cDNA (in 5 µl) with 10 µl LightCycler 480 Probes Master Mix (Roche), 0.4 µl Universal 
Probe Library Probe #21 (Roche), 1.2 µl 10 µM miRNA and stem loop specific primer 
mix and 3.4 µl nuclease free water on a Corbett Rotor Gene 6000 5 Plex with a 3 step 
PCR (15 seconds denaturation at 95oC, 55 seconds annealing at 60oC, 5 seconds 
elongation at 72oC). Data were analysed with RotorGene 6000 series software version 
1.7, exported into Microsoft Excel and relative changes of the samples calculated. 
2.2.4 DNA analysis 
2.2.4.1 qPCR 
qPCR was performed using 10 ng cDNA or DNA (in a volume of 4 µl) with a reaction mix 
of 10 µl SensiMix™ Plus (Bioline), 1 µl 5mM gene specific primer mix and 5 µl nuclease 
free water on a Corbett Rotor Gene 6000 5 Plex (QIAGEN) with a 3 step PCR (15 
seconds denaturation at 95oC, 30 seconds annealing at 60oC, 20 seconds elongation at 
72oC). Data were analysed with Rotor-Gene 6000 series software version 1.7, exported 
into Microsoft Excel and relative changes of the samples calculated using the ΔΔCT 
method. For this, all samples were normalised against the housekeeping gene GAPDH 
and quantified using comparative CT analysis unless otherwise stated. 
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2.2.4.2 Virus replication assay 
Changes in viral load were analysed using qPCR. 1 x 106 293T rKSHV.219 cells were 
transfected with miRIDIAN miRNA inhibitors as described in section 2.2.1.5 or plasmid 
DNA as described in section 2.2.1.2. Following transfection, cells were either treated 
with sodium butyrate and TPA to induce KSHV lytic replication or left untreated as 
latent controls. After 7 days, cells were harvested by centrifugation at 500 x g for 5 
minutes and DNA was extracted using a QIAGEN QIAamp DNA mini kit, according to 
manufacturer’s instructions. In short, cell pellets were resuspended in 200 µl PBS and 
20 µl Proteinase K was added to each sample. 200 µl buffer AL is then added to the 
samples, mixed and incubated at 56oC for 10 minutes to ensure cell lysis. 200 µl 100% 
ethanol was then added to each sample, mixed and each sample was added to a 
QIAamp Mini spin column and centrifugated at 6,000 x g. Flow through was discarded 
and DNA bound to each column was then washed with 500 µl buffer AW1 at 6,000 x g 
and flow through was discarded. A second wash step was performed with buffer AW2, 
followed by centrifugation at 6,000 x g and the flow through was discarded. Each spin 
column was then placed inside a 1.5 ml microcentrifuge tube and 150 µl nuclease free 
water (Sigma-Aldrich®) was added to each spin column and incubated for 2 minutes. 
The spin column was then centrifugated at 6,000 x g for 2 minutes to elute the DNA. 
qPCR was then performed as described in Section 2.2.4.1 using primers specific to 
ORF47 and GAPDH.  
2.2.4.3 Virus reinfection assay 
Changes in viral reinfection were analysed using qPCR. 1 x 106 293T rKSHV.219 cells 
were transfected with miRIDIAN miRNA inhibitors as described in section 2.2.1.5 or 
plasmid DNA as described in section 2.2.1.2. Following transfection, cells were either 
treated with sodium butyrate and TPA to induce KSHV lytic replication or untreated as 
latent controls. 7 days later, cells and media were harvested by centrifugation at 500 x 
g for 5 minutes. 1 ml supernatant containing mature virions was then used to infect 1 x 
106 naïve HEK 293T cells. DNA was extracted from these HEK 293T cells after 24 hours 
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using a QIAGEN QIAamp DNA mini kit, as described in Section 2.2.4.2. qPCR was then 
performed as described in Section 2.2.4.1 using primers specific to ORF47 and GAPDH. 
2.2.5 Molecular cloning 
2.2.5.1 Bacterial transformation 
Chemically competent E. coli DH5α were incubated with 1 ng plasmid DNA for 15 
minutes on ice and then “heat shocked” at 42oC for 45 seconds, before again being 
incubated on ice for 2 minutes. Cells were then precultured for 1 hour at 37oC in S.O.C. 
medium (0.5% [w/v] yeast extract, 2% [w/v] Tryptone, 10 mM NaCl, 2.5 mM KCl, 10 
mM MgCl2, 10 mM MgSO4, 20 mM Glucose) with gentle agitation before plating onto 
lysogeny broth (LB)-agar (1.5% [w/v] microagar in LB medium) plates with an 
appropriate antibiotic for selection (50 µg Ampicillin or Kanamycin). Single colonies 
were picked after 16 hours at 37oc for the subsequent inoculation of liquid culture. 
2.2.5.2 Large scale plasmid DNA purification 
Large scale purifications of plasmid DNA were performed with a QIAGEN Plasmid Maxi 
Kit according to the manufacturer’s recommendations. In brief, 100 ml overnight 
cultures of bacteria were grown at 37oC in LB media containing an appropriate 
antibiotic, pelleted by centrifugation and resuspended in 10 ml buffer P1. 10 ml lysis 
buffer P2 was then added and gently mixed by inversion of the sample tube. The 
solution was then incubated at room temperature for 5 minutes to allow alkaline lysis 
to occur. 10 ml buffer P3 was subsequently added, mixed and incubated on ice for 20 
minutes. The precipitate was removed by centrifugation at 4,500 x g for 30 minutes 
and the supernatant was allowed to flow through a pre-equilibrated QIAGEN-tip 500 
column by gravity flow. Columns were washed twice with 30 ml of wash buffer QC, and 
DNA was eluted with 15 ml elution buffer QF. Plasmid DNA was precipitated by the 
addition of 10.5 ml isopropanol and pelleted at 4,500 x g at 4oC for 30 minutes. The 
pelleted DNA was washed with 70% ethanol and allowed to air dry. DNA was 
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resuspended in 200 µl sterile, nuclease free water and the DNA concentration 
determined by absorption at λ=260 nm in a NanoDrop ND-1000 (NanoDrop 
Technologies) spectrophotometer. 
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CHAPTER 3 
~ 
ORF57 interacts with Prp19 to interrupt the cellular DNA damage 
response   
82 
 
3 ORF57 interacts with Prp19 to interrupt the cellular DNA damage 
response 
3.1 Introduction 
The KSHV lytic replication cycle, as with many herpesviruses, can be categorised by 
three stages of gene expression: immediate early, early and late (Sun et al., 1999). 
Immediately after gaining entry to the host cell nucleus, the KSHV RTA (ORF50) protein 
is able to drive the expression of its own gene and a number of viral genes such as 
ORF57 (MTA) (Sun et al., 1998; Lukac et al., 1998; Gradoville et al., 2000). These 
immediate early proteins then begin a cascade of gene activation, culminating in the 
production of viral proteins involved in DNA replication and viral structural proteins 
which subsequently lead to the biogenesis of mature viral progeny (Sun et al., 1999).  
ORF57 has been well characterised and associates with a large number of host cell 
proteins belonging to many distinct cellular biochemical pathways (Jackson et al., 
2012; Majerciak and Zheng, 2015). The most widely characterised interactions are 
between ORF57 and the host cell post-transcriptional mRNA processing machinery, of 
which there are three distinct subsets: capping, splicing and polyadenylation-
associated proteins (Rodríguez-Navarro and Hurt, 2011; Boyne et al., 2008; Majerciak 
et al., 2008; Jackson et al., 2012). As such, ORF57 has been shown to enhance nuclear 
stability, export and translation of viral intronless mRNAs, and to facilitate splicing of 
viral intron-containing mRNAs (Sahin et al., 2010; Boyne et al., 2008; Boyne et al., 
2010; Majerciak et al., 2008). Furthermore, ORF57 has been shown to interact with the 
nucleolar protein B23 and appears to localise primarily in the nucleolus using 
fluorescence microscopy analysis (Boyne and Whitehouse, 2006; Boyne and 
Whitehouse, 2009). 
The nucleolus is a tripartite, subnuclear structure that forms around ribosomal DNA 
loci, known as nucleolar organizing regions (NORs). It is involved in a number of host 
cell processes including ribosome biogenesis, cell cycle progression and regulation of 
the response to various types of cellular stress (Paniagua et al., 1986; Wachtler et al., 
1986; Boisvert et al., 2007). There are many examples of viruses from various 
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Baltimore classes, including viruses that replicate in the cytoplasm, which interact with 
the nucleolus in order to promote their own replication. This suggests that this 
subnuclear organelle is of particular importance during many viral replication cycles 
(Hiscox, 2002; Hiscox, 2007; Salvetti and Greco, 2014). The nucleolus can be purified 
from cells using a relatively straightforward fractionation protocol, enabling the use of 
modern mass spectrometry-based proteomic approaches to examine the nucleolar 
proteome at various stages of virus infection in an unbiased manner (Andersen et al., 
2002; Emmott et al., 2008; Lam et al., 2010). 
One such method is SILAC (stable isotope labelling with amino acids in cell culture), 
which can be coupled to LC-MS/MS in order to detect a large number of proteins 
present in multiple samples at the same time, and compare the relative amounts of 
these proteins between samples (Ong et al., 2002; Owen et al., 2014). This approach 
first requires the incorporation of different stable isotopes of amino acids into both 
the host cell and viral proteins. This is achieved by culturing cells in medium containing 
either the naturally occurring isotopes of these amino acids containing 12C and 1H (light 
medium), or amino acids containing heavy stable isotopes of these amino acids 
containing 13C and 2H. Arginine and lysine are the most commonly used amino acids for 
this labelling, ensuring each peptide fragment generated by tryptic digest before LC-
MS/MS will contain at least one labelled amino acid, allowing the identification of each 
peptide, and subsequent assignment of the protein. Two populations are split from an 
initial culture of cells and then grown for at least five passages in the presence of each 
medium. These two populations are then treated differently, for example either mock 
infected or infected with a virus. Proteins are then harvested from each population of 
cells using the same extraction protocol, before the samples are mixed in a 1:1 ratio 
and analysed by LC-MS/MS. Peptides from each sample may then be distinguished by 
the mass shift caused by the presence of the differentially weighted isotopes, and the 
relative quantities of each present in the initial sample will be directly correlated with 
the m/z peak intensity. This approach represents a reliable, quantifiable and unbiased 
method for the detection of changes in the abundance of a large number of proteins 
between any two proteomes. This approach and similar variants are now widely used 
in molecular biology-based studies, clearly demonstrating the potential to uncover 
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large numbers of protein alterations and interactions that had previously been 
unidentified and uncharacterised.  
In this chapter, SILAC-based quantitative proteomic approaches are employed to 
discover an interaction between the cellular mRNA splicing factor Prp19 and the viral 
ORF57 protein. Interestingly, this interaction does not appear to play a role in viral 
mRNA maturation or translation, but instead has implications for the ATR-Chk1 cellular 
DNA damage response pathway, of which Prp19 is an important early signalling factor. 
ORF57 limits the Prp19-mediated activation of the ATR-Chk1 pathway, and associates 
with Prp19, as well as ATRIP, another important factor in this pathway, in discrete 
nuclear foci, believed to be sites of damaged euchromatin.   
3.2 Subnuclear fractionation of differentially labelled cell populations 
In order to examine the interactions between KSHV and the proteomes of subnuclear 
organelles of infected host cells over the full course of the lytic replication cycle, four 
populations of TREx BCBL1-Rta cells harbouring a latent KSHV genome capable of being 
induced to initiate the lytic replication cascade with the addition of doxycycline hyclate 
(dox) were labelled with light or heavy SILAC medium for five passages (Nakamura et 
al., 2003). Cells grown in heavy medium were then reactivated for 8, 16 or 24 hours, 
whilst cells grown in light medium were kept under latent KSHV conditions (uninduced) 
(Fig. 3.1A). Subnuclear fractionation was then performed using a previously described 
protocol with modifications (Fig. 3.1B) (Andersen et al., 2002).  
Harvested proteins from each of the lytically infected populations were individually 
mixed at a 1:1 ratio with proteins from the latently infected control cells (protein ratios 
were judged using a combination of Coomassie/silver stain/immunoblot analysis (Fig. 
3.2) and Bio-Rad Bradford reagent based protein assay). Mixed samples were then 
sent for LC-MS/MS analysis at the University of Bristol Proteomics Facility. 
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Figure 3.1: Subnuclear fractionation of TREx BCBL 1-Rta cells.  
(a) Four populations of TREx BCBL1-Rta cells were split from a single population and each then grown in 
SILAC media containing different isotopes of the amino acids Arginine (R) and Lysine (K) (3 populations 
were grown in R10K8 media, one population was grown in R0K0 media). Each population was allowed to 
grow to ~90% of their maximum capacity before being passaged 5 times. KSHV lytic reactivation was 
then induced in cells grown in R10K8 media for 8, 16 or 24 hours, and all cells were then pelleted and 
individual populations were subjected to a fractionation procedure resulting in the isolation of enriched 
subnuclear body proteins. Reactivated samples were then mixed in a one to one protein ratio with the 
latent control sample, resulting in three samples; 0h + 8h, 0h + 16h and 0h + 24h. These samples were 
then sent for mass spectrometry analysis at the University of Bristol. (b) Microscope images taken 
during subnuclear fractionation of TREx BCBL1-Rta cells clearly showing cells at different stages of the 
protocol. (i) Cells were swollen in hypotonic buffer. (ii) Cells were passed through a dounce 
homogeniser, causing the swollen membrane to burst and releasing cytoplasmic debris and intact 
nuclei. Enriched nuclei were then obtained by centrifuging this material through a sucrose cushion. (iii) 
Enriched nuclear material was sonicated, bursting the nuclear membrane and releasing subnuclear 
bodies (nucleoli are clearly seen as bright puncta). (iv) Enrichment of subnuclear bodies was achieved by 
centrifugation of sonicate through a sucrose cushion. 
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Figure 3.2: Generation of SILAC enriched subnuclear body protein samples. 
(a) Cytoplasmic, nuclear and subnuclear fractions obtained from subnuclear fractionation were 
separated by SDS-PAGE and then analysed by silver stain to assess different protein band profiles.  (b) 
Fractions were also analysed by SDS-PAGE and immunoblots for protein markers for the cytoplasm 
(GAPDH), nuclear envelope (Lamin B), nucleolus (B23) and KSHV lytic infection (ORF57).  
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3.3 Bioinformatic analysis of proteomics data 
Metadata generated by LC-MS/MS analysis of subnuclear fractionation/SILAC samples, 
as well as previously generated data from subcellular fractionation (cytoplasmic, 
nuclear and nucleolar fractions)/SILAC and SILAC based immunoprecipitation of 
ORF57-GFP using GFP (additional SILAC experiments performed by Dr. Marko 
Noerenberg) as a control were analysed using DAVID bioinformatics (Huang et al., 
2007). This metadata approach, combining several datasets was used to increase the 
likelihood of discovering genuine KSHV/host cell protein interactions and also aiming 
to reduce the possibility of attempting to validate false positive results due to the 
imperfect nature of the fractionation protocol employed. As anticipated, bioinformatic 
analysis revealed a large number of proteins involved in mRNA maturation, as well as a 
previously characterised interaction between KSHV and the mRNA decay protein, Xrn1 
(Fig. 3.3A) (Covarrubias et al., 2011). On closer inspection, a large proportion of 
splicing-related proteins could be seen to associate with subnuclear structures and 
ORF57 over the course of KSHV lytic infection, including proteins from major 
spliceosome subunits, the Prp19 complex and the hTREX complex (Fig. 3.3B). As the 
interaction between the hTREX complex and KSHV ORF57 has been well characterised, 
we elected to further analyse the involvement of the Prp19 complex in KSHV lytic 
infection. Initially, we focused on the Prp19 protein, which was shown to interact with 
ORF57 in both the ORF57 SILAC IP analysis and also to increase in abundance in the 
nucleolus in the ORF57 subcellular fractionation SILAC analysis (Fig. 3.3C).   
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Figure 3.3: Bioinformatic analysis of SILAC results.  
(a) Table displaying a subset of mRNA processing related proteins found at increased levels in the 
subnuclear fractions of lytically infected TREx BCBL1-Rta cells. Numbers shown are maximum increase 
over latently infected (unreactivated) cells. (b) DAVID bioinformatics analysis output showing all of the 
splicing related proteins identified at increased levels in both lytic KSHV subnuclear fractionation SILAC 
and KSHV ORF57 SILAC-IP experiments. (c) Fold change increase of Prp19 protein levels in subcellular 
fractions of ORF57 SILAC samples compared to control cells. 
3.4 Prp19 interacts with ORF57 in an RNA independent manner 
To initially validate whether Prp19 functioned in the KSHV lytic infection cycle, confocal 
microscopy analysis was performed using an HA tagged Prp19 fusion protein 
cotransfected in the presence of GFP (control) or ORF57-GFP (Fig. 3.4A). Prp19-HA 
colocalised with a portion of ORF57-GFP protein in discrete subnuclear structures 
believed to be the nuclear speckles. Interestingly, overexpression of Prp19-HA 
appeared to modulate the normal localisation of ORF57-GFP, which is usually observed 
mainly localising to the nucleolus with only a diffuse presence in other regions of the 
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nucleus. This experiment was repeated to examine the localisation of ORF57 and 
endogenous Prp19 using ORF57- and Prp19-specific antibodies in TREx BCBL1-Rta cells 
(Fig 3.4B). Prp19 exhibited diffuse nuclear localisation, clearly excluded from the 
nucleolus in control cells transfected with GFP, in contrast, Prp19 was seen to 
accumulate at high levels in the nucleolus upon overexpression of ORF57-GFP. These 
results suggest that Prp19 interacts with ORF57 and the levels of either protein can 
regulate the subcellular localisation of the other protein.  
 
Figure 3.4: ORF57 co-localises with Prp19-HA in nuclear speckles.  
(a) HEK 293T cells transfected with pEGFP-N1/pORF57-EGFP and Prp19-HA or (b) 
Unreactivated/reactivated TREx BCBL1-Rta were fixed with paraformaldehyde and stained using primary 
antibodies specific to (a) HA and (b) Prp19 and ORF57 and secondary antibodies conjugated to Alexa-
Fluor 488 and 548 fluorophores. Stained cells were then mounted on slides with mounting media 
containing DAPI. Slides were analysed using a Zeiss LSM 510 confocal laser scanning microscope. 
In order to examine the potential for a direct protein-protein interaction between 
Prp19 and ORF57, co-immunoprecipitation experiments were performed using cells 
transfected with GFP or ORF57-GFP (Fig. 3.5). Input and IP samples were examined for 
the presence of GFP/ORF57-GFP and endogenous Prp19 in the presence of RNase A to 
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prevent the identification of RNA bridged interactions. Prp19 was shown to interact 
with ORF57-GFP but not the GFP control or unconjugated agarose beads. As both 
ORF57 and Prp19 proteins are known to interact with mRNA, the identification of an 
unbridged protein-protein interaction, in the presence of RNase A, suggests KSHV has 
evolved to exploit the cellular protein Prp19 to enhance viral replication.  
 
Figure 3.5: ORF57 interacts with Prp19. 
HEK 293T cells were transfected with pEGFP-N1 or pORF57-EGFP. After 24 hours lysates were harvested, 
(a) treated with RNase A and immunoprecipitation with GFP-trap beads was performed. Input and Co-IP 
samples were separated by SDS-PAGE and immunoblots were performed using antibodies specific for 
Prp19 and GFP (b) RNA levels were equalised, and either treated with RNase A or left untreated. 
Samples were then DNase treated and reverse transcribed, before GAPDH levels were analysed by 
qPCR. Ct values were not compared against GAPDH control for ΔΔCT normalisation, and instead inverse 
Ct values were used to quantify RNA levels (b - performed by Dr. Anja Berndt). 
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3.5 Prp19 overexpression does not affect nuclear stability or export of viral 
intronless mRNAs or splicing of viral intron containing mRNAs. 
As Prp19 has previously been characterised as an important factor in the splicing and 
export of cellular mRNA (Grote et al., 2010), it was hypothesised that KSHV ORF57 may 
be hijacking this cellular protein in order to facilitate the export of KSHV mRNAs. 
Previous work has already shown that the cellular hTREX complex to be of vital 
importance in this process, and occupancy of Prp19 at maturing mRNAs has previously 
been demonstrated to be an essential factor in the recruitment of the hTREX complex 
to both intron containing and intronless mRNAs (Masuda et al., 2005; Katahira, 2012; 
Chanarat et al., 2011). As the majority of KSHV encoded transcripts are intronless 
(Arias et al., 2014), the effect of overexpressing Prp19-HA on the nuclear export of the 
viral intronless reporter mRNA, ORF47, was examined using a well characterised viral 
mRNA nuclear export assay (Boyne et al., 2008). It was hypothesised that if Prp19 was 
involved in the nuclear export of viral intronless mRNAs, its overexpression should 
increase the amount of viral mRNA found in the cytoplasmic fraction, relative to the 
nuclear fraction. However, surprisingly results showed that overexpression of Prp19-
HA appeared to have no effect. Expression of ORF57 did significantly enhance the 
amount of viral intronless mRNA exported to the cytoplasm, as well as their nuclear 
stability, as has been shown previously (Fig. 3.6) (Boyne and Whitehouse, 2009). 
As overexpression of Prp19-HA did not appear to enhance the export of viral intronless 
transcripts, it was hypothesised that Prp19 may be utilised by ORF57 to promote the 
splicing of viral intron-containing mRNAs. ORF57 has previously been shown to be a 
vital component in the splicing of the final intron of the KSHV K8β transcript resulting 
in the fully spliced K8α transcript (Majerciak et al., 2008). Therefore, the efficiency of 
KSHV K8β splicing was assessed in the presence of Prp19 overexpression, as it was 
hypothesised that if ORF57 is hijacking Prp19 to promote the splicing of this important 
viral transcript, overexpression of Prp19-HA would further enhance this effect. Results 
again showed that overexpression of Prp19 has no effect on the levels of viral splicing 
during KSHV lytic replication (Unpaired T-test: p=0.1621) (Fig. 3.7). This suggests that 
KSHV is able to use other cellular or viral machinery to facilitate the splicing of viral 
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intron-containing mRNAs, or that endogenous Prp19 is present in high enough 
abundance to maximise splicing efficiency of KSHV intron-containing mRNA. 
3.6 Depletion of endogenous Prp19 does not affect nuclear stability, export of 
intronless viral mRNAs, splicing of viral intron containing mRNAs or production of 
late viral protein. 
As the overexpression of Prp19-HA did not appear to enhance the export of intronless 
viral mRNAs or the splicing of viral intron-containing transcripts, it was hypothesised 
that endogenous levels of Prp19 were probably sufficient to achieve maximum levels 
of either or both of these processes. Therefore, reducing endogenous levels of Prp19 
using siRNA appeared a more appropriate way to examine the effect of Prp19 on the 
splicing and export of viral transcripts. siRNA-mediated depletion of endogenous Prp19 
was tested in both HEK 293T cells and in a HEK 293T based cell line harbouring a latent 
viral genome; 293T rKSHV.219 cells (Vieira and O’Hearn, 2004). Prp19 directed siRNA 
had a clear inhibitory effect on cellular Prp19 levels in both cell lines after 24 hours, 
with a greater reduction at 48 and 72 hours, when compared with untransfected cells 
or cell transfected with a scramble siRNA control (Fig. 3.8). 
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Figure 3.6: Prp19-HA overexpression does not affect nuclear stability or ORF57 mediated export of 
intronless KSHV mRNAs. 
(a) HEK 293T cells were transfected with pEGFP-N1/pORF57-EGFP and pORF47 ± pPrp19-HA. 24 hours 
post transfection cells were separated into cytoplasmic and nuclear fractions. RNA was extracted from 
each fraction and extracted RNA was subjected to DNase treatment. RNA was then reverse transcribed 
into cDNA using an oligo dT primer and qPCR was performed using primers specific to ORF47. 3 
biological replicates were combined, the relative values were displayed on a graph and the standard 
deviation was calculated. Error bars = SD, p<0.01 = **, p<0.05 = * compared with same fraction from 
GFP/ORF57-GFP control samples (b) Fractionation samples were separated by SDS-PAGE and 
immunoblots were performed using antibodies specific for Lamin B, GAPDH, Prp19 and GFP. 
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Figure 3.7: Prp19-HA overexpression does not affect ORF57 mediated splicing of KSHV K8 mRNA. 
(a) Schematic of the alternative splicing of the KSHV K8 mRNA and the proteins that result from each 
spliceoform. Image adapted from Majerciak et al. (2007) (b, c) 293T rKSHV.219 cells were transfected 
without DNA (mock) or with pPrp19-HA. 48 hours after transfection cells were either reactivated with 
NaBu and TPA for 24 hours (lytic infection) or left unreactivated (latent - control). (b) RNA was then 
extracted from cells, samples were treated with DNase and reverse transcription was performed. PCR 
was then performed on the resulting cDNA using primers specific for KSHV K8. GAPDH was used as a 
loading control. (c) Lysates were harvested at 0 and 48 hours post viral reactivation. Samples were 
separated by SDS-PAGE and immunoblots were performed using antibodies specific to Prp19, ORF57 
and GAPDH. 
 
The effect of Prp19 depletion on the export of the intronless viral mRNA ORF47 was 
then examined, and it was hypothesised that if ORF57 was hijacking Prp19 to enhance 
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the export of KSHV intronless transcripts, depletion of Prp19 would dramatically 
reduce or ablate this process. The mRNA export assay described in Section 3.5 was 
employed using siRNAs directed against Prp19 or scramble (control) in cells 
cotransfected with ORF47 and ORF57-GFP or GFP (control). Results show that 
depletion of Prp19 did not affect viral intronless mRNA nuclear export (Unpaired T-
test: p=0.5629), surprisingly, however, Prp19 depletion did cause a minor disruptive 
effect on the nuclear stability of viral intronless mRNAs (Unpaired T-test: p=0.0183). 
ORF57 was again observed to increase the nuclear stability and export of the intronless 
ORF47 transcript, as previously described, demonstrating that the assay was working 
correctly (Fig 3.9). 
 
Figure 3.8: Prp19 is efficiently depleted using siRNAs in HEK 293T and 293T rKSHV.219 cells . 
(a) HEK 293T cells and (b) 293T rKSHV.219 cells were transfected with siRNA specific to Prp19 or 
scramble siRNA. Lysates were harvested at 24, 48 and 72 hours post transfection. Samples were 
separated by SDS-PAGE and immunoblots were performed using antibodies specific to Prp19 and 
GAPDH. 
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Figure 3.9: Prp19 knockdown does not affect nuclear stability or ORF57 mediated export of intronless 
KSHV mRNAs. 
(a) HEK 293T cells were transfected with pEGFP-N1/pORF57-EGFP and pORF47 ± Prp19 specific siRNA. 
24 hours post transfection cells were separated into cytoplasmic and nuclear. RNA was extracted from 
each fraction and subjected to DNase treatment. RNA was then reverse transcribed into cDNA using an 
oligo dT primer and qRT-PCR was performed using primers specific to ORF47. 3 biological replicates 
were combined, the relative values were displayed on a graph and the standard deviation was 
calculated. Error bars = SD, p<0.01 = **, p<0.05 = * compared with same fraction from GFP/ORF57-GFP 
+ scramble control samples (b) Fractionation samples were separated by SDS-PAGE and immunoblots 
were performed using antibodies specific for Lamin B, GAPDH, Prp19 and GFP.  
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Secondly, the effect of Prp19 depletion on the ORF57-mediated splicing of the K8β 
transcript was subsequently examined as previously described in Section 3.5. Again, it 
was hypothesised that if ORF57 was hijacking Prp19 in order to promote the 
production of the K8α transcript, this effect would be severely reduced or ablated with 
the depletion of Prp19. Results show that Prp19 depletion appeared to have no effect 
on this process, as cells undergoing lytic reactivation were able to produce similar 
levels of both the K8β and K8α transcripts when transfected with siRNAs directed 
against Prp19 or scramble siRNA (control) (Fig 3.10).  
 
Figure 3.10: Prp19 knockdown does not affect ORF57 mediated splicing of KSHV K8 mRNA. 
293T rKSHV.219 cells were transfected with Prp19 specific siRNA or scramble siRNA. 48 hours after 
transfection cells were either reactivated with NaBu and TPA for 24 hours (lytic infection) or left 
unreactivated (latent - control). (a) RNA was then extracted from cells, samples were treated with 
DNase and reverse transcription was performed. PCR was then performed on the resulting cDNA using 
primers specific for KSHV K8. GAPDH was used as a loading control.  (b) Lysates were harvested at 0 and 
48 hours post viral reactivation. Samples were separated by SDS-PAGE and immunoblots were 
performed using antibodies specific to Prp19, ORF57 and GAPDH. 
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In order to determine whether depletion of Prp19 had any effect on the lytic 
replication cycle, the effect of Prp19-HA overexpression or depletion of endogenous 
Prp19 on production of the late viral protein, minor capsid protein, was examined. It 
was hypothesised that if Prp19 has a role at immediate early, early, or late stages 
during KSHV lytic infection, this would be most evident at a late time point due to a 
magnification effect further along the lytic gene cascade. Therefore, levels of the KSHV 
minor capsid protein (mCP) were examined as a working antibody was available for 
this protein and other late KSHV protein antibodies tested were ineffective. 293T 
rKSHV.219 cells were transfected with either Prp19-HA, siRNAs directed against 
endogenous Prp19, scramble siRNA (control) or left untransfected (control). Following 
transfection for 24 hours (plasmid DNA) or 72 hours (siRNA) cells were either induced 
for the KSHV lytic cycle using sodium butyrate and TPA, or left uninduced (control). 
After a further 72 hours cell lysates were harvested and examined by immunoblot. 
Data indicated that neither Prp19-HA overexpression nor endogenous Prp19 depletion 
had any discernible effect on the production of KSHV minor capsid protein (Unpaired 
T-test: p>0.05) (Fig. 3.11). 
3.7 Assessing the role of other Prp19 complex components in ORF57 function  
Previous results have demonstrated that overexpression or depletion of Prp19 
displayed no effects on any of the viral pathways examined. It was therefore 
hypothesised that this could be due to potential redundancy in the Prp19/CDC5L 
complex. The predicted architecture of the Prp19/CDC5L complex shows Prp19 to be 
present as 4 molecules on one side of the complex, only interacting with SPF27 (Fig. 
3.12) (Grote et al., 2010). However, CDC5L  was also shown to interact with ORF57 in 
the SILAC immunoprecipitation experiment (Fig. 3.3B). Furthermore, SILAC analysis 
showed a similar increase in the nucleolar levels of CDC5L as Prp19 (Fig 3.13A). 
Therefore, CDC5L represented another potential option for depletion in order to 
further examine the effects of the Prp19 complex on the KSHV lytic cycle.  
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Figure 3.11: Prp19 overexpression/knockdown has no effect on KSHV minor capsid protein (mCP) 
ORF26 expression. 
(a) 293T rKSHV.219 cells were transfected without DNA (mock), pPrp19-HA, Prp19 specific siRNA or 
scramble siRNA. 48 hours after transfection cells were either reactivated with NaBu and TPA for 72 
hours (lytic infection) or left unreactivated (latent - control). Lysates were then harvested and proteins 
were separated by SDS-PAGE. Immunoblots were performed with antibodies specific to KSHV ORF57, 
GAPDH, Prp19 and KSHV mCP ORF26. GAPDH specific antibody was used to control for equal loading. (b) 
The fold change in mCP levels was calculated for each reactivated sample when compared with mock 
transfected reactivated 293T rKSHV.219 cells. Immunoblots were analysed using ImageJ software. 
Values are average of 3 independent immunoblots. Error bars = SD, p<0.01 = **, p<0.05 = * compared 
with 72h control sample. 
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Figure 3.12: Predicted Prp19/CDC5L complex architecture and predicted effects of depletion of both 
Prp19 and CDC5L. 
The predicted architecture of the Prp19/CDC5L complex based on numerous protein-protein interaction 
assays (Grote et al., 2010) and a predicted model of how this architecture would be altered by the 
depletion of Prp19 and CDC5L proteins by siRNA.  
To examine whether ORF57 interacted with CDC5L, a co-immunoprecipitation assay 
was performed (Fig 3.13B). Results show that CDC5L was able to interact with ORF57, 
in contrast to GFP control or unconjugated beads. This immunoprecipitation was 
performed in the presence of RNase A, suggesting this interaction is not bridged by 
RNA and is a direct protein-protein interaction. 
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Figure 3.13: ORF57 interacts with CDC5L. 
(a) Fold change increase in CDC5L levels in subcellular fractions of HEK 293T expressing an inducible 
ORF57 protein compared to uninduced cells. (b) HEK 293T cells were transfected with pEGFP-N1 or 
pORF57-EGFP. After 24 hours lysates were harvested, treated with RNase A and immunoprecipitation 
with GFP-trap beads was performed. Input and IP samples were separated by SDS-PAGE and 
immunoblots were performed using antibodies specific for CDC5L, Prp19 and GFP. Samples used for this 
immunoblot analysis came from the same experiment as shown in Figure 3.5.  
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Figure 3.14: CDC5L and Prp19 are efficiently knocked down by siRNAs in HEK 293T and 293T 
rKSHV.219 cells. 
(a) HEK 293T cells or (b) 293T rKSHV.219 cells were transfected with siRNA specific to CDC5L or both 
Prp19 and CDC5L or scramble siRNA. Lysates were harvested at 24, 48 and 72 hours post transfection. 
Samples were separated by SDS-PAGE and immunoblots were performed using antibodies specific to 
CDC5L, Prp19 and GAPDH. GAPDH specific antibody was used to control for equal loading.  
In order to examine a possible role of CDC5L in the KSHV lytic cycle, siRNAs targeted 
specifically to CDC5L were used, and the efficiency of CDC5L knockdown was examined 
in HEK 293T and 293T rKSHV.219 cells (Fig. 3.14). Cells were transfected with either 
scramble control siRNA, or siRNA directed against CDC5L in the absence or presence of 
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siRNA directed against Prp19 for 24, 48 or 72 hours. Following incubation with siRNAs, 
cells were harvested and protein samples were then separated by SDS PAGE and 
analysed by immunoblot using antibodies directed against Prp19, CDC5L and GAPDH. 
Results showed that siRNAs targeted against CDC5L were highly effective at reducing 
CDC5L protein levels at 24 hours post transfection, with increased efficiency at 48 and 
72 hours. In addition, they were also efficient when cells were simultaneously treated 
with siRNA directed against Prp19. Interestingly, Prp19 protein levels were observed to 
decrease after 72 hours incubation with siRNA directed against CDC5L. This may be 
due to the inability of the Prp19/CDC5L complex to splice Prp19 mRNA efficiently 
without the CDC5L protein present, or decreased complex stability. 
3.8 Depletion of Prp19, CDC5L or both simultaneously has little effect on the 
nuclear export or stability of KSHV intronless mRNAs, or the splicing of KSHV 
intron containing mRNAs 
Previous attempts to examine the effects of the Prp19/CDC5L complex on the nuclear 
export and stability of viral intronless mRNAs only focussed on Prp19 and did not 
include CDC5L depletion. Therefore, the same previously described set of experiments 
were repeated upon CDC5L depletion or in combination with Prp19 depletion. Cells 
were transfected with GFP or ORF57-GFP, as well as either scramble siRNA, siRNA 
directed against Prp19, siRNA directed against CDC5L or a combination of siRNAs 
directed against both Prp19 and CDC5L simultaneously. Cells were then split into 
cytoplasmic and nuclear fractions, and immunoblots were performed to analyse the 
levels of GAPDH, LaminB, Prp19, CDC5L, GFP and ORF57-GFP present in the fractions 
(Fig. 3.15A). Fractionation was shown to be efficient by the presence of GAPDH only in 
the cytoplasmic fractions, and LaminB only in the nuclear fractions. Levels of extracted 
ORF47 and GAPDH mRNA were analysed using qRT-PCR, and the relative changes in 
ORF47 mRNA levels were determined (Fig. 3.15B). Results showed that depletion of 
Prp19, CDC5L or both simultaneously did not appear to have an effect on the nuclear 
export or stability of ORF47 mRNA. This data suggests that the Prp19/CDC5L complex is 
not involved in the nuclear export or stability of KSHV intronless mRNAs.     
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To examine a possible role of CDC5L on the splicing of viral intron-containing mRNA, 
the K8 splicing assay was also repeated in the presence of CDC5L specific siRNAs. Cells 
were transfected with either scramble siRNA, siRNA directed against Prp19, siRNA 
directed against CDC5L or a combination of siRNAs directed against both Prp19 and 
CDC5L simultaneously. Cells were subsequently exposed to KSHV lytic replication for 
24 hours, or remained untreated as a latent control, before total RNA was harvested 
and levels of partially and fully spliced K8 mRNA were analysed using RT-PCR. GAPDH 
was used as a loading control. Results showed that depletion of Prp19, CDC5L or both 
simultaneously had no noticeable effect on the levels of partially or fully spliced K8 
mRNA after 24 hours of virus lytic cycle reactivation in 293T rKSHV.219 cells. This data 
suggests the Prp19/CDC5L complex is not involved in the splicing of KSHV encoded 
intron containing mRNAs.  
3.9 Depletion of both CDC5L and Prp19 results in a minor reduction in KSHV 
minor capsid protein levels 
Previous attempts to examine the effects of Prp19 on the levels of KSHV encoded late 
protein production failed to show any effect. Therefore the experiment was repeated 
using cells that were also depleted of CDC5L. Cells were transfected with either 
scramble siRNA, siRNA directed against Prp19, siRNA directed against CDC5L, a 
combination of siRNAs directed against both Prp19 and CDC5L simultaneously, or 
untransfected (control). Cells were subsequently exposed to KSHV lytic cycle for 72 
hours, or untreated as a latent control, before cells were lysed with modified RIPA 
buffer. Protein samples were separated by SDS PAGE and levels of CDC5L, Prp19, 
GAPDH and KSHV minor capsid protein were analysed by immunoblot (Fig. 3.17A). 
Results showed that depletion of CDC5L failed to reduce the amount of KSHV mCP, 
however, depletion of both CDC5L and Prp19 resulted in a minor reduction of ~34% in 
KSHV mCP levels present in the sample when analysed by densitometry (Fig. 3.17B). 
This suggests that inhibition of Prp19/CDC5L complex formation and function may 
have a minor inhibitory effect on KSHV mRNA or protein levels during the lytic cycle.  
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Figure 3.15: CDC5L and Prp19 double knockdown does not affect nuclear stability or ORF57 mediated 
export of intronless KSHV mRNAs. 
(a) HEK 293T cells were transfected with scramble siRNA (control), Prp19 specific siRNA, CDC5L specific 
siRNA or a combination of both for 48 hours, then transfected with either pORF47 and either pEGFP-N1 
or pORF57-EGFP. 24 hours later cells were separated into cytoplasmic and nuclear fractions. RNA was 
then extracted from each fraction and subjected to DNase treatment. RNA was then reverse transcribed 
into cDNA and qRT-PCR was performed using primers specific to ORF47. 3 biological replicates were 
combined, the relative values were displayed on a graph and the standard deviation was calculated. 
Error bars = SD, p<0.01 = **, p<0.05 = * compared with same fraction from GFP/ORF57-GFP + scramble 
control samples. (b) Fractionation samples were separated by SDS-PAGE and immunoblots were 
performed using antibodies specific for LaminB, GAPDH, Prp19, CDC5L and GFP. 
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Figure 3.16: Prp19 and CDC5L double knockdown does not affect ORF57 mediated splicing of KSHV K8 
mRNA. 
293T rKSHV.219 cells were transfected with Prp19 or CDC5L specific siRNA, a combination of both or 
scramble siRNA. 48 hours after transfection cells were either reactivated with NaBu and TPA for 24 
hours (lytic infection) or left unreactivated (latent - control). (a) RNA was then extracted from cells, 
samples were treated with DNase and reverse transcription was performed. PCR was then performed on 
the resulting cDNA using primers specific for KSHV K8. PCR products were run on a 1% Agarose gel and 
visualised with a UV scanner. GAPDH was used as a loading control. (b) Lysates were harvested at 0 and 
48 hours post viral reactivation. Samples were separated by SDS-PAGE and immunoblots were 
performed using antibodies specific to Prp19, CDC5L, ORF57 and GAPDH. 
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Figure 3.17: Depletion of both Prp19 and CDC5L causes minor reduction in KSHV minor capsid protein 
production. 
(a) 293T rKSHV.219 cells were transfected without DNA (mock), pPrp19-HA, Prp19 specific siRNA or 
scramble siRNA. 48 hours after transfection cells were either reactivated with NaBu and TPA for 72 
hours (lytic infection) or left unreactivated (latent - control). Lysates were then harvested and proteins 
were separated by SDS-PAGE. Immunoblots were performed with antibodies specific to KSHV ORF57, 
GAPDH, Prp19 and KSHV mCP ORF26. GAPDH specific antibody was used to control for equal loading. (b) 
The fold change in mCP levels was calculated for each reactivated sample when compared with mock 
transfected reactivated 293T rKSHV.219 cells. Immunoblots were analysed using ImageJ software. 
Values are average of 3 independent immunoblots. Error bars = SD, p<0.01 = **, p<0.05 = * compared 
with No siRNA control sample. 
108 
 
3.10 ORF57 limits activation of the DNA damage response signalling cascade 
caused by Prp19 overexpression 
Prp19 has been demonstrated to play a role in the early stages of the DNA damage 
signalling pathway, sensing sites of RPA bound single stranded DNA, ubiquitylating RPA 
through its E3 ubiquitin ligase function and facilitating the recruitment of ATRIP and 
ATR to these sites (Maréchal et al., 2014). These interactions support the well 
characterised ATR-Chk1 DNA damage response pathway, ultimately leading to one of 
two potential outcomes: DNA damage repair or apoptosis (Shiloh, 2001).  
Previous work has shown that ORF57 induces DNA damage, primarily through the 
recruitment of the human TREX complex, in a process that is necessary for intronless 
viral mRNA nuclear stability, export and efficient translation (Jackson et al., 2014). The 
DNA damage occurs due to the inhibition of events during cellular transcription, when 
a short 8bp RNA:DNA duplex forms in the transcription bubble (Westover, 2004). 
hTREX usually binds newly synthesised mRNA, increasing stability and efficiency of 
nuclear export, but also reducing the potential of the newly synthesised mRNA to 
“thread back” and bind to an extended region of its complementary DNA sequence 
before the DNA duplex can reanneal. Inhibition of this process leads to the formation 
of an RNA:DNA hybrid known as an R-Loop (Köhler and Hurt, 2007; Masuda et al., 
2005; Aguilera and García-Muse, 2012). R-loops have previously been characterised as 
agents of DNA damage (Gan et al., 2011). During KSHV lytic replication, ORF57-
mediated recruitment of hTREX onto viral mRNAs also leads to R-loop formation and 
subsequent DNA damage (Jackson et al., 2014). This coupled with the involvement of 
Prp19 in the DNA damage response, led to the hypothesis that ORF57 and Prp19 may 
prevent a DDR at sites of R-Loop formation and, therefore, also prevent cell cycle 
arrest/apoptosis which would limit the replication potential of KSHV. 
To explore a possible link between ORF57 and Prp19 in the DNA damage response, a 
positive control was required, and the compound camptothecin was elected for this 
purpose. Camptothecin binds and stabilises topoisomerase I bound DNA, preventing 
the ligation of DNA by topoisomerase I, thus initiating a DNA damage response and, 
ultimately, apoptosis (Liu et al., 2000). Camptothecin has been shown to cause DNA 
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strand breaks in cells, eventually leading to apoptosis, and therefore mimics the 
predicted effects of widespread R-loop formation and a subsequent lack of a 
productive DNA damage response (Yamauchi et al., 2011). The effect of camptothecin 
on HEK 293T cells was examined by incubating cells with increasing amounts of 
camptothecin for 4 hours, compared with DMSO control. Protein lysates were 
harvested following treatment, and samples were analysed by immunoblotting, using 
antibodies directed against S15 phosphorylated p53, T21 phosphorylated RPA, RPA32 
and GAPDH (loading control) (Fig. 3.18). Camptothecin treatment, but not DMSO 
treatment, caused the phosphorylation of both RPA and p53 at all tested 
concentrations.     
 
Figure 3.18: Camptothecin induces DNA damage response in HEK 293T cells. 
(a) HEK 293T cells were treated with 0.75% DMSO in DMEM (control) or 1, 2.5, 5 or 7.5μM camptothecin 
(CPT) in DMEM for 4 hours. Lysates were harvested, samples were separated by SDS-PAGE and 
immunoblots were performed with antibodies specific to p53 (phosphorylated at S15), RPA 
(phosphorylated at T21), RPA, and GAPDH. GAPDH specific antibody was used to control for equal 
loading.  
In order to investigate the effect of the Prp19-mediated DNA damage response during 
ORF57 expression, HEK 293T cells were transfected with either ORF57-GFP or a GFP 
control plasmid, in the presence or absence of overexpressed Prp19-HA. 24 hours post 
transfection, cells were treated with either 5 μM camptothecin or DMSO (control) for 4 
hours. Protein lysates were subsequently harvested and the levels of GAPDH, Prp19, 
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Prp19-HA, ORF57-GFP, GFP, T21 phosphorylated RPA and S15 phosphorylated p53 
were examined by immunoblot, using GAPDH as a loading control (Fig. 3.19). GFP 
control cells expressing Prp19-HA exhibited a dramatic increase in phosphorylated RPA 
and p53. This effect has not been previously reported, however, the ubiquitylated 
form of Prp19 is known to be significantly increased upon Prp19 overexpression, and 
this form is also increased during the activation of the ATR-Chk1 DDR pathway (Lu and 
Legerski, 2007). This may suggest that Prp19 overexpression is enough to trigger the 
phosphorylation and activation of certain proteins in this pathway. Interestingly, 
ORF57-GFP expressing cells did not exhibit this significant increase in p53 and RPA 
phosphorylation following Prp19-HA overexpression. ORF57-GFP expressing cells did 
exhibit a slightly higher background level of RPA and p53 phosphorylation to negative 
controls, but these levels were significantly lower than those in the Prp19-HA 
expressing GFP cells. This suggests that the interaction between ORF57 and Prp19 may 
act to inhibit some functions of Prp19 in the ATR-Chk1 DNA damage response 
pathway, ultimately limiting the phosphorylation of p53 and RPA. Importantly, 
camptothecin treated cells all exhibited similar levels of RPA and p53 phosphorylation, 
irrespective of ORF57-GFP, GFP or Prp19-HA expression, suggesting that ORF57 
expression is unable to override these phosphorylation events following camptothecin 
induced DNA damage. This suggests some redundancy in this pathway, and indeed 
other agents are known to be able to phosphorylate p53 and RPA following activation 
of the ATR-Chk1 DNA damage response pathway. 
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Figure 3.19: ORF57 expression limits DNA damage response caused by Prp19-HA overexpression in 
HEK 293T cells. 
(a)  HEK 293T cells transfected with pEGFP-N1/pORF57-EGFP and no DNA (mock) or pPrp19-HA were 
treated with 0.5% DMSO in DMEM or 5 μM camptothecin in DMEM. 4 hours after treatment lysates 
were harvested and separated by SDS-PAGE. Immunoblots were performed using antibodies specific for 
GAPDH, Prp19, GFP, RPA (phosphorylated at T21) and p53 (phosphorylated at S15). GAPDH specific 
antibody was used to control for equal loading. 
3.11 ORF57 ablates RPA speckle formation and relocalises to discrete subnuclear 
puncta with Prp19 during Camptothecin induced DNA damage  
The canonical DNA strand break response begins with RPA binding to single stranded 
DNA, before becoming hyperphosphorylated (Wu et al., 2005). RPA coated ssDNA is 
sensed and bound by various components of the DDR, including Prp19, ATR and ATRIP 
(Maréchal et al., 2014 p. 19). Prp19 recruits more ATRIP and ATR to the damaged site, 
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and also ubiquitinates RPA, and both of these processes lead to the subsequent 
phosphorylation of ATR substrates. p53 is then phosphorylated by ATR, and this 
process leads to the activation of the p53-mediated signalling cascade, ultimately 
triggering apoptosis (Fig. 3.20). In order to further investigate the putative ORF57-
mediated inhibition of Prp19 during the ATR-Chk1 DNA damage response pathway, the 
localisation of the closest (temporal and spatial) known proteins involved in the 
signalling cascade were examined upon ORF57-GFP expression. To this end, the 
subcellular localisation of Prp19 and RPA was examined in control vs ORF57 expressing 
cells in the absence or presence of DNA damage (Fig. 3.21). Prp19 specifically localised 
to nucleoli upon ORF57 expression, as had been previously been observed (Fig. 3.4). 
During DMSO treatment, RPA showed diffuse nuclear staining in both ORF57-GFP and 
GFP expressing cells (Fig. 3.21A). However, during camptothecin treatment, GFP 
expressing cells displayed a speckled nuclear distribution of RPA. RPA foci have 
previously been observed, and it has been suggested that they represent sites of RPA 
bound ssDNA. Surprisingly, Prp19 was not observed to localise to these foci, suggesting 
either that the involvement of RPA or Prp19 in this process is transient, or that the 
observed foci are not sites of ssDNA. RPA subnuclear puncta were not seen in ORF57-
GFP expressing cells (Fig. 3.21B), suggesting that ORF57 is able to block an as yet 
uncharacterised function of RPA. Furthermore, upon camptothecin treatment, ORF57-
GFP and Prp19 were seen to localise to discrete nuclear foci, particularly evident at the 
nuclear periphery, and somewhat reminiscent of the previously described RPA 
speckles. This localisation of ORF57-GFP has not been previously reported, and further 
indicates an effect of ORF57 on the roles of Prp19 during the ATR-Chk1 DDR. Prp19 and 
ORF57-GFP still appeared to colocalise in the nucleoli of camptothecin treated cells, 
but this effect was partially masked by the large numbers of other nuclear foci. 
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Figure 3.20: Involvement of RPA, ATRIP, ATR, p53 and Prp19 in the DNA single strand break response. 
Following the generation of a DNA single strand break, RPA binds to the exposed strand and is 
subsequently phosphorylated. Phosphorylated RPA is able to recruit ATR, the ATR cofactor ATRIP and 
Prp19. ATR is able to phosphorylate p53 and Prp19 is then able to recruit more ATR/ATRIP complexes to 
the site. ATR then phosphorylates Chk1, and this begins a signalling cascade designed to bring more DNA 
damage response proteins to the damaged site, resulting in strand break repair. 
Prp19-HA overexpression was previously demonstrated to cause a relocalisation of 
ORF57 to nuclear speckles, suggesting ORF57 is able to exert control over the lower 
endogenous levels of Prp19, but not overexpressed Prp19 (Fig. 3.4). It was therefore 
hypothesised that overexpression of Prp19-HA may be able to overcome the proposed 
block of function attributed to ORF57. Therefore, a similar experiment was performed 
to examine the effect of overexpression of Prp19-HA during camptothecin induced 
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DNA damage. Prp19-HA was shown to relocalise to the nuclear periphery, but not 
specifically to ORF57-GFP peripheral speckles (Fig 3.22). Prp19-HA overexpression 
failed to rescue the RPA speckle phenotype in ORF57-GFP expressing cells in the 
presence of camptothecin.  
 
Figure 3.21: Aberrantly localised ORF57-Prp19 complex inhibits relocalisation of RPA to discrete 
nuclear puncta during Camptothecin treatment in HEK 293T cells.  
(a) HEK 293T cells transfected with pEGFP-N1 or pORF57-EGFP were treated with 0.5% DMSO and (b) 5 
μM CPT for 2 hours before being fixed and stained with antibodies specific to Prp19 and RPA. Slides 
were analysed using a Zeiss LSM510 confocal laser scanning microscope. 
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Figure 3.22: Prp19-HA overexpression does not rescue RPA defect or affect speckled rearrangement of 
ORF57-GFP and Prp19. 
(a) HEK 293T cells transfected with pPrp19-HA as well as pEGFP-N1 or pORF57-EGFP were treated with 
0.5% DMSO and (b) 5 μM CPT for 2 hours before being fixed and stained with antibodies specific to 
Prp19 and RPA. Slides were analysed using a Zeiss LSM510 confocal laser scanning microscope.  
3.12 ATRIP colocalises with ORF57-Prp19 puncta during Camptothecin induced 
DNA damage 
A second protein which has a close temporal and spatial involvement to Prp19 in the 
ATR-Chk1 DDR pathway is the ATR cofactor ATRIP. In order to further characterise the 
ORF57-Prp19 subnuclear puncta that form in the presence of DNA damage, ATRIP 
localisation was examined in the presence of ORF57-GFP/GFP and in cells treated with 
either camptothecin/DMSO using confocal microscopy (Fig. 3.23). ATRIP displayed 
diffuse cellular staining in GFP control cells treated with DMSO and camptothecin, 
however, surprisingly, ATRIP localised to nucleoli in ORF57-GFP expressing cells treated 
with DMSO, and displayed a similar distribution to Prp19 in ORF57-GFP expressing cells 
treated with camptothecin. These results indicate that Prp19 and ATRIP are still able to 
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interact at ORF57 nuclear foci as well as nucleoli. The association at the nuclear foci 
may indicate that Prp19 is not inhibited from its role in recruiting ATRIP following DNA 
damage, however the presence of ATRIP at nucleoli may suggest that the interaction 
between ORF57 and Prp19 leads to the recruitment of ATRIP, even in the absence of 
DNA damage, via an unknown mechanism.  
 
Figure 3.23: ATRIP colocalises with ORF57-Prp19 complex in discrete subnuclear puncta during 
Camptothecin treatment in HEK 293T cells.  
(a) HEK 293T cells transfected with pEGFP-N1 or pORF57-EGFP were treated with 0.5% DMSO and (b) 5 
μM CPT for 2 hours before being fixed and stained with antibodies specific to ATRIP. Slides were 
analysed using a Zeiss LSM510 confocal laser scanning microscope. 
The ablation of RPA speckles in the presence of ORF57-GFP, combined with the 
relocalisation of ORF57-GFP, Prp19 and ATRIP to distinct nuclear foci led to the 
hypothesis that ORF57-GFP, Prp19 and ATRIP localise to sites of DNA damage, but 
ORF57 is able to block one or more functions of Prp19, ultimately preventing an 
unknown modification of RPA and causing a partial block on the ATR-Chk1 pathway 
(Fig. 3.24). This is also believed to apply to cells undergoing DNA damage by ORF57-
mediated R-loops, however, this effect is likely to be less obvious than in cells 
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subjected to camptothecin induced DNA damage. Indeed, a few small ORF57 speckles 
can be observed in many of the ORF57-GFP expressing DMSO control cells examined 
by confocal microscopy, possibly indicating sites of R-loop induced DNA damage. This 
would suggest that ORF57 recruits Prp19 and ATRIP to sites of DNA damage, and that 
the recruitment of these proteins to nucleoli is a side effect of this process, brought 
about by the high levels of ORF57 present in nucleoli. 
 
Figure 3.24: Formation of R-loops and inhibition of DNA damage response by ORF57. 
ORF57 recruitment of hTREX complex prevents hTREX binding to newly synthesised mRNAs, allowing 
mRNAs to bind to complementary DNA strand, forming R-loops. Prp19, ATRIP and ORF57 are recruited 
to sites of DNA damage, but normal RPA function is inhibited by an unknown mechanism, preventing 
the formation of RPA speckles.  
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Figure 3.25: ORF57 nuclear foci localise within close proximity of the nuclear pore complex. 
(a) HEK 293T cells transfected with pEGFP-N1 or pORF57-EGFP were treated with 0.5% DMSO and (b) 5 
μM CPT for 2 hours before being fixed and stained with antibodies specific to Nup414 and LaminB. (c) 
Enhanced image demonstrating close proximity between ORF57-GFP (green) and Nup414 (red), 
indicated by white arrows. Slides were analysed using a Zeiss LSM510 confocal laser scanning 
microscope. 
The observed ORF57/Prp19/ATRIP speckles appeared to line the nuclear periphery in a 
discontinuous manner, and their appearance by confocal microscopy was suggestive of 
close proximity to nuclear pore complexes. Heterochromatin/euchromatin barriers are 
often found close to nuclear pores, allowing for efficient export of newly transcribed 
mRNAs. Moreover, euchromatin is believed to be more susceptible to DNA damaging 
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agents such as camptothecin, as the DNA is more accessible in this arrangement. 
Therefore, in order to further investigate the hypothesis that ORF57, Prp19 and ATRIP 
localise to sites of DNA damage, the localisation of Nucleoporin 414 and LaminB was 
examined in the presence of ORF57-GFP/GFP and in cells treated with either 
camptothecin/DMSO using confocal microscopy (Fig. 3.25). ORF57 nuclear foci were 
observed to localise in close proximity to the discontinuous Nup414 foci (Fig. 3.25C). 
This ORF57 staining is indicative of localisation to euchromatin, and likely sites of DNA 
damage. 
3.12 Discussion 
The Prp19/CDC5L complex has previously been thought to be necessary for the splicing 
of mRNAs (Makarova et al., 2004)), however it does not appear to be necessary for the 
splicing of KSHV encoded intron containing transcripts. Furthermore, the depletion of 
two key members of this protein complex, Prp19 and CDC5L, failed to reduce the 
nuclear export or stability of KSHV encoded intronless mRNAs. This is surprising, as 
both of these processes have previously been attributed to hTREX activity, and it has 
previously been suggested that the Prp19/CDC5L complex is necessary for hTREX 
recruitment to both intron-containing and intronless genes, both of which are encoded 
by KSHV (Lei et al., 2011; Chanarat et al., 2011). This phenomenon, however, can be 
explained by the direct interaction between ORF57 and members of the hTREX 
complex, particularly Aly, which allows ORF57 to directly recruit the hTREX complex to 
KSHV encoded mRNAs, bypassing the need for the Prp19/CDC5L complex in this 
mechanism. 
In addition to its role in splicing, Prp19 has recently been identified as an important 
protein in the early stages of the ATR-Chk1 DNA damage response pathway (Maréchal 
et al., 2014). Upon the induction of DNA strand breaks by either replication stress or 
exposure to DNA damage inducing agents, Replication Protein A (RPA) binds to and 
coats single stranded DNA, forming a structure known as RPA-ssDNA. RPA-ssDNA is 
bound by ATRIP, facilitating the activation of the ATR kinase, leading to the 
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phosphorylation of RPA and Chk1, resulting in a productive DNA damage response 
(Zou and Elledge, 2003; Maréchal et al., 2014 p. 19) 
. It has been demonstrated that Prp19 acts as a sensor of RPA-ssDNA, and is necessary 
for the recruitment of higher levels of the ATR kinase and its cofactor ATRIP to these 
sites in order to amplify the ATR-Chk1-dependent DNA damage response (Maréchal et 
al., 2014 p. 19).  
ORF57 has previously been implicated as a DNA damage factor, causing R-Loops which 
lead to genome instability (Aguilera and García-Muse, 2012; Jackson et al., 2014). R-
loop formation is believed to occur due to the sequestration of the hTREX complex by 
ORF57, as hTREX would normally bind to newly transcribed mRNAs, stabilising them 
and preventing the binding of these mRNAs to the complementary DNA strand that 
they were transcribed from. Herein, it is hypothesised that the widespread formation 
of R-loops would ultimately culminate in apoptosis via a DNA damage response. 
Therefore, the role that Prp19 may play in the DNA damage response during ORF57 
induced DNA damage was investigated. Surprisingly, both Prp19 and ATRIP are 
recruited to nucleoli in the presence of ORF57-GFP. However, both also dramatically 
relocalise to subnuclear speckles in cells that have been subjected to camptothecin 
induced DNA damage, and this coincides with an ablation of RPA speckle formation, 
normally observed during DNA damage. Therefore, it is hypothesised that upon the 
induction of DNA damage, ORF57 is recruited to sites of strand breaks, where it is able 
to block one or more functions of Prp19, ultimately preventing the formation of RPA 
speckles. Although ORF57-GFP expression was able to limit the phosphorylation of RPA 
at the T21 residue during Prp19-HA overexpression, this is unlikely to contribute to the 
RPA speckle phenotype observed during camptothecin treatment, as levels of T21 
phosphorylated RPA were comparable between both GFP and ORF57-GFP expressing 
cells undergoing camptothecin induced DNA damage. As Prp19 is able to ubiquitinate 
RPA, it is possible that the relocalisation of RPA to these subnuclear speckles is 
dependent on its ubiquitination, and that this is prevented by the interaction between 
ORF57 and Prp19. 
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Small foci containing ORF57, Prp19 and ATRIP were also observed in DMSO control 
cells, albeit at a much lower level than in camptothecin treated cells. It is hypothesised 
that these speckles also represent sites of DNA damage, following ORF57-mediated R-
loop induced DNA damage, and that a similar process occurs at these sites. These foci 
occupied sites near the nuclear periphery, similarly to many of the observed 
camptothecin induced ORF57/Prp19/ATRIP foci, attributed to DNA damage at 
euchromatin. As R-loops form at sites of transcription, which in turn occurs at 
euchromatin, this localisation is to be expected if this hypothesis is correct.  
Interestingly, the ATM and DNA-PK DNA damage response pathways have both been 
shown to respond to KSHV lytic infection (Hollingworth et al., 2015). Activation of the 
ATM pathway, in particular, appears to be required, as the treatment of lytically 
infected cells with an ATM inhibitor reduces levels of viral replication. Furthermore, it 
was demonstrated that Chk1 phosphorylation is inhibited during lytic infection, while 
RPA is recruited to sites of viral DNA replication. It remains to be seen whether the 
formation of RPA speckles, possibly formed via Prp19-mediated ubiquitination of RPA, 
could inhibit the recruitment of RPA to viral replication centres. This would represent 
further explanation of the unusual interactions between ORF57 and the machinery of 
the early ATR-Chk1 response, where inhibition of modified RPA speckles both restricts 
the DNA damage response and subsequent apoptosis, while also allowing unmodified 
RPA to be recruited to viral replication centres. 
These hypotheses have led to the formation of a model in which ORF57, Prp19 and 
ATRIP associate with sites of R-loop mediated DNA damage at euchromatin. An 
interaction between ORF57 and Prp19 then prevents an unknown modification of RPA, 
presumed to be ubiquitination. In turn, this inhibits the formation of RPA speckles, 
preventing the full activation of the ATR-Chk1 DDR pathway and allowing recruitment 
of unmodified RPA to KSHV replication centres (Fig. 3.26). 
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Figure 3.26: Model of ORF57 inhibition of Prp19 functions during the ATR-Chk1 DDR pathway. 
ORF57 interacts with Prp19 at sites of DNA damage, blocking one or more functions of Prp19 and 
ultimately preventing a modification of RPA, preventing the speckled localisation of RPA. Blue and black 
RPA represent unmodified and modified forms respectively. 
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CHAPTER 4 
~ 
Host cell microRNAs 151a-5p and 365a-3p are dysregulated during KSHV 
lytic infection  
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4 Host cell microRNAs 151a-5p and 365a-3p are dysregulated during 
KSHV lytic infection 
4.1 Introduction 
The discovery of microRNAs represents a relatively recent addition to the general 
understanding of gene expression, adding an extra layer of complexity in the form of 
post transcriptional regulation (Cannell et al., 2008). These short, 17-25 nucleotide 
RNA fragments are used to target complementary mRNAs for degradation or 
translational repression, in a process very closely related to the RNA interference 
mechanism first discovered in plants (Gurtan and Sharp, 2013; Agrawal et al., 2003; 
Napoli, 1990). The biogenesis of miRNAs usually begins with the transcription of a pri-
miRNA, a 5’ capped and 3’ polyadenylated RNA sequence, containing one or more ~80 
nucleotide hairpin structures (Ha and Kim, 2014). Drosha, a ribonuclease enzyme, then 
releases ~60 nucleotides of the hairpin from the surrounding sequence by a cleaving 
mechanism involving the Drosha cofactor DGCR8, generating a pre-miRNA (Han, 2004). 
The pre-miRNA is subsequently exported from the nucleus through the nuclear pore 
complex, mediated by Exportin-5 (Yi et al., 2003) (Fig. 4.1). Once in the cytoplasm, the 
tip of the pre-miRNA stem loop is cleaved, generating a double stranded 
miRNA/miRNA* duplex, which is subsequently loaded onto Argonaute (Ago), a 
component of the RNA Induced Silencing Complex (RISC) (Boland et al., 2011). The 
miRNA:miRNA* duplex is then separated into single strands, the passenger strand is 
ejected while the guide strand remains bound to Ago and is used to target 
complementary mRNAs for degradation or translational repression (Ha and Kim, 2014). 
Virally-encoded miRNAs possess great utility as they are non-immunogenic and require 
much less space to encode than viral proteins, and so it is no surprise that there are 
numerous viruses that encode their own miRNAs, including many of the herpesviruses 
(Skalsky and Cullen, 2010). Epstein-Barr virus encodes 25 pre-miRNAs, 22 of which are 
expressed during latency II, and 3 in latency III (Barth et al., 2011). Cytomegalovirus 
encodes 15 miRNAs that are, surprisingly, expressed during the lytic cycle. It is 
currently unknown whether HCMV encoded miRNAs play a role in latency, as with 
other herpesviruses (Shen et al., 2014). Other examples from outside the herpesvirus 
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family include Adenovirus, which produces 2 dsRNAs known as virus associated (VA) 
RNAs that act to limit miRNA action through the inhibition of Dicer, but which are, 
themselves, processed into RISC associating miRNAs (Andersson et al., 2005; Aparicio 
et al., 2006). Moreover, Heliothis virescens ascovirus encodes a miRNA that depletes 
the levels of viral DNA polymerase transcripts during late stages of infection, oddly 
acting to reduce viral replication (Hussain et al., 2008). Furthermore, polyomaviruses 
such as SV40, Merkel cell polyomavirus, human BK virus and JC virus all express a 
miRNA known as miR-S1, and its temporal expression, sequence and spatial 
organisation in the genome are all highly conserved (Cantalupo et al., 2005; Seo et al., 
2008). There are also many examples of viruses altering host miRNA expression to 
enhance viral replication. Again the majority of these examples have been discovered 
during herpesvirus infection. EBV is able to induce the expression of both miR-146a 
and miR-155 in B cells, leading to the degradation of a number of interferon responsive 
genes (Cameron et al., 2008)(Lu et al., 2008), while HCMV downregulates miR-100 and 
miR-101, both of which regulate mTOR pathway dynamics (F.-Z. Wang et al., 2008). In 
a complete reversal of the usual miRNA mechanism, Hepatitis C virus utilises miR-122 
in a mechanism that is necessary for viral replication, binding to the 5’ UTR of the viral 
RNA to protect it from degradation by the host exonuclease Xrn1 (Y. Li et al., 2013). 
The introduction and rapid increase in the utility of RNA sequencing technologies 
means that it is now possible to size select and sequence miRNAs (Buermans et al., 
2010; Lee et al., 2010; Pritchard et al., 2012). Furthermore, algorithms have now been 
developed to allow greater quantitation of RNA sequencing data, allowing for the 
investigation of global changes in miRNA levels over multiple samples (Li et al., 2012; 
Metpally et al., 2013). This powerful technology is proving extremely useful in 
unravelling the additional layer of complexity associated with miRNAs in the dynamics 
of gene regulation, particularly in the context of virus infection (Huang et al., 2012; 
Szeto et al., 2014; Shrinet et al., 2014). 
Herein it is demonstrated that KSHV is able to dysregulate a number of host miRNAs 
during lytic infection, including miR-151a-5p and miR-365a-3p. Furthermore, inhibition 
of the function of these miRNAs during KSHV infection increases viral load but 
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decreases viral reinfection, suggesting that these miRNAs play important roles in the 
egress of mature KSHV virions.  
 
Figure 4.1: The role of Exportin-5 in miRNA nuclear export.  
The biogenesis of miRNAs begins in the nucleus with the transcription of pri-miRNAs, capped and 
polyadenylated transcripts containing one or more hairpin structures. The hairpin is cleaved out of the 
surrounding sequence by Drosha, and this newly generated pre-miRNA is subsequently exported into 
the cytoplasm by Exportin-5 in a Ran-GTP dependent mechanism. 
4.2 Exportin-5 and SMARCA4 proteins are found at increased levels in ORF57 
SILAC datasets 
KSHV expresses 18 mature viral miRNAs, all encoded by the latency associated region 
of the viral genome (Qin et al., 2012). They are associated with a number of latent 
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processes, including inhibition of the lytic switch protein, RTA (Bellare and Ganem, 
2009; Lu et al., 2010). It was, therefore, striking when Exportin-5 and the telomerase 
interacting SWI/SNF protein SMARCA4, 2 essential factors in miRNA biogenesis, were 
observed at increased levels in the nucleolus in ORF57 SILAC datasets (Fig. 4.2) (Yi et 
al., 2003; Lassmann et al., 2015). This observation suggests that ORF57 may be able to 
modulate the processing of miRNAs, as well as mRNAs. Due to the lytic expression of 
ORF57 and the latent expression of the KSHV encoded miRNAs, it would appear that 
this alteration is likely to affect the biogenesis or functioning of host miRNAs. Based on 
this hypothesis, the expression of cellular miRNAs was investigated during the course 
of a KSHV lytic replication cycle. To this end, miRNA-seq was performed, where small 
RNA libraries were generated and analysed using next generation sequencing. To 
perform these experiments RNA samples were initially harvested from KSHV infected B 
cells at three different stages of infection, 0h (latent control), 8h (lytic) and 18h (lytic). 
These times allowed for the investigation of early and late stages of infection, as well 
as the observation of general trends in host miRNA levels over the course of the viral 
lytic cycle. The levels of the viral lytic gene ORF57 were examined in the generated 
RNA samples, in order to ensure a progression of the lytic cycle over the chosen times 
(Fig. 4.3). These RNA samples were also subjected to analysis by an Agilent Bioanalyzer 
to ensure the high integrity required for reliable analysis by next generation RNA 
sequencing. 
4.3 Generation of miRNA sequencing libraries 
Following confirmation that the generated total RNA samples were suitable for 
analysis, an Illumina RiboZero kit was employed, which uses magnetic rRNA probes and 
magnetic beads to remove ribosomes from the RNA sample, and the samples were 
assessed by bioanalyzer (Fig. 4.4a). Following this, miRNA sequencing libraries were 
prepared using a NEBNext Small RNA Library Preparation kit. In short, adaptor oligos 
were hybridised to the 3’ end of the RNA, and a complementary primer was also added 
to bind to this adaptor. A 5’ adaptor was also added to the RNA, and the RNA was 
reverse transcribed into cDNA. PCR was then performed to enrich the sample for 
correctly amplified cDNA, and then a clean-up and gel-electrophoresis based size 
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selection protocol was employed to ensure good library quality prior to sequencing. 
Following this, samples were again examined by bioanalyzer (Fig. 4.4b). Following the 
addition of adaptor sequences, the miRNAs were ~160bp in length, and the 
bioanalyzer trace showed a large spike at the corresponding point, with little other 
material present in the sample, suggesting that the libraries were highly enriched for 
miRNAs. The libraries were pooled and sequenced on an Illumina HiSeq at the Leeds 
Institute of Biomedical and Clinical Sciences (LIBACS) by Dr. Sally Harrison.  
 
Figure 4.2: Exportin-5 and SMARCA4 levels increase in nucleolar fraction of KSHV ORF57 expressing 
cells. 
(a) Fold change increase in Exportin-5 and (b) SMARCA4 levels in subcellular fractions of HEK 293T 
expressing an inducible ORF57 protein compared to uninduced cells. 
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Figure 4.3: Extraction of high integrity RNA from TREx BCBL1-Rta cells at 0, 8 and 18 hours post lytic 
reactivation. 
(a) TREx BCBL1-Rta cells were unreactivated (latent control) or reactivated (lytic infection) for 8 or 18 
hours with doxycycline hyclate before total RNA was isolated. This RNA was used to generate cDNA and 
ORF57 specific primers were used to analyse ORF57 mRNA levels in each sample by qRT-PCR. (b) 
Extracted RNA samples were analysed using an Agilent Bioanalyzer and an RNA Integrity Number (RIN) 
was calculated for each sample. 
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Figure 4.4: Preparation of small RNA sequencing libraries from TREx BCBL1-Rta cells at 0, 8 and 18 
hours post lytic reactivation. 
Total RNA samples extracted from TREx BCBL1-Rta cells were processed into small RNA libraries using a 
NEBNext Small RNA Library Prep kit for Illumina. Final libraries were analysed using an Agilent 
Bioanalyzer. 
4.4 KSHV lytic infection affects the expression levels of 19 mature host miRNAs 
The reads generated by miRNA-seq were aligned to a database of all known Homo 
sapiens miRNAs (miRBase version 19). Reads that aligned at more than one location 
were assigned to the most probable location of origin using SeqEM (Martin et al., 
2010). Read counts were normalised using edgeR (Robinson et al., 2010). 
Bioinformatics analysis using SeqEM and edgeR was performed by Dr. Alastair Droop 
and Dr. Lucy Stead at the Leeds Biomedical Health Research Centre. Over 3 million 
reads mapped to canonical miRNAs across the 3 samples. miRNAs displaying the 
greatest fold change between latent and lytic stages were identified and grouped by 
their expression trend over the 3 stages of infection (Fig. 4.5). Most of these miRNAs 
had not previously been identified as altered during KSHV infection, however, both 
miR-221-5p and miR-222-5p have been identified as targets of the KSHV latent nuclear 
antigen (LANA) and Kaposin B, and are, therefore, depleted during latent KSHV 
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infection in endothelial cells (Wu et al., 2011). These miRNAs are believed to play roles 
in reducing endothelial cell migration, and therefore their depletion by LANA and 
Kaposin B is thought to contribute to the increased migration of endothelial cells 
during KSHV infection (Wu et al., 2011). It is not surprising, therefore, that the miRNA 
sequencing data generated from TREx cells shows a large increase in the levels of both 
miR-221-5p and miR-222-5p over the course of KSHV lytic infection. 
It is also interesting to note that many of these miRNAs, including miR-221-5p and miR-
222-5p, have previously been identified in B cell cancer samples (Lim et al., 2015). 
Many miRNAs exhibit cell type specificity, and may even present utility in 
characterising different forms of cancer and cells of origin and may ultimately be used 
as prognostic indicators (Sood et al., 2006; Lim et al., 2015).  
 
Figure 4.5: Identification of 19 mature miRNAs with altered expression levels during KSHV lytic 
infection. 
Small RNA libraries generated from TREx BCBL1-Rta cells at 0 (latent control) 8 and 18 (lytic infection) 
hours post infection were sequenced using an Illumina HiSeq. Sequence reads were analysed by SeqEM 
and aligned to known Homo sapiens miRNA sequences (this work was performed by Dr. Lucy Stead and 
Dr. Alastair Droop – BHRC, Leeds). Read numbers of miRNAs that were significantly altered during the 
course of KSHV lytic infection were plotted on 4 bar charts using MS Excel according to their general 
trend. 
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In order to validate the trends observed in the miRNA-seq data, a highly specific, 
quantitative approach to identify levels of mature miRNAs was required. The stem 
loop qRT-PCR method meets all of these needs, and represents a relatively quick and 
affordable way to verify miRNA sequencing data (Chen, 2005) (Fig. 4.6). The assay 
involves the reverse transcription of a mature miRNA, where specificity is achieved 
using a reverse transcription primer containing a hairpin structure with only ~6 
nucleotides to bind to a target. Despite this relatively short binding sequence, the 
hairpin structure prevents non-specific binding by acting as a barrier. A universal probe 
library (UPL) probe #21 binding site is present in the hairpin sequence, and therefore 
UPL #21 can only bind following denaturation of the reverse transcribed mature 
miRNA. UPL #21 is a short oligo attached to a fluorophore and quencher at each end. 
During Taq Polymerase amplification of the target strand, the quencher and 
fluorophore are released from the oligos, producing a quantifiable signal.  
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Figure 4.6: Stem loop qRT-PCR specifically amplifies mature miRNAs. 
Stem loop qRT-PCR begins with the extraction of total RNA and the subsequent reverse transcription of 
a miRNA of interest using a primer specific to the final 6 nucleotides of the miRNA, containing a hairpin 
loop structure to prevent the binding of non-specific targets. Following reverse transcription, 
quantitative PCR is performed using a Universal Probe Library probe specific to a sequence present in 
the hairpin structure, which is only accessible following the denaturation step. The DNA polymerase 
used in the assay has exonuclease function and is therefore able to release both the fluorophore and 
quencher attached to the probe, producing signal specifically when the target is amplified. 
The KSHV lytic cycle occurs in both B cells and endothelial cells of patients afflicted by 
all KSHV-related malignancies (Ganem, 2007). Therefore, miRNAs that are 
dysregulated by KSHV in multiple cell types would represent the best potential as 
novel drug targets. For this reason, stem loop qRT-PCR was used to investigate the 
expression levels of these miRNAs across 3 different cell lines harbouring a latent KSHV 
genome that could be reactivated (Nakamura et al., 2003; Vieira and O’Hearn, 2004; 
Myoung and Ganem, 2011). Levels of both miR-151a-5p and miR-365a-3p followed 
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similar trends to those seen in the miRNA-seq data across all 3 cell lines (Fig. 4.7). 
Importantly, both of these miRNAs were present at a relative abundance greater than 
0.01% (100 reads per million) in at least one of the samples analysed by miRNA-seq (of 
those that aligned to the known Homo sapiens miRNAs annotated in miRDB). Neither 
of the miRNA trends validated in TREx BCBL1-Rta cells displayed the same levels of 
change as identified in the miRNA-seq expression data. This may be due to biases in 
the miRNA-seq library preparation stages, such as concentration of miRNA levels 
during gel purification.   
As the reads generated by miRNA-seq had only been aligned to the known miRNAs in 
miRDB, it was important to verify that both validated KSHV dysregulated miRNAs were 
not viral in origin. To this end, pairwise alignments were performed between both 
validated miRNAs and all known KSHV encoded mature miRNAs, using the Sequence 
Manipulation Suite Pairwise Align DNA program (Fig. 4.8). Maximum scores were 
generated by aligning each validated miRNA with itself, and scores for KSHV encoded 
miRNAs were then compared to this maximum score, and a percentage calculated. The 
closest similarity between the validated miRNAs and KSHV encoded miRNAs was 
between miR-151a-5p and KSHV miR-K3-5p, at 33%. This result indicates that neither 
of the validated KSHV dysregulated miRNAs are viral in origin, and suggests that they 
have both been correctly identified as cellular miRNAs. 
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Figure 4.7: Validation of changes to miR-151a-5p and miR-365a-3p expression levels over KSHV lytic 
infection in TREx BCBL1-Rta, 293T rKSHV.219 and iSLK.219 cells.  
(a) miR-151a-5p and (b) miR-365a-3p levels over the course of KSHV lytic infection in 3 KSHV-positive 
cell lines. RNA was extracted from TREx BCBL1-Rta, iSLK.219 and 293T rKSHV.219 cells at 0 (latent 
control), 8 and 18 (lytic infection) hours post infection and extracted RNA was subjected to DNase 
treatment. RNA was then reverse transcribed into cDNA using a miRNA specific stem loop RT primer and 
qPCR was performed using primers specific to the mature miRNAs and the stem loop sequence. 3 
biological replicates were combined, the relative values were displayed on a graph and the standard 
deviation was calculated. Error bars = SD, p<0.01 = **, p<0.05 = *compared with 0 h sample from same 
cell line. 
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Figure 4.8: Alignment based rejection of KSHV origins of identified miRNAs. 
(a) List of all 18 known mature miRNAs encoded by KSHV and their nucleotide sequences, as well as 
those of hsa-mir-151a-5p and hsa-mir-365a-3p. (b) Scores were generated for each KSHV encoded 
miRNA to determine their similarity with hsa-mir-151a-5p and has-mir-365a-3p using Sequence 
Manipulation Suite Pairwise Align DNA program. 
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Figure 4.9: The role of miRIDIANs in the inhibition of miRNA action. 
Following nuclear export, pre-miRNAs are cleaved at the tip of the stem loop by Dicer, producing a 
double stranded RNA molecule known as a miRNA:miRNA* duplex. A single strand of this duplex is 
selected by the RISC complex, and separated from its counterpart strand. The selected strand, now 
bound by RISC, is used to target complementary mRNAs for degradation. This process can theoretically 
be ablated by miRIDIAN miRNA inhibitors, which bind to the guide strand and prevent miRNA directed 
mRNA degradation. 
4.5 miRIDIAN miRNA inhibitors specifically prevent action of targeted miRNAs 
In order to assess the possible effects of miR-151a-5p and miR-365a-3p during KSHV 
lytic infection, attempts were made to inactivate their functions. This was achieved 
using miRIDIAN miRNA inhibitors: oligos complementary to miRNAs, consisting of a 
complementary sequence to the targeted miRNA, flanked by hairpin structures on 
either side (Thermo Scientific, 2009; Robertson et al., 2010). These molecules also 
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contain modifications to increase their binding affinity (proprietary information – 
modifications not disclosed). They then function by binding to the targeted mature 
miRNAs that have been selected as guide strands by the RISC complex, miRIDIANs are 
predicted to prevent the use of the guide strand to bind complementary mRNAs, and 
therefore ablate their degradative effects on these mRNAs (Fig. 4.9). 
The effects of targeted miRIDIAN miRNA inhibitors on the validated KSHV dysregulated 
miRNAs were therefore examined. To this end, 293T rKSHV.219 cells were transfected 
with miRIDIANs and 72 hours following transfection, cells were treated to induce the 
KSHV lytic cycle for 0 (control), 8 or 18 hours. Scramble siRNA was used as a control, 
and both miRIDIANs were also used as controls against each other. Total RNA was then 
extracted and subjected to stem loop qRT-PCR as described previously. miRIDIAN 
miRNA inhibitors were shown to specifically decrease detection of their targeted 
miRNA, though miRIDIAN 365a-3p treatment appeared to result in a ~50% reduction in 
the detectable levels of miR-151a-5p at all examined stages of infection, suggesting 
miRIDIAN 365a-3p may exhibit some off target binding (Fig. 4.10). miRIDIAN miRNA 
inhibitors are not predicted to deplete levels of targeted miRNAs, and this result may 
instead indicate that miRIDIAN miRNA inhibitors bind to their target miRNA at higher 
temperatures and with greater efficiency than the stem loop RT primer used during 
the stem loop miRNA qRT-PCR reaction. Alternatively, miRIDIAN miRNA inhibitors may 
inhibit the amplification of reverse transcribed miRNAs during the qPCR stage of the 
technique. Regardless, this data suggests that miRIDIAN miRNA inhibitors can be used 
to interfere with miRNA-target binding to further investigate the roles of miR-151a-5p 
and miR-365a-3p during the KSHV lytic cycle.    
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Figure 4.10: miRidian inhibitors efficiently inhibit target miRNAs from being amplified by stem loop 
miRNA qRT-PCR. 
(a) miR-151a-5p and (b) miR-365a-3p levels following miRIDIAN antagomiR treatment over the course of 
KSHV lytic infection in 293T rKSHV.219  cells. Cells were transfected with scramble siRNA (control) or 
miRidian inhibitor specific to hsa-mir-151a-5p or hsa-mir-365a-3p. 72 hours after transfection lytic 
infection was induced for 0 (latent control) 8 or 18 (lytic infection) hours using NaBu and TPA. Total RNA 
was then harvested and subjected to DNase treatment. RNA was then reverse transcribed into cDNA 
using a stem loop hsa-mir-151a-5p or hsa-mir-365a-3p RT primer and qPCR was performed using 
primers specific to hsa-mir-151a-5p or hsa-mir-365a-3p and the stem loop sequence. 3 biological 
replicates were combined, the relative values were displayed on a graph and the standard deviation was 
calculated. Error bars = SD, p<0.01 = **, p<0.05 = * compared with scramble control for the same time 
point. 
4.6 Inhibition of miR-365a-3p, but not miR-151a-5p, has a minor effect on viral 
RNA expression but no effect on late viral protein expression 
As miRNAs function at a post-transcriptional level, the levels of a panel of KSHV 
encoded mRNAs were examined by qRT-PCR in the presence of both miRIDIANs, as 
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well as scramble siRNA control. The levels of all 5 examined mRNAs were partially 
depleted upon miRIDIAN 365a-3p treatment, while miRIDIAN 151a-5p treatment 
produced discontinuous results, with some KSHV mRNAs becoming depleted, while 
others increased in expression. Interestingly, miRIDIAN 365a-3p caused a dramatic 
reduction in the level of PAN RNA, a long noncoding RNA that is retained in the nucleus 
(Sun et al., 1996; Zhong et al., 1996). During HCV infection, miR-122 has been shown to 
protect viral RNA from degradation (Y. Li et al., 2013), however, miRNAs mature in the 
cytoplasm, and in order for miR-365a-3p to protect PAN in a similar manner, it would 
need to be transported back into the nucleus. 
In order to further investigate whether the slight reduction in viral gene expression 
observed caused a reduction in viral protein production, the effects of miRIDIAN 
miRNA inhibitors on the expression of a late viral protein, the minor capsid protein, 
were examined. Minor capsid protein levels were not affected in the presence of 
miRIDIAN 151a-5p and 365a-3p, according to densitometry. This suggests that the lytic 
gene cascade remains relatively unaffected during miRIDIAN treatment. 
4.7 Inhibition of miR-151a-5p or miR-365a-3p increases viral load following lytic 
replication 
In order to investigate the effect of inhibition of miR-151a-5p and miR-365a-3p on the 
process of viral DNA replication, cells were treated to induce lytic infection for 7 days, 
or left untreated as a latent control, total DNA was subsequently extracted and qPCR 
was performed to assess the levels of KSHV ORF47 present, using GAPDH as a 
normalisation control. Inhibition of miR-151a-5p caused a ~23% increase in viral load, 
while inhibition of miR-365a-3p exhibited a more dramatic effect, increasing viral load 
by ~70%.  
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Figure 4.11: Minor reduction of early KSHV mRNA levels caused by miRidian inhibitors. 
293T rKSHV.219  cells were transfected with scramble siRNA (control), miRidian inhibitor specific to hsa-
mir-151a-5p or miRidian inhibitor specific to hsa-mir-365a-3p . 72 hours after transfection lytic infection 
was induced for 0 (latent control) 8 or 18 (lytic infection) hours using NaBu and TPA. Total RNA was then 
harvested and subjected to DNase treatment. RNA was then reverse transcribed into cDNA using an 
oligo dT primer and qPCR was performed using primers specific to K12, ORF47, ORF57, ORF74 and PAN 
RNA. 3 biological replicates were combined, the relative values were displayed on a graph and the 
standard deviation was calculated. Error bars = SD, p<0.01 = **, p<0.05 = * compared with scramble 
control from the same time point. 
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Figure 4.12: miRIDIANs do not affect levels of late KSHV proteins. 
(a) 293T rKSHV.219 cells transfected with scramble siRNA (control) or miRIDIAN miRNA inhibitors 
targeting either miR-151a-5p or miR-365a-3p were left untreated (latent control) or treated to induce 
lytic replication for 72 hours before protein lysates were harvested and analysed by immunoblot to 
observe the levels of KSHV minor capsid protein, using GAPDH as a loading control. (b) Densitometry 
analysis was performed on the minor capsid protein immunoblot to assess the levels of protein present 
in each reactivated sample. Error bars = SD, p<0.01 = **, p<0.05 = * compared with scramble control. 
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Figure 4.13: miRIDIANs increase viral load following KSHV lytic infection. 
293T rKSHV.219 cells were transfected with scramble siRNA (control) or miRIDIAN miRNA inhibitors 
directed against miR-151a-5p or miR-365a-3p. 72 hours after transfection, cells were treated to induce 
KSHV lytic replication, or left untreated as a latent control. After 7 days, DNA was harvested and viral 
load was assessed using qPCR against ORF47 using GAPDH as a normalisation control. Fold change was 
calculated and graphs were plotted using Microsoft Excel. Error bars = SD, p<0.01 = **, p<0.05 = * 
compared with scramble control from the same time point. 
4.8 Inhibition of miR-151a-5p in KSHV positive cells reduces reinfection of naïve 
cells 
In order to investigate whether the increase in viral load observed during miR-151a-5p 
and miR-365a-3p inhibition was due to increased viral replication or decreased viral 
egress, a viral reinfection assay was performed. 293T rKSHV.219 cells were transfected 
with miRIDIANs or scramble siRNA (control) and reactivated for 7 days before the virus 
containing supernatant was used to infect naïve HEK 293T cells. Viral load was then 
assessed in HEK 293T cells by qPCR (Fig. 4.14). Reinfection using supernatant from 
miRIDIAN 151a-5p treated cells produced a ~19% reduction in viral load in naïve HEK 
293T cells, while miRIDIAN 365a-3p caused a slightly increased reduction of ~23%. This 
data, taken together with data from the viral load assay (Fig. 4.13) suggest that 
inhibition of miR-151a-5p and miR-365a-3p causes a reduction in viral egress, with a 
stronger effect produced by inhibition of miR-365a-3p.  
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Figure 4.14: miRIDIAN 151a-5p and miRIDIAN 365a-3p decrease the ability of newly generated KSHV 
virions to infect naïve cells. 
293T rKSHV.219 cells were transfected with scramble siRNA (control) or miRIDIAN miRNA inhibitors 
directed against miR-151a-5p or miR-365a-3p. 72 hours after transfection, cells were treated to induce 
KSHV lytic replication, or left untreated as a latent control. After 7 days, supernatant was used to infect 
naïve HEK 293T cells. 24 hours post reinfection, DNA was harvested and viral load was assessed using 
qPCR against ORF47 using GAPDH as a normalisation control. Fold change was calculated and graphs 
were plotted using Microsoft Excel. Error bars = SD, p<0.01 = **, p<0.05 = * compared with scramble 
control from the same time point. 
4.9 Discussion 
The utilisation of host miRNAs by viruses represents a relatively new field of biological 
study, and may be of great use in the near future as an area to exploit in the 
development of new antiviral drugs. KSHV, as with many other viruses, particularly the 
Herpesviridae, encodes its own miRNAs but is also able to alter host miRNA dynamics 
to increase the efficiency of mature virion synthesis. Herein, inhibition of miR-365a-3p 
has been demonstrated to increase viral load and decrease reinfection of naïve cells, 
leading to the hypothesis that miR-365a-3p is able to increase the efficiency of viral 
egress. miRNAs are believed to act at a post-transcriptional level and, therefore, it is 
likely that this effect is due to the targeting of specific cellular mRNAs, either for 
degradation or translation repression, by miR-365a-3p. 
miRNA sequencing represents a valuable and high resolution approach for identifying 
dysregulation of global miRNA levels in an unbiased manner. The identification of the 
upregulation of the miR-221/222 cluster during KSHV lytic infection confirms previous 
reports that miR-221 and miR-222 are downregulated by latent KSHV gene products, 
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and also validates the miRNA-seq approach used in this study. 19 mature cellular 
miRNAs were identified as dysregulated during KSHV lytic infection at some point 
between 8 and 18 hours. The validation approaches used in this study confirmed that 
at least 2 of these miRNAs; miR-151a-5p and miR-365a-3p, are dysregulated due to 
KSHV infection, as their levels follow similar trends in 3 different lytically infected cell 
types. This approach did, however, limit the possibility of identifying B cell specific 
miRNA dysregulation during KSHV lytic infection. This means that any future 
therapeutics designed to target miR-151a-5p or miR-365a-3p will have a better chance 
of working in multiple KSHV positive cell types, and therefore is likely to make these 
therapeutics better at treating KS, rather than acting as a preventative measure. 
The use of miRIDIAN antagomiRs has been demonstrated, both here and in other 
studies, to reduce the detection of targeted mature miRNAs by miRNA specific stem 
loop qRT-PCR. It is not predicted that these miRIDIANs will lead to the degradation of 
the mature miRNAs, therefore, this effect is believed to be due to highly efficient 
binding of miRIDIANs to their target miRNA. miRNA sponges also represent a viable 
means of ablating miRNA function, however, as each miRNA sponge is targeted against 
multiple miRNAs, often miRNA families, the use of miRIDIAN antagomiRs is more 
appropriate in this study as well as other studies investigating the roles of specific 
individual miRNAs. 
Exportin-5 and SMARCA4 were observed to localise to the nucleolus of ORF57 
expressing cells by subcellular fractionation and SILAC analysis. Both of these proteins 
play important roles in the biogenesis of mature host miRNAs, and were observed at 
higher levels in nucleolar fractions during ORF57 expression, suggesting a similar effect 
may occur during KSHV lytic infection. As KSHV encoded miRNAs are believed to be 
expressed solely during latent infection, an investigation into the effect of KSHV lytic 
infection on the levels of host encoded miRNAs was undertaken. However, the 
relocalisation of Exportin-5 and SMARCA4 was not further characterised. ORF57 
localises predominantly to the nucleolus of infected cells, and has been shown to 
interact with many RNA interacting proteins, particularly those involved in mRNA 
biogenesis and maturation. It remains to be seen whether ORF57 is also able to exert 
its influence on miRNA related processes, as indicated by the aforementioned 
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relocalisation of Exportin-5 and SMARCA4, and so a further investigation into this 
phenomenon is certainly warranted. 
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CHAPTER 5 
~ 
KSHV dysregulated microRNA miR-365a-3p depletes levels of DOCK5 
mRNA during late infection, and DOCK5 overexpression reduces viral 
shedding 
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5 KSHV dysregulated microRNA miR-365a-3p depletes levels of DOCK5 
mRNA during late infection, and DOCK5 overexpression reduces viral 
shedding  
5.1 Introduction 
The sequencing of mRNAs is rapidly replacing microarray technology for transcriptional 
profiling experiments (Ozsolak and Milos, 2011; Law et al., 2013). The advantages of 
these next generation sequencing technologies are manifold, allowing the discovery of 
novel mRNAs, as well as the detection of RNAs containing sequence polymorphisms, 
alternative isoforms and edited molecules, whilst also reducing background noise 
associated with fluorescence-based quantification methods and removing the 
possibility for non-specific signal detection (Wang et al., 2009; Malone and Oliver, 
2011; Zhao et al., 2014).  
The regulation of mRNA abundance is a key aspect of gene regulation, and can be 
affected by a number of different mechanisms (Valencia-Sanchez, 2006; Garneau et al., 
2007; Wu and Brewer, 2012; Fu et al., 2014). These include mRNA degradation, 
through well characterised processes such as exo/endonuclease activity, as seen with 
KSHV ORF37 encoded protein SOX, which is able to cleave host mRNAs, allowing the 
cellular exonuclease Xrn1 to bring about large scale degradation of host mRNA 
molecules (Covarrubias et al., 2011). Furthermore, SOX exerts control over numerous 
other cellular mRNA maturation/degradation factors, whilst also appearing to affect 
mRNA trafficking pathways (Sokoloski et al., 2009; Lee and Glaunsinger, 2009; Arias et 
al., 2009). This demonstrates the importance of regulating host mRNA abundance 
during lytic viral infection. Conversely, the actions of many miRNAs have also been 
shown to negatively affect the abundance of target mRNAs (Fabian et al., 2010; 
Valinezhad Orang et al., 2014). Indeed, this is now believed to be the major role of 
miRNAs, and hundreds of host miRNA-host mRNA interactions have now been 
observed. Interestingly, many viruses have been shown to encode miRNAs to target 
host pathways, and have also developed ways to alter the levels of host miRNAs to 
dysregulate host gene regulation (Skalsky and Cullen, 2010). Moreover, multiple viral 
proteins appear to target host miRNA transcription factors in order to further exploit 
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the cell and increase replication efficacy (Z. Li et al., 2013). Furthermore, some viruses 
utilise host miRNAs in non-canonical mechanisms, such as HCV, which is able to 
protect its viral genomic RNA, using miR-122 as a shield, preventing the activity of Xrn1 
at the 5’ end of the genome (Y. Li et al., 2013).  
In this chapter, mRNA sequencing has been employed to examine the expression levels 
of predicted cellular mRNA targets of miR-151a-5p and miR-365a-3p at multiple points 
during KSHV lytic infection. Results highlight an interaction between miR-365a-3p and 
at least two cellular mRNAs, leading to degradation of these mRNAs during late KSHV 
lytic infection. Importantly, this effect is much more pronounced than the effect 
caused by the SOX induced host shutoff alone. 
5.2 Generation of mRNA sequencing libraries 
In order to further understand the effects of miR-151a-5p and miR-365a-3p 
dysregulation during KSHV lytic replication, mRNA sequencing was utilised in an 
attempt to find target mRNAs affected by these miRNAs. To this end, total RNA was 
extracted from TREx BCBL1-Rta cells at 0h (latent control), 8h and 18h post KSHV lytic 
infection, and examined using an Agilent Bioanalyzer (Figure 5.1A). Samples were of 
high integrity, and suitable for mRNA-sequencing. mRNA sequencing libraries were 
then generated using an Illumina TruSeq Stranded mRNA Library Prep Kit and libraries 
were examined using an Agilent Bioanalyzer (Figure 5.1B). Loss of ribosomal RNA was 
observed, along with an increase in abundance of RNAs between 25 and 500 base 
pairs, believed to be total mRNA following fragmentation. Libraries were pooled at a 
1:1:1 ratio and sequenced using an Illumina HiSeq by Dr. Sally Harrison and Dr. 
Catherine Daly (LIBACS). Reads were aligned to the Homo sapiens genome and gene 
expression analysis was performed by Dr. Ian Carr (LIBACS). 
150 
 
 
Figure 5.1: Preparation of mRNA sequencing libraries from TREx BCBL1-Rta cells at 0, 8 and 18 hours 
post lytic reactivation.  
(a) Total RNA samples extracted from TREx BCBL1-Rta cells and (b) mRNA sequencing libraries. Samples 
were analysed using an Agilent Bioanalyzer and RNA integrity values were calculated.  
5.3 KSHV dysregulation of miR-365a-3p does not affect abundance of IL-6 or vIL-6 
transcripts 
An interaction between miR-365a-3p and the cellular IL-6 transcript has previously 
been reported, resulting in the degradation of IL-6 transcripts (Xu et al., 2011). In order 
to examine whether this interaction plays a role during KSHV lytic infection, IL-6 read 
counts over the course of KSHV lytic infection were plotted on a bar chart (read counts 
were used instead of quantified expression data due to issues with normalisation 
caused by the KSHV host shutoff phenomenon as well as the increasing complement of 
viral mRNA in samples from later timepoints) (Fig. 5.2A). IL-6 transcript levels 
appeared to increase over the course of infection, as previously reported (Aoki et al., 
1999; Polson et al., 2002). This suggests miR-365a-3p does not deplete the abundance 
of IL-6 mRNA during KSHV infection in TREx BCBL1-Rta cells. To further investigate this, 
293T rKSHV.219 cells were transfected with scramble siRNA control or miRIDIANs 
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directed against miR-151a-5p or miR-365a-3p and levels of cellular IL-6 mRNA, as well 
as the viral homolog vIL-6 mRNAs were quantified by qRT-PCR at 0h (latent control), 8h 
and 18h post lytic infection (Fig. 5.2B). Abundance of both cellular and viral IL-6 
mRNAs were observed to increase over the course of infection, in agreement with the 
mRNA sequencing data from TREx BCBL1-Rta cells. Taken together, these data suggest 
that KSHV does not upregulate miR-365a-3p in order to regulate IL-6 or vIL-6 mRNA 
levels.  
 
Figure 5.2: Interleukin-6 mRNA levels are not depleted during KSHV lytic infection in TREx BCBL1-Rta 
cells.  
(a) Read counts from mRNA sequencing of TREx BCBL1-Rta cells corresponding to Interleukin 6 over the 
course of KSHV lytic infection. (b) 293T rKSHV.219  cells were transfected with scramble siRNA (control), 
or miRidian inhibitors specific to hsa-mir-151a-5p or hsa-mir-365a-3p. 72 hours after transfection lytic 
infection was induced for 0 (latent control) 8 or 18 (lytic infection) hours. Total RNA was then harvested 
and extracted RNA was subjected to DNase treatment. RNA was then reverse transcribed into cDNA 
using an oligo dT primer and qRT-PCR was performed using primers specific to IL-6 and vIL-6. GAPDH 
was used as a normalisation control. 3 biological replicates were combined, the relative values were 
displayed on a graph and the standard deviation was calculated. Error bars = SD, p<0.01 = **, p<0.05 = * 
compared with scramble control from the same time point. 
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5.4 Prediction and validation of cellular mRNAs targeted by miR-151a-5p and 
miR-365a-3p 
In order to determine potential mRNA targets of miR-151a-5p and miR-365a-3p, open 
source miRNA target prediction programs, miRDB.org and microRNA.org, were 
employed (Betel et al., 2007; Wong and Wang, 2015). Genes identified in these 
analyses were then cross referenced with the mRNA sequencing data in order to 
examine their read counts. The trends of the predicted mRNA targets of miR-151a-5p 
and miR-365a-3p were then plotted on a scatter graph after normalising the read 
counts so that each mRNA started at a value of 1 in the 0h sample (Fig. 5.3). The vast 
majority of mRNAs appeared to decrease in abundance by 8 hours, and this effect was 
more dramatic by 18 hours. This phenomenon has previously been reported during 
KSHV and is known as the host shutoff response, mainly caused by the interaction 
between the viral protein SOX (shutoff and exonuclease) and the cellular 
exoribonuclease Xrn1 (Covarrubias et al., 2011). In order to compensate for this effect, 
the 4 mRNAs that were depleted to the largest extent were selected for each miRNA 
(solid lines, Fig. 5.3). It was hypothesised that the more rapid and enhanced depletion 
of these mRNAs may demonstrate an additional degradative effect due to the action of 
the identified miRNAs. HOXA3 was selected as the fourth predicted target of miR-
151a-5p, as its expression trend inversely correlated with that of the miRNA during 
KSHV lytic infection. Therefore, these mRNAs were taken forward for further analysis.  
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Figure 5.3: mRNA-seq expression data for predicted miR-151a-5p and miR-365a-3p target genes.   
(a) miRNA target prediction software was used to identify mRNAs predicted to be bound by miR-151a-
5p and (b) miR-365a-3p. Predicted mRNAs were cross referenced with mRNA sequencing data from 
KSHV infected TREx BCBL1-Rta cells. Read counts for identified mRNAs were all normalised to give a 
value of 1 in the 0h sample. Trends were then plotted on scattergraphs. Solid lines indicate 4 mRNAs 
that are most depleted over the course of KSHV infection. 
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In order to assess the validity of the predicted miRNA-mRNA interactions, the 
abundance of the mRNAs were investigated during KSHV lytic infection in the presence 
of scramble siRNA as well as miRIDIANs directed against miR-151a-5p and miR-365a-
3p. However, a suitable reference gene was required in order to normalise the data. 
The criteria set for this reference gene were that it should remain at the same 
abundance over the course of the KSHV infection (i.e. should not be subjected to the 
host shutoff response) and that its abundance should not be affected by either 
miRIDIAN or scramble siRNA. A number of candidate RNAs were chosen for 
investigation: 5s and 18s ribosomal RNA should remain stable over a range of cellular 
stresses; ABI3, DSP, FAM9C and SPINK2 all remained at relatively stable levels in the 
mRNA sequencing data, and GAPDH was also examined as this gene is commonly used 
as a normalisation control in many laboratories across the world. The host shutoff 
response was visualised by counting up the total number of reads that aligned to the 
Homo sapiens genome in each sample analysed by mRNA sequencing and a scatter 
graph was plotted (Fig. 5.4). The levels of candidate genes were then assessed at 0h, 
8h and 18h post KSHV lytic infection in the presence of scramble siRNA, and miRIDIANs 
directed against miR-151a-5p and miR-365a-3p. The levels were then displayed in bar 
charts (Fig. 5.4). Surprisingly, levels of both 5s and 18s rRNA were dramatically altered 
between different samples, appearing to be depleted by KSHV infection, and stabilised 
at the 8h time point by either miRIDIAN. Levels of ABI3 and FAM9C transcripts 
displayed an increase at 0h in the presence of miRIDIAN 365a-3p, whilst levels of 
SPINK2 appeared to increase at 18h in the presence of scramble siRNA. DSP and 
GAPDH appeared to be the most appropriate reference genes for qRT-PCR involving 
miRIDIANs and KSHV infection. GAPDH was eventually chosen because although 
transcript levels drop over the course of KSHV lytic infection, the error between 
samples at individual timepoints was less than that of DSP. 
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Figure 5.4: Determination of GAPDH as a suitable qRT-PCR reference gene during KSHV lytic 
reactivation in 293T rKSHV.219 cells. 
293T rKSHV.219  cells were transfected with scramble siRNA (control), or miRidian inhibitors specific to 
hsa-mir-151a-5p or hsa-mir-365a-3p. 72 hours after transfection lytic infection was induced for 0 (latent 
control) 8 or 18 (lytic infection) hours. Total RNA was then harvested and subjected to DNase treatment. 
RNA was then diluted to 50ng µl
-1
 and reverse transcribed into cDNA using random hexamers (for 5s and 
18s rRNA) or oligo dT primers and qRT-PCR was performed using primers specific to 5s rRNA, 18srRNA, 
ABI3, DSP, FAM9C, GAPDH and SPINK2. 3 biological replicates were combined, the relative values were 
displayed on a graph and the standard deviation was calculated. Error bars = SD, p<0.01 = **, p<0.05 = * 
compared with scramble control of the same time point. 
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The levels of 4 predicted mRNA targets of miR-151a-5p; HOXA3, HSPA8, SLC15A4 and 
ZNF512 were then assessed using qRT-PCR in the presence of scramble siRNA or 
miRIDIANs directed against miR-151a-5p or miR-365a-3p (Fig. 5.5). miRIDIAN 151a-5p 
did not appear to produce a stabilising effect on any of the mRNAs tested, suggesting 
that miR-151a-5p does not cause an enhanced degradation of these predicted target 
mRNAs during KSHV host shutoff. This therefore, suggests that the viral host shutoff 
response alone degrades these mRNAs more rapidly than many of the other mRNAs 
predicted to interact with miR-151a-5p. Interestingly, in 293T rKSHV.219 cells, the 
levels of both HOXA3 and HSPA8 appeared stable when compared with GAPDH, 
suggesting they are depleted at the same rate, differing from the trend observed in the 
TREx BCBL1-Rta mRNA sequencing data. Furthermore, levels of SLC15A4 appeared to 
increase in scramble control samples when normalised to GAPDH, suggesting this gene 
is depleted at a slower rate than GAPDH, again differing from the trend seen in the 
mRNA sequencing data. ZNF512 was seen to decrease over the course of the 
experiment when normalised to GAPDH, following the trend observed in the mRNA 
sequencing data. This highlights the differences between the dynamics of mRNA 
expression in different cell lines.   
The levels of 4 predicted mRNA targets of miR-365a-3p; DOCK5, PRUNE2, FMN2 and 
SGK1 were assessed using qRT-PCR in the presence of scramble siRNA or miRIDIANs 
directed against miR-151a-5p or miR-365a-3p (Fig. 5.6). miRIDIAN 365a-3p did not 
appear to produce a stabilising effect on FMN2 or SGK1, suggesting that miR-365a-3p 
does not cause an enhanced degradation of these mRNAs during KSHV host shutoff. 
Both of these mRNAs were degraded at a higher rate than GAPDH, in agreement with 
the mRNA sequencing data. Interestingly, both DOCK5 and PRUNE2 mRNA levels were 
stabilised by miRIDIAN 365a-3p at 18h post KSHV lytic infection, meaning that without 
the action of miR-365a-3p these mRNAs are degraded at the same rate as GAPDH. This 
suggests that KSHV is able to utilise host miRNAs to degrade specific host mRNAs at a 
much greater rate than by the SOX induced host shutoff response alone. This effect is 
clearly most pronounced after 8 hours, as the lytic cycle moves from the immediate 
early into the early stage – coinciding with the expression of a large number of viral 
genes, including ORF37 (SOX).  
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Figure 5.5: Predicted miR-151a-5p target gene levels are not affected by inhibition of miR-151a-5p 
action using miRidian inhibitor. 
293T rKSHV.219  cells were transfected with scramble siRNA (control), or miRidian inhibitors specific to 
hsa-mir-151a-5p or hsa-mir-365a-3p. 72 hours after transfection lytic infection was induced for 0 (latent 
control) 8 or 18 (lytic infection) hours. Total RNA was then harvested and subjected to DNase treatment. 
RNA was then reverse transcribed into cDNA using an oligo dT primer and qRT-PCR was performed using 
primers specific to HSPA8, SLC15A4, HOXA3 and ZNF512. GAPDH was used as a normalisation control. 3 
biological replicates were combined, the relative values were displayed on a graph and the standard 
deviation was calculated. Error bars = SD, p<0.01 = **, p<0.05 = * compared with scramble control of 
the same time point. 
5.5 DOCK5 overexpression does not affect KSHV RNA or late protein expression 
As miR-365a-3p inhibition appeared to affect KSHV RNA and protein expression levels, 
it was hypothesised that DOCK5 overexpression may also cause a similar effect. In 
order to investigate this, 293T rKSHV.219 were transfected with DOCK5-GFP or GFP 
(control) and either induced for 0 (latent control) 8 or 18 hours lytic infection. The 
expression levels of a panel of KSHV encoded RNAs were then examined by qRT-PCR 
(Fig. 5.7). DOCK5-GFP overexpression did not appear to affect the levels of any KSHV 
RNAs tested at various times post infection. This indicates that the reduction in KSHV 
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RNA levels observed in the presence of miRIDIAN 365a-3p is likely due to the inhibition 
of interactions between miR-365a-3p and other mRNA targets.  
 
Figure 5.6: Expression levels of predicted miR-365a-3p target genes DOCK5 and PRUNE2 are stabilised 
by inhibition of miR-365a-3p action using miRidian inhibitor. 
293T rKSHV.219 cells were transfected with scramble siRNA (control), or miRidian inhibitors specific to 
hsa-mir-151a-5p or hsa-mir-365a-3p. 72 hours after transfection lytic infection was induced for 0 (latent 
control) 8 or 18 (lytic infection) hours. Total RNA was then harvested and subjected to DNase treatment. 
RNA was then reverse transcribed into cDNA using an oligo dT primer and qRT-PCR was performed using 
primers specific to DOCK5, PRUNE2, FMN2 and SGK1. GAPDH was used as a normalisation control. 3 
biological replicates were combined, the relative values were displayed on a graph and the standard 
deviation was calculated. Error bars = SD, p<0.01 = **, p<0.05 = * compared with scramble control of 
the same time point. 
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Figure 5.7: DOCK5-GFP overexpression has no effect on expression levels of KSHV RNAs. 
293T rKSHV.219  cells were transfected with DOCK5-GFP or GFP (control). 24 hours after transfection 
lytic infection was induced for 0 (latent control) 8 or 18 (lytic infection) hours. Total RNA was then 
harvested and subjected to DNase treatment. RNA was then reverse transcribed into cDNA using an 
oligo dT primer and qRT-PCR was performed using primers specific to K12, ORF47, ORF57, ORF74 and 
PAN. GAPDH was used as a normalisation control. 3 biological replicates were combined, the relative 
values were displayed on a graph and the standard deviation was calculated. Error bars = SD, p<0.01 = 
**, p<0.05 = * compared with GFP control of the same time point. 
The effects of DOCK5-GFP overexpression on late viral protein expression was also 
examined. 293T rKSHV.219 cells transfected with DOCK5-GFP, GFP (control) or 
untransfected (control) were induced for 0 (control) or 72 hours lytic infection. Lysates 
were harvested and immunoblotting was performed to examine the levels of DOCK5-
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GFP, GFP and minor capsid protein, using GAPDH as a loading control (Fig. 5.8). 
Overexpression of DOCK5-GFP was not observed to significantly affect the levels of 
minor capsid protein produced by densitometry analysis. This suggests that 
overexpression of DOCK5-GFP does not significantly affect the efficiency of the viral 
lytic gene cascade.  
5.6 DOCK5 overexpression reduces rate of viral shedding 
DOCK5 is a member of the DOCK-A family of proteins, which are believed to act as 
guanine nucleotide exchange factors (GEFs) with the ultimate goal of activating small G 
proteins (Sanders et al., 2009; Ogawa et al., 2014). DOCK5, specifically, mediates Rac 
activity, and therefore may play an important regulatory role in a diverse range of Rac-
related cellular processes (Cote, 2002; Brugnera et al., 2002; Meller et al., 2002). 
Interestingly, other members of the DOCK family have been shown to influence 
cytoskeletal change through activation of Rac (Sanui, 2003; Xu and Jin, 2012). The host 
cell cytoskeleton plays important roles during many viral infections, and can act in both 
pro- and anti-viral mechanisms (Johnson and Huber, 2002; Mothes et al., 2010; 
Fletcher and Mullins, 2010; Delorme-Axford and Coyne, 2011; Taylor et al., 2011; Xu et 
al., 2014; Knight et al., 2015). Herpesviruses in particular have been shown to use actin 
networks during ingress in certain cell types (Clement et al., 2006). Furthermore, it has 
been demonstrated that some herpesviruses use an ATP-dependent mechanism in 
order to translocate nucleocapsids inside the nucleus of an infected cell, with actin 
standing out as a prime candidate for the mediation of this process (Forest et al., 
2005). Conversely, the cortical actin network can act as an inhibitor to viral egress, as it 
has evolved to function as a barrier that must be overcome prior to the secretion of 
granules and other small biological structures (Ward, 2011). Myosin Va (myoVa) is a 
key protein in this mechanism, and allows such secretory structures to pass through 
the cortical actin network, and this has also been implicated in HSV-1 egress (Roberts 
and Baines, 2010). Furthermore, myoVa expression is important for the correct 
localisation of the HSV-1 encoded gD, gB and gM glycoproteins (Roberts and Baines, 
2010).  
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Figure 5.8: Overexpression of DOCK5-GFP does not affect KSHV mCP expression in 293T rKSHV.219 
cells. 
(a) 293T rKSHV.219 cells were transfected without DNA (mock), pEGFP-N1 or pDOCK5-GFP. 48 hours 
after transfection cells were either reactivated with NaBu and TPA for 72 hours (lytic infection) or left 
unreactivated (latent - control). Lysates were then harvested and immunoblot analysis was performed 
with antibodies specific to GFP, GAPDH and KSHV mCP ORF26. GAPDH specific antibody was used to 
control for equal loading. (b) The fold change in mCP levels was calculated for each reactivated sample 
when compared with scramble siRNA control. Immunoblots were analysed using ImageJ software. 
Values are average of 3 independent immunoblots. Error bars = SD, p<0.01 = **, p<0.05 = * compared 
with Untransfected control. 
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Therefore, it was hypothesised that by stimulating the overexpression of miR-365a-3p, 
KSHV may deplete levels of DOCK5 in order to overcome the cortical actin barrier. As 
such, it was also hypothesised that DOCK5-GFP overexpression would limit viral egress. 
In order to investigate these hypotheses, 293T rKSHV.219 cells were transfected with 
DOCK5-GFP or GFP (control). 24 hours post transfection, cells were induced for lytic 
reactivation, or left uninduced (latent control). 7 days post lytic infection, cells were 
collected by centrifugation, DNA was harvested and viral load was measured by qPCR 
(Fig. 5.9). DOCK5-GFP overexpression was observed to increase viral load by 50% after 
7 days, which may suggest one of two possibilities. Firstly, that DOCK5-GFP 
overexpression promotes viral replication, or secondly, limits viral egress.  
 
Figure 5.9: DOCK5-GFP overexpression increases viral load following lytic replication in 293T 
rKSHV.219 cells.  
293T rKSHV.219  cells were transfected with DOCK5-GFP or GFP (control). 24 hours after transfection 
lytic infection was induced for 0 (latent control) or 7 days (lytic infection). Total DNA was then harvested 
and qPCR was performed using primers specific to ORF47. GAPDH was used as a normalisation control. 3 
biological replicates were combined, the relative values were displayed on a graph and the standard 
deviation was calculated. Error bars = SD, p<0.01 = **, p<0.05 = * compared with GFP control of the 
same reactivation state. 
 
In order to determine whether DOCK5-GFP overexpression caused enhanced viral 
expression or reduced viral egress, a reinfection assay was performed using KSHV 
naïve cells. 293T rKSHV.219 cells were transfected with DOCK5-GFP or GFP (control). 
24 hours post transfection, cells were induced for lytic reactivation, or left uninduced 
(latent control). 7 days post lytic infection, cells were pelleted by centrifugation and 
supernatant was used to infect KSHV naïve HEK 293T cells. 1 day post infection, DNA 
was harvested and viral load was measured by qPCR (Fig. 5.10). Reinfection was 
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impaired using supernatant from DOCK5-GFP expressing cells when compared with 
GFP expressing cells. Taken together in combination with the results from the viral 
load assay in 293T rKSHV.219 cells (Fig. 5.9), these data suggest that DOCK5-GFP 
overexpression is able to reduce KSHV egress. Furthermore, this suggests that KSHV 
upregulates miR-365a-3p levels in order to deplete levels of DOCK5 overcoming this 
inhibitory effect of DOCK5 and increasing viral egress.    
 
Figure 5.10: DOCK5-GFP overexpression reduces the ability of newly generated KSHV virions to infect 
naïve cells. 
293T rKSHV.219  cells were transfected with DOCK5-GFP or GFP (control). 24 hours after transfection 
lytic infection was induced for 0 (latent control) or 7 days (lytic infection). Total DNA was then harvested 
and qPCR was performed using primers specific to ORF47. GAPDH was used as a normalisation control. 3 
biological replicates were combined, the relative values were displayed on a graph and the standard 
deviation was calculated. Error bars = SD, p<0.01 = **, p<0.05 = * compared with GFP control of the 
same reactivation state. 
 
5.7 Discussion 
It is becoming evident that by combining multiple high throughput, high resolution 
approaches, further insight can be gained into biological phenomena than by the 
application of any individual approach. Herein, it is demonstrated that by combining 
miRNA-seq, open source miRNA target prediction and mRNA-seq during viral infection, 
it is possible to identify dysregulated miRNAs, as well as their downstream targets. 
These approaches have variable false positive rates, and in this particular study of 8 
predicted target mRNAs examined, only 2 were found to be associated with real 
biological effects, representing a 25% success rate, albeit with a very small sample size. 
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This emphasises the requirement for validation of results attained through these 
approaches in a wet laboratory setting. It has also previously been demonstrated that 
by repeating the initial analyses, the data obtained tend to exhibit an increased 
percentage of positive hits. Nevertheless, in this study 2 previously unreported mRNA 
targets of miR-365a-3p have been identified, and DOCK5 has been demonstrated to 
have an inhibitory effect on a lytic viral process prior to the release of a mature 
infectious virion, hypothesised to be viral egress. 
DOCK5 belongs to the DOCK family of proteins, which are believed to contribute 
towards cytoskeleton organisation, particularly through the polymerization of actin (Li 
et al., 2001; Kaipa et al., 2013). Many viruses have been shown to interact with the 
host cytoskeleton in order to mediate viral ingress, movement of viral material to 
various subcellular structures, viral egress, cell to cell spread as well as cell motility and 
metastatic potential (Johnson and Huber, 2002; Mothes et al., 2010; Taylor et al., 
2011; Knight et al., 2015). This demonstrates the importance of the host cytoskeleton, 
both as a functional highway for the movement of various molecules around the 
intracellular environment, and also as a barrier to molecules attempting to gain access 
to or escape from the cell (Fletcher and Mullins, 2010; Delorme-Axford and Coyne, 
2011). Furthermore, the involvement of the cytoskeleton in cell to cell spread and 
virally induced metastasis demonstrates that these intracellular dynamics can affect 
intercellular processes, particularly during viral infection (Radtke et al., 2006; Taylor et 
al., 2011; Xu et al., 2014; Knight et al., 2015). It is not surprising, therefore, that many 
viruses exert considerable control over the host cytoskeleton at multiple levels and 
times during infection. Expression of the hypothesised actin regulator protein DOCK5, 
or inhibition of miR-365a-3p, which is herein shown to also increase DOCK5 during 
KSHV lytic infection, increases the viral load of treated cells, whilst reducing the release 
of infectious mature virions for reinfection in naïve cells. It is therefore hypothesised 
that DOCK5 expression inhibits viral egress. Furthermore, it is hypothesised that this 
effect is, at least in part, associated with actin dynamics, possibly involved in capsid 
movement following the assembly and partial maturation of a new virion.  
Alternatively, actin may interfere with egress at the point of viral release from the cell, 
as actin forms a network near the cellular periphery known as the cortical actin 
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network. Indeed, the cortical actin network has been shown to act as a barrier to HSV-
1 egress (Roberts and Baines, 2010). HSV-1 is able to overcome this effect via an 
interaction with the molecular motor protein Myosin Va, which is able to mediate the 
movement of HSV-1 virions through the cortical actin network, ultimately leading to 
the efficient egress of infectious mature virions. 
The effects of PRUNE2 overexpression on the KSHV lytic cycle have not been explored. 
PRUNE2 is a 340 kDa protein that has been characterised as a proapoptotic factor, 
associated with a favourable prognosis in neuroblastoma and epithelial-derived 
cancers (Machida et al., 2006; Tatsumi et al., 2015). PRUNE2 expression produces 
downstream effects on a number of proteins associated with the DNA damage 
response, including AKT, forkhead box protein O3 (FOXO3a) and ATM, via an 
interaction with apoptosis regulator Bcl-2 (Bcl-2) (Tatsumi et al., 2015). It has yet to be 
determined whether the downregulation of PRUNE2 mRNA produces an effect at the 
protein level, however this may correlate with a decrease in apoptosis of KSHV 
infected cells, which has already been discussed in chapter 3 of this work. 
Furthermore, low expression of PRUNE2 is associated with poor prognosis in a number 
of cancers, and therefore may also be of research interest with respect to Kaposi’s 
sarcoma and the development of novel therapeutics against this important disease.   
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6 Discussion and future perspectives 
Since the discovery of KSHV in 1994, the virus has been extensively studied and 
important many virus-host interactions have been identified (Chang et al., 1994). 
Despite this, a significant number of interactions remain uncharacterised, and many 
more are yet to be discovered. High throughput, high resolution “omics” approaches 
represent powerful technologies to aid our understanding of these interactions and 
processes. Herein, three of these approaches, SILAC-based quantitative proteomics, 
miRNA sequencing and mRNA sequencing, have been utilised to identify and 
characterise novel interactions between KSHV and the host cell.  
In chapter 3, it is observed that KSHV lytic infection leads to the increased abundance 
of a number of splicing factors, including Prp19 (Chanarat and Sträßer, 2013), in 
subnuclear bodies such as the nucleolus and nuclear speckles. Prp19 was observed to 
interact with the KSHV encoded ORF57 protein, which plays an important role in all 
stages of the maturation and nuclear export of KSHV encoded mRNAs (Schumann et 
al., 2013). KSHV encodes both intron-containing and intronless transcripts (Arias et al., 
2014 p. 0), and therefore the interactions between Prp19 and both of these types of 
viral mRNAs were examined, using both overexpression and depletion of Prp19, as well 
as its cofactor, CDC5L (Grote et al., 2010). Unexpectedly, depletion of either or both of 
these proteins did not appear to affect KSHV transcript maturation or protein 
production, despite previous suggestions that Prp19/CDC5L complex recruitment is 
essential for hTREX occupancy at both inton-containing and intronless transcripts 
(Chanarat et al., 2011). While this effect can be explained by the ORF57 dependent 
direct recruitment of hTREX to viral intronless transcripts (Boyne et al., 2008), it is 
particularly striking that KSHV encoded intron-containing transcript maturation and 
export is not affected by Prp19 and CDC5L depletion. Although it is possible that a 
small pool of both of these proteins remains in the cell following depletion by siRNA 
treatment, it seems unlikely that this greatly reduced pool would achieve the same 
efficiency of mRNA maturation and export. This may suggest that ORF57 is able to 
exert considerable influence on the splicing of viral intron-containing transcripts, 
allowing them to bypass the requirement for Prp19/CDC5L complex activity in this 
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process. Indeed, in support of this, ORF57 is necessary for the complete splicing of the 
alternatively spliced viral K8 transcript (Majerciak et al., 2008). 
Prp19 overexpression was observed to contribute to a minor activation of several DNA 
damage response pathway proteins. Although this effect has not been previously 
described, Prp19 ubiquitylation is known to increase during overexpression (Lu and 
Legerski, 2007 p. 19), and this modification is also observed during the involvement of 
Prp19 in the ATR-Chk1 DNA damage signalling pathway, which may partially explain 
this unexpected effect. Interestingly, ORF57 overexpression limits this phenomenon, 
suggesting that the interaction between ORF57 and Prp19 may be a pro-viral response 
to prevent activation of the ATR-Chk1 dependent DNA damage response. Indeed, it has 
been previously observed that while the ATM-Chk2 and DNA-PK dependent DNA 
damage response pathways are both activated during KSHV lytic infection, 
downstream signalling of the ATR-Chk1 dependent pathway remains inactive 
(Hollingworth et al., 2015). It was subsequently demonstrated that, upon DNA damage 
induction, ORF57, Prp19 and ATRIP all localise to subnuclear puncta, often observed 
near the nuclear pore, possibly indicating sites of euchromatin (Jerabek and 
Heermann, 2014). Euchromatin is more susceptible to both camptothecin induced 
DNA damage (Bassi et al., 1998), as well as the R-loop induced DNA damage that is 
known to occur during KSHV infection (Jackson et al., 2014). It is therefore 
hypothesised that ORF57 blocks a role of Prp19 in the ATR-Chk1 DNA damage 
signalling pathway, limiting downstream pathway activation, presumably to prevent 
apoptosis or cell cycle arrest which would likely be detrimental to viral replication. 
Further investigation is necessary in order to demonstrate that ORF57 is, indeed, able 
to specifically block Prp19 function in this pathway, and that this interaction is not a 
side effect of ORF57 inhibition of ATRIP function, or the function of any other ATR-
Chk1 DNA damage response pathway proteins that may be associated with these foci. 
This could initially be investigated by analysing post translational modifications of RPA, 
which is ubiquitylated by Prp19 during early stages of the ATR-Chk1 pathway. 
Furthermore, additional studies are necessary to demonstrate that inhibition of the 
ATR-Chk1 DNA damage response pathway is beneficial to the virus, particularly as the 
ATM-Chk2 and DNA-PK pathways do not appear to be affected, and are all believed to 
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contribute to similar downstream effects (Hollingworth et al., 2015; Branzei and Foiani, 
2008). Constitutively active Chk1 mutants have been identified, and could be 
expressed to characterise the effect of pathway activation on KSHV lytic replication 
(Wang et al., 2012). Finally, additional SILAC-based quantitative proteomic analysis of 
the nucleolus of lytically infected cells, as well as ORF57 SILAC immunoprecipitation 
experiments suggest that ORF57 interacts with multiple splicing components, including 
other members of the Prp19/CDC5L complex. Further work is, therefore, required to 
assess whether these other factors play a role in the maturation of KSHV intron-
containing or intronless transcripts, or indeed whether any of these factors are 
involved in the ATR-Chk1 DNA damage response, which may explain their association 
with ORF57. 
The SILAC data analysed in chapter 3 also revealed the increased abundance of 
proteins associated with miRNA biogenesis in subnuclear bodies during KSHV lytic 
infection. KSHV encoded miRNAs are expressed during latency (Qin et al., 2012), and 
therefore, work presented in chapter 4 describes the utilisation of miRNA sequencing, 
and the subsequent identification of 19 mature host miRNAs that display altered 
expression levels during lytic KSHV infection in TREx BCBL1-Rta cells. Cell type 
specificity is commonly observed for different miRNAs, however, the strategy 
described herein was able to identify two host miRNAs, miR-151a-5p and miR-365a-3p, 
that display similar expression trends in three different cell lines undergoing KSHV lytic 
infection. This is hypothesised to allow for greater therapeutic potential if the 
interactions between these host miRNAs and the KSHV lytic cycle become viable 
targets for therapeutic intervention, particularly as KSHV infects both B cells and 
endothelial cells in infected individuals (Chen and Lagunoff, 2005). Interestingly, these 
miRNAs exhibit different expression trends during the course of KSHV lytic infection, 
with miR-151a-5p displaying maximum levels at 8 hours, while miR-365a-3p was most 
upregulated at 18 hours. These two miRNAs have different genomic contexts, with 
miR-151a-5p found in an intronic sequence, while miR-365a-3p is an intergenic miRNA. 
These genomic contexts may have some involvement in the different trends observed 
for these miRNAs during the KSHV lytic cycle, and it would be interesting to further 
characterise the specific mechanisms leading to their biogenesis and dysregulation. 
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This would first require an investigation into the precise genomic context of each 
dysregulated miRNA, as parent transcript expression, alternative splicing and proximity 
of pri-miRNAs to splice junctions have been shown to contribute to the regulation of 
intronic miRNA expression (Melamed et al., 2013). Conversely, intergenic miRNAs are 
transcribed by RNA polymerase II using their own promoters, and likely requiring the 
activities of cellular transcription factors (Lee et al., 2004). A detailed analysis of 
transcript biogenesis and regulation could, therefore, be attempted by first using DNA-
affinity purification followed by mass spectrometry-based identification of associated 
transcription and splicing factors (Y. Wang et al., 2008).  
Interestingly, inhibition of either miRNA using miRIDIAN antagomiRs does not appear 
to have serious implications for viral RNA or protein expression levels, suggesting that 
dysregulation of either miR-151a-5p or miR-365a-3p does not represent an anti-viral 
response directed against the virus by the host cell. Subsequently, it was hypothesised 
that the increased expression of these miRNAs at different times during KSHV lytic 
infection, contributed to a pro-viral process, and that the miRNAs were likely to target 
cellular transcripts. To investigate this, mRNA sequencing was employed to observe 
changes in host transcript expression levels over the course of the KSHV lytic cycle. 
Open source miRNA target prediction software was used to predict likely target host 
cell mRNAs of miR-151a-5p and miR-365a-3p, and the predicted target transcript levels 
were analysed by cross referencing this list with the mRNA sequencing data. The data 
displayed the effects of both the KSHV-mediated host-shutoff response and an 
increasing viral mRNA component present in the sample, resulting in the vast majority 
of host transcripts decreasing in abundance over the course of the lytic cycle. 
Therefore, predicted target transcripts that appeared to be most severely depleted 
were examined in the presence of the two miRIDIANs at different times during lytic 
infection. The four predicted targets of miR-151a-5p did not appear to be stabilised in 
the presence of the miR-151a-5p miRIDIAN at any time during infection, suggesting 
that these transcripts do not interact with miR-151a-5p. In contrast, however, two 
predicted mRNA targets of miR-365a-3p, DOCK5 and PRUNE2, were stabilised 
specifically in the presence of a miRIDIAN directed against miR-365a-3p at 18 hours 
post induction of the KSHV lytic cycle. The levels of miR-365a-3p gradually increase 
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over the course of lytic infection, with maximum expression at 18 hours post 
induction. However, it is surprising that treatment with the miRIDIAN directed against 
miR-365a-3p does not appear to stabilise either DOCK5 or PRUNE2 transcripts at 8 
hours, when there is also an increased abundance of the miRNA. It is possible that the 
miR-365a-3p is only functional at certain levels, and this may reflect a stoichiometric 
effect between a miRNA and its target transcript. 
A plasmid encoding a DOCK5-GFP fusion protein was acquired in order to investigate 
the effects of DOCK5 overexpression, as this was predicted to overcome miR-365a-3p 
activity. DOCK5-GFP overexpression could not account for the minor reduction in KSHV 
RNA levels observed when cells were treated with a miRIDIAN directed against miR-
365a-3p, suggesting that this effect is due to another gene or possibly represents an 
off target effect of the antagomiR. DOCK5-GFP overexpression did, however, result in a 
reduced reinfection rate when supernatant harvested from transfected cells 
undergoing lytic infection for 7 days was used to infect naïve cells. This correlated with 
an increased viral load in the initial cells after this time, and therefore suggests that 
DOCK5 expression inhibits a viral process following DNA replication, but prior to 
egress. Similar data were obtained when cells were treated with miRIDIANs, with a 
miRIDIAN directed against miR-365a-3p showing similar viral load in both cell types to 
DOCK5-GFP overexpression, and a miRIDIAN directed against miR-151a-5p exhibiting 
an intermediate effect. The overexpression of DOCK5-GFP is unlikely to produce the 
same levels of DOCK5 protein, or DOCK5 activity, as miR-365a-3p inhibition. Therefore, 
it remains to be seen whether other targets of miR-365a-3p also contribute to this 
effect. 
Other members of the DOCK family, sharing considerable homology to DOCK5, activate 
Rac1 and Cdc42, influencing actin dynamics, specifically polymerisation (Laurin and 
Cote, 2014; Ruiz-Lafuente et al., 2015). Herpesviruses interact with components of the 
host cell cytoskeleton at multiple stages during infection (Lyman and Enquist, 2009), 
however, intracellular capsid movement studies with herpesviruses suggest that 
microtubules are primarily used for viral translocation (Sodeik et al., 1997; Douglas et 
al., 2004; Lee et al., 2006). It is hypothesised, therefore, that DOCK5 mediates the 
polymerisation of actin in the cortical actin network, and that this acts as a barrier to 
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KSHV egress. HSV-1 has been shown to require Myosin Va activity for egress, and it is 
believed that this interaction allows the capsid to traffic through the cortical actin 
network prior to egress (Roberts and Baines, 2010). This suggests that cortical actin 
can act as an anti-viral factor that must be overcome, and it is therefore hypothesised 
that KSHV upregulates miR-365a-3p, targeting DOCK5 mRNA for degradation or 
translational repression, ultimately reorganising the cortical actin network to increase 
the efficiency of viral egress. Further work will now be conducted to characterise 
changes in cortical actin morphology during KSHV lytic replication in the absence or 
presence of DOCK5 overexpression or miRIDIAN 365a. In addition, an intracellular 
infectivity assay will be performed to further confirm that viral egress is the specific 
mechanism being inhibited. 
To date, PRUNE2 overexpression and its effect on the KSHV lytic cycle has not been 
investigated. PRUNE2 is an endosomal protein, associated with the AP-2 cargo adaptor 
complex, and is associated with positive prognosis in neuroblastoma (Harris et al., 
2013; Machida et al., 2006). Endosomes are believed to play an important role during 
herpesvirus secondary envelopment prior to egress (Johnson and Baines, 2011). It is 
interesting to note that the downregulation of both DOCK5 and PRUNE2 via the 
activity of a single miRNA during KSHV lytic infection may contribute to increased 
efficiency of viral egress. As miR-365a-3p is a cellular miRNA, the identification of these 
targeted processes may suggest it plays a role in exocytosis. Interestingly, miR-365a-3p 
is intergenic, and so its expression is not directly coupled to the transcription of an 
mRNA. In addition, it has been identified in multiple tissues including cerebellum, 
kidney and heart, suggesting involvement in a general cellular process rather than a 
tissue specific mechanism. Further investigations into the requirements for miR-365a-
3p expression may shed more light on its function in uninfected cells. An investigation 
into the effects of PRUNE2 overexpression, similar to work already undertaken using 
DOCK5-GFP, may help to further characterise miR-365a-3p and its role in KSHV lytic 
replication.  
Taken together, the work described in this thesis will broaden our understanding of 
the interactions that occur during KSHV lytic infection. This work may have 
implications for KSHV pathology, as well as potentially increasing general 
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understanding of factors involved in both cellular and cancer biology. Finally, 
interactions identified in this work, such as the interactions between ORF57 and Prp19, 
or miR-365a and DOCK5 may represent novel targets for therapeutic intervention 
against KSHV-associated malignancies. 
I 
 
References 
Abraham, G., Rhodes, D.P. and Banerjee, A.K. 1975. The 5’ terminal structure of the 
methylated mRNA synthesized in vitro by vesicular stomatitis virus. Cell. 
5(1),pp.51–58. 
Adams, M.D., Kelley, J.M., Gocayne, J.D., Dubnick, M., Polymeropoulos, M.H., Xiao, H., 
Merril, C.R., Wu, A., Olde, B. and Moreno, R.F. 1991. Complementary DNA 
sequencing: expressed sequence tags and human genome project. Science 
(New York, N.Y.). 252(5013),pp.1651–1656. 
Agrawal, N., Dasaradhi, P.V.N., Mohmmed, A., Malhotra, P., Bhatnagar, R.K. and 
Mukherjee, S.K. 2003. RNA interference: biology, mechanism, and applications. 
Microbiology and Molecular Biology Reviews. 67(4),pp.657–685. 
Aguilera, A. and García-Muse, T. 2012. R loops: from transcription byproducts to 
threats to genome stability. Molecular Cell. 46(2),pp.115–124. 
Ahn, J.-Y., Li, X., Davis, H.L. and Canman, C.E. 2002. Phosphorylation of threonine 68 
promotes oligomerization and autophosphorylation of the Chk2 protein kinase 
via the forkhead-associated domain. The Journal of Biological Chemistry. 
277(22),pp.19389–19395. 
Akhtar, J. and Shukla, D. 2009. Viral entry mechanisms: cellular and viral mediators of 
herpes simplex virus entry: Cellular and viral mediators of HSV entry. FEBS 
Journal. 276(24),pp.7228–7236. 
Amen, M.A. and Griffiths, A. 2011. Packaging of non-coding RNAs into herpesvirus 
virions: comparisons to coding RNAs. Frontiers in Genetics. [Online]. 2. 
[Accessed 25 June 2015]. Available from: 
http://journal.frontiersin.org/article/10.3389/fgene.2011.00081/abstract. 
Anastasiadou, E., Boccellato, F., Vincenti, S., Rosato, P., Bozzoni, I., Frati, L., Faggioni, 
A., Presutti, C. and Trivedi, P. 2010. Epstein-Barr virus encoded LMP1 
downregulates TCL1 oncogene through miR-29b. Oncogene. 29(9),pp.1316–
1328. 
Andersen, J.S., Lyon, C.E., Fox, A.H., Leung, A.K.L., Lam, Y.W., Steen, H., Mann, M. and 
Lamond, A.I. 2002. Directed proteomic analysis of the human nucleolus. 
Current biology: CB. 12(1),pp.1–11. 
Andersson, M.G., Haasnoot, P.C.J., Xu, N., Berenjian, S., Berkhout, B. and Akusjärvi, G. 
2005. Suppression of RNA interference by adenovirus virus-associated RNA. 
Journal of Virology. 79(15),pp.9556–9565. 
An, J. 2004. Transcriptional coactivation of c-Jun by the KSHV-encoded LANA. Blood. 
103(1),pp.222–228. 
II 
 
Aoki, Y., Jaffe, E.S., Chang, Y., Jones, K., Teruya-Feldstein, J., Moore, P.S. and Tosato, G. 
1999. Angiogenesis and hematopoiesis induced by Kaposi’s sarcoma-associated 
herpesvirus-encoded interleukin-6. Blood. 93(12),pp.4034–4043. 
Aparicio, O., Razquin, N., Zaratiegui, M., Narvaiza, I. and Fortes, P. 2006. Adenovirus 
virus-associated RNA is processed to functional interfering RNAs involved in 
virus production. Journal of Virology. 80(3),pp.1376–1384. 
Aravind, L. 1999. Conserved domains in DNA repair proteins and evolution of repair 
systems. Nucleic Acids Research. 27(5),pp.1223–1242. 
Arias, C., Walsh, D., Harbell, J., Wilson, A.C. and Mohr, I. 2009. Activation of host 
translational control pathways by a viral developmental switch B. Sugden, ed. 
PLoS Pathogens. 5(3),p.e1000334. 
Arias, C., Weisburd, B., Stern-Ginossar, N., Mercier, A., Madrid, A.S., Bellare, P., 
Holdorf, M., Weissman, J.S. and Ganem, D. 2014. KSHV 2.0: a comprehensive 
annotation of the Kaposi’s sarcoma-associated herpesvirus genome using next-
generation sequencing reveals novel genomic and functional features D. P. 
Dittmer, ed. PLoS Pathogens. 10(1),p.e1003847. 
Arvin, A.M. (ed.). 2007. Human herpesviruses: biology, therapy, and 
immunoprophylaxis. Cambridge ; New York: Cambridge University Press. 
Bainbridge, M.N., Warren, R.L., Hirst, M., Romanuik, T., Zeng, T., Go, A., Delaney, A., 
Griffith, M., Hickenbotham, M., Magrini, V., Mardis, E.R., Sadar, M.D., Siddiqui, 
A.S., Marra, M.A. and Jones, S.J.M. 2006. Analysis of the prostate cancer cell 
line LNCaP transcriptome using a sequencing-by-synthesis approach. BMC 
genomics. 7,p.246. 
Ballestas, M.E. and Kaye, K.M. 2011. The latency-associated nuclear antigen, a 
multifunctional protein central to Kaposi’s sarcoma-associated herpesvirus 
latency. Future Microbiology. 6(12),pp.1399–1413. 
Banerji, J., Rusconi, S. and Schaffner, W. 1981. Expression of a beta-globin gene is 
enhanced by remote SV40 DNA sequences. Cell. 27(2 Pt 1),pp.299–308. 
Bartek, J., Falck, J. and Lukas, J. 2001. CHK2 kinase--a busy messenger. Nature Reviews. 
Molecular Cell Biology. 2(12),pp.877–886. 
Barth, S., Meister, G. and Grässer, F.A. 2011. EBV-encoded miRNAs. Biochimica et 
Biophysica Acta (BBA) - Gene Regulatory Mechanisms. 1809(11-12),pp.631–
640. 
Bassi, L., Palitti, F., Mosesso, P. and Natarajan, A.T. 1998. Distribution of camptothecin-
induced break points in Chinese hamster cells treated in late S and G2 phases 
of the cell cycle. Mutagenesis. 13(3),pp.257–261. 
III 
 
Batushansky, A., Kirma, M., Grillich, N., Toubiana, D., Pham, P.A., Balbo, I., Fromm, H., 
Galili, G., Fernie, A.R. and Fait, A. 2014. Combined transcriptomics and 
metabolomics of Arabidopsis thaliana seedlings exposed to exogenous GABA 
suggest its role in plants is predominantly metabolic. Molecular Plant. 
7(6),pp.1065–1068. 
Belgnaoui, S.M., Fryrear, K.A., Nyalwidhe, J.O., Guo, X. and Semmes, O.J. 2010. The 
viral oncoprotein Tax sequesters DNA damage response factors by tethering 
MDC1 to chromatin. Journal of Biological Chemistry. 285(43),pp.32897–32905. 
Bellare, P. and Ganem, D. 2009. Regulation of KSHV lytic switch protein expression by a 
virus-encoded microRNA: an evolutionary adaptation that fine-tunes lytic 
reactivation. Cell Host & Microbe. 6(6),pp.570–575. 
Benoist, C. and Chambon, P. 1981. In vivo sequence requirements of the SV40 early 
promotor region. Nature. 290(5804),pp.304–310. 
Beral, V., Peterman, T.A., Berkelman, R.L. and Jaffe, H.W. 1990. Kaposi’s sarcoma 
among persons with AIDS: a sexually transmitted infection? Lancet (London, 
England). 335(8682),pp.123–128. 
Berget, S.M., Moore, C. and Sharp, P.A. 1977. Spliced segments at the 5’ terminus of 
adenovirus 2 late mRNA. Proceedings of the National Academy of Sciences of 
the United States of America. 74(8),pp.3171–3175. 
Betel, D., Wilson, M., Gabow, A., Marks, D.S. and Sander, C. 2007. The microRNA.org 
resource: targets and expression. Nucleic Acids Research. 
36(Database),pp.D149–D153. 
Bienroth, S., Keller, W. and Wahle, E. 1993. Assembly of a processive messenger RNA 
polyadenylation complex. The EMBO journal. 12(2),pp.585–594. 
Bohnsack, M.T., Czaplinski, K. and Gorlich, D. 2004. Exportin 5 is a RanGTP-dependent 
dsRNA-binding protein that mediates nuclear export of pre-miRNAs. RNA (New 
York, N.Y.). 10(2),pp.185–191. 
Boisvert, F.-M., van Koningsbruggen, S., Navascués, J. and Lamond, A.I. 2007. The 
multifunctional nucleolus. Nature Reviews. Molecular Cell Biology. 8(7),pp.574–
585. 
Boland, A., Huntzinger, E., Schmidt, S., Izaurralde, E. and Weichenrieder, O. 2011. 
Crystal structure of the MID-PIWI lobe of a eukaryotic Argonaute protein. 
Proceedings of the National Academy of Sciences. 108(26),pp.10466–10471. 
Bollard, C.M., Rooney, C.M. and Heslop, H.E. 2012. T-cell therapy in the treatment of 
post-transplant lymphoproliferative disease. Nature Reviews Clinical Oncology. 
9(9),pp.510–519. 
IV 
 
Bondarenko, P.V., Chelius, D. and Shaler, T.A. 2002. Identification and relative 
quantitation of protein mixtures by enzymatic digestion followed by capillary 
reversed-phase liquid chromatography-tandem mass spectrometry. Analytical 
Chemistry. 74(18),pp.4741–4749. 
Boshoff, C. and Weiss, R.A. 2001. Epidemiology and pathogenesis of Kaposi’s sarcoma-
associated herpesvirus. Philosophical Transactions of the Royal Society B: 
Biological Sciences. 356(1408),pp.517–534. 
Bottero, V., Sharma-Walia, N., Kerur, N., Paul, A.G., Sadagopan, S., Cannon, M. and 
Chandran, B. 2009. Kaposi Sarcoma-associated herpes virus (KSHV) G protein-
coupled receptor (vGPCR) activates the ORF50 lytic switch promoter: A 
potential positive feedback loop for sustained ORF50 gene expression. Virology. 
392(1),pp.34–51. 
Boyne, J.R., Colgan, K.J. and Whitehouse, A. 2008. Recruitment of the complete hTREX 
complex is required for Kaposi’s sarcoma-associated herpesvirus intronless 
mRNA nuclear export and virus replication. PLoS pathogens. 4(10),p.e1000194. 
Boyne, J.R., Jackson, B.R., Taylor, A., Macnab, S.A. and Whitehouse, A. 2010. Kaposi’s 
sarcoma-associated herpesvirus ORF57 protein interacts with PYM to enhance 
translation of viral intronless mRNAs. The EMBO journal. 29(11),pp.1851–1864. 
Boyne, J.R. and Whitehouse, A. 2009. Nucleolar disruption impairs Kaposi’s sarcoma-
associated herpesvirus ORF57-mediated nuclear export of intronless viral 
mRNAs. FEBS letters. 583(22),pp.3549–3556. 
Boyne, J.R. and Whitehouse, A. 2006. Nucleolar trafficking is essential for nuclear 
export of intronless herpesvirus mRNA. Proceedings of the National Academy of 
Sciences of the United States of America. 103(41),pp.15190–15195. 
Branzei, D. and Foiani, M. 2008. Regulation of DNA repair throughout the cell cycle. 
Nature Reviews. Molecular Cell Biology. 9(4),pp.297–308. 
Brennecke, J., Stark, A., Russell, R.B. and Cohen, S.M. 2005. Principles of microRNA–
target recognition. PLoS Biology. 3(3),p.e85. 
Brigneti, G. 1998. Viral pathogenicity determinants are suppressors of transgene 
silencing in Nicotiana benthamiana. The EMBO Journal. 17(22),pp.6739–6746. 
Brugnera, E., Haney, L., Grimsley, C., Lu, M., Walk, S.F., Tosello-Trampont, A.-C., 
Macara, I.G., Madhani, H., Fink, G.R. and Ravichandran, K.S. 2002. 
Unconventional Rac-GEF activity is mediated through the Dock180–ELMO 
complex. Nature Cell Biology. [Online]. [Accessed 15 June 2015]. Available 
from: http://www.nature.com/doifinder/10.1038/ncb824. 
Buermans, H.P., Ariyurek, Y., van Ommen, G., Dunnen, J.T. den and Hoen, P.A. ’t 2010. 
New methods for next generation sequencing based microRNA expression 
profiling. BMC Genomics. 11(1),p.716. 
V 
 
Caesar, R., Manieri, M., Kelder, T., Boekschoten, M., Evelo, C., Müller, M., Kooistra, T., 
Cinti, S., Kleemann, R. and Drevon, C.A. 2010. A combined transcriptomics and 
lipidomics analysis of subcutaneous, epididymal and mesenteric adipose tissue 
reveals marked functional differences A. Bartolomucci, ed. PLoS ONE. 
5(7),p.e11525. 
Cai, Q., Banerjee, S., Cervini, A., Lu, J., Hislop, A.D., Dzeng, R. and Robertson, E.S. 2013. 
IRF-4-Mediated CIITA Transcription Is Blocked by KSHV Encoded LANA to Inhibit 
MHC II Presentation S.-J. Gao, ed. PLoS Pathogens. 9(10),p.e1003751. 
Cai, Q., Lan, K., Verma, S.C., Si, H., Lin, D. and Robertson, E.S. 2006. Kaposi’s sarcoma-
associated herpesvirus latent protein LANA interacts with HIF-1 to upregulate 
Rta expression during hypoxia: latency control under low oxygen conditions. 
Journal of Virology. 80(16),pp.7965–7975. 
Cameron, J.E., Yin, Q., Fewell, C., Lacey, M., McBride, J., Wang, X., Lin, Z., Schaefer, B.C. 
and Flemington, E.K. 2008. Epstein-Barr Virus Latent Membrane Protein 1 
Induces Cellular MicroRNA miR-146a, a Modulator of Lymphocyte Signaling 
Pathways. Journal of Virology. 82(4),pp.1946–1958. 
Cannell, I.G., Kong, Y.W. and Bushell, M. 2008. How do microRNAs regulate gene 
expression? Biochemical Society Transactions. 36(Pt 6),pp.1224–1231. 
Cantalupo, P., Doering, A., Sullivan, C.S., Pal, A., Peden, K.W.C., Lewis, A.M. and Pipas, 
J.M. 2005. Complete nucleotide sequence of polyomavirus SA12. Journal of 
Virology. 79(20),pp.13094–13104. 
Caputi, M. and Zahler, A.M. 2002. SR proteins and hnRNP H regulate the splicing of the 
HIV-1 tev-specific exon 6D. The EMBO journal. 21(4),pp.845–855. 
Cardone, G., Winkler, D.C., Trus, B.L., Cheng, N., Heuser, J.E., Newcomb, W.W., Brown, 
J.C. and Steven, A.C. 2007. Visualization of the herpes simplex virus portal in 
situ by cryo-electron tomography. Virology. 361(2),pp.426–434. 
Carmody, S.R. and Wente, S.R. 2009. mRNA nuclear export at a glance. Journal of Cell 
Science. 122(12),pp.1933–1937. 
Cazalla, D., Yario, T. and Steitz, J.A. 2010. Down-Regulation of a Host MicroRNA by a 
Herpesvirus saimiri Noncoding RNA. Science. 328(5985),pp.1563–1566. 
Cesarman, E., Chang, Y., Moore, P.S., Said, J.W. and Knowles, D.M. 1995. Kaposi’s 
sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-
cavity-based lymphomas. The New England Journal of Medicine. 
332(18),pp.1186–1191. 
Chakraborty, S., Veettil, M.V. and Chandran, B. 2012. Kaposi’s Sarcoma Associated 
Herpesvirus Entry into Target Cells. Frontiers in Microbiology. [Online]. 3. 
[Accessed 26 June 2015]. Available from: 
http://journal.frontiersin.org/article/10.3389/fmicb.2012.00006/abstract. 
VI 
 
Challberg, M.D. and Kelly, T.J. 1979. Adenovirus DNA replication in vitro. Proceedings 
of the National Academy of Sciences of the United States of America. 
76(2),pp.655–659. 
Chanarat, S., Seizl, M. and Strässer, K. 2011. The Prp19 complex is a novel transcription 
elongation factor required for TREX occupancy at transcribed genes. Genes & 
Development. 25(11),pp.1147–1158. 
Chanarat, S. and Sträßer, K. 2013. Splicing and beyond: The many faces of the Prp19 
complex. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 
1833(10),pp.2126–2134. 
Chandhasin, C., Ducu, R.I., Berkovich, E., Kastan, M.B. and Marriott, S.J. 2008. Human 
T-Cell Leukemia Virus Type 1 Tax Attenuates the ATM-Mediated Cellular DNA 
Damage Response. Journal of Virology. 82(14),pp.6952–6961. 
Chang, P.-J., Shedd, D., Gradoville, L., Cho, M.-S., Chen, L.-W., Chang, J. and Miller, G. 
2002. Open reading frame 50 protein of Kaposi’s sarcoma-associated 
herpesvirus directly activates the viral PAN and K12 genes by binding to related 
response elements. Journal of Virology. 76(7),pp.3168–3178. 
Chang, P.-J., Shedd, D. and Miller, G. 2005. Two subclasses of Kaposi’s sarcoma-
associated herpesvirus lytic cycle promoters distinguished by open reading 
frame 50 mutant proteins that are deficient in binding to DNA. Journal of 
Virology. 79(14),pp.8750–8763. 
Chang, T.-W. 1984. Herpesvirus diseases of veterinary importance. Clinics in 
Dermatology. 2(2),pp.147–151. 
Chang, Y., Cesarman, E., Pessin, M.S., Lee, F., Culpepper, J., Knowles, D.M. and Moore, 
P.S. 1994. Identification of herpesvirus-like DNA sequences in AIDS-associated 
Kaposi’s sarcoma. Science (New York, N.Y.). 266(5192),pp.1865–1869. 
Chelius, D. and Bondarenko, P.V. 2002. Quantitative profiling of proteins in complex 
mixtures using liquid chromatography and mass spectrometry. Journal of 
Proteome Research. 1(4),pp.317–323. 
Chen, B.P.C., Uematsu, N., Kobayashi, J., Lerenthal, Y., Krempler, A., Yajima, H., 
Löbrich, M., Shiloh, Y. and Chen, D.J. 2007. Ataxia telangiectasia mutated (ATM) 
is essential for DNA-PKcs phosphorylations at the Thr-2609 cluster upon DNA 
double strand break. The Journal of Biological Chemistry. 282(9),pp.6582–6587. 
Chen, C. 2005. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic 
Acids Research. 33(20),pp.e179–e179. 
Cheng, H., Dufu, K., Lee, C.-S., Hsu, J.L., Dias, A. and Reed, R. 2006. Human mRNA 
export machinery recruited to the 5’ end of mRNA. Cell. 127(7),pp.1389–1400. 
VII 
 
Chen, L. and Lagunoff, M. 2005. Establishment and Maintenance of Kaposi’s Sarcoma-
Associated Herpesvirus Latency in B Cells. Journal of Virology. 79(22),pp.14383–
14391. 
Chentoufi, A.A., Kritzer, E., Tran, M.V., Dasgupta, G., Lim, C.H., Yu, D.C., Afifi, R.E., 
Jiang, X., Carpenter, D., Osorio, N., Hsiang, C., Nesburn, A.B., Wechsler, S.L. and 
BenMohamed, L. 2011. The Herpes Simplex Virus 1 Latency-Associated 
Transcript Promotes Functional Exhaustion of Virus-Specific CD8+ T Cells in 
Latently Infected Trigeminal Ganglia: a Novel Immune Evasion Mechanism. 
Journal of Virology. 85(17),pp.9127–9138. 
Chen, W., Hilton, I.B., Staudt, M.R., Burd, C.E. and Dittmer, D.P. 2010. Distinct p53, 
p53:LANA, and LANA Complexes in Kaposi’s Sarcoma-Associated Herpesvirus 
Lymphomas. Journal of Virology. 84(8),pp.3898–3908. 
Chen, Y.-B., Rahemtullah, A. and Hochberg, E. 2007. Primary effusion lymphoma. The 
Oncologist. 12(5),pp.569–576. 
Chiang, H.R., Schoenfeld, L.W., Ruby, J.G., Auyeung, V.C., Spies, N., Baek, D., Johnston, 
W.K., Russ, C., Luo, S., Babiarz, J.E., Blelloch, R., Schroth, G.P., Nusbaum, C. and 
Bartel, D.P. 2010. Mammalian microRNAs: experimental evaluation of novel 
and previously annotated genes. Genes & Development. 24(10),pp.992–1009. 
Chi, B., Wang, Q., Wu, G., Tan, M., Wang, L., Shi, M., Chang, X. and Cheng, H. 2013. Aly 
and THO are required for assembly of the human TREX complex and association 
of TREX components with the spliced mRNA. Nucleic Acids Research. 
41(2),pp.1294–1306. 
Cho, E.J., Kobor, M.S., Kim, M., Greenblatt, J. and Buratowski, S. 2001. Opposing effects 
of Ctk1 kinase and Fcp1 phosphatase at Ser 2 of the RNA polymerase II C-
terminal domain. Genes & Development. 15(24),pp.3319–3329. 
Chow, L.T., Gelinas, R.E., Broker, T.R. and Roberts, R.J. 1977. An amazing sequence 
arrangement at the 5’ ends of adenovirus 2 messenger RNA. Cell. 12(1),pp.1–8. 
Choy, E.Y.-W., Siu, K.-L., Kok, K.-H., Lung, R.W.-M., Tsang, C.M., To, K.-F., Kwong, D.L.-
W., Tsao, S.W. and Jin, D.-Y. 2008. An Epstein-Barr virus-encoded microRNA 
targets PUMA to promote host cell survival. The Journal of Experimental 
Medicine. 205(11),pp.2551–2560. 
Chua, M.A., Schmid, S., Perez, J.T., Langlois, R.A. and Tenoever, B.R. 2013. Influenza A 
virus utilizes suboptimal splicing to coordinate the timing of infection. Cell 
Reports. 3(1),pp.23–29. 
Cimprich, K.A. and Cortez, D. 2008. ATR: an essential regulator of genome integrity. 
Nature Reviews. Molecular Cell Biology. 9(8),pp.616–627. 
VIII 
 
Clauson, C., Scharer, O.D. and Niedernhofer, L. 2013. Advances in Understanding the 
Complex Mechanisms of DNA Interstrand Cross-Link Repair. Cold Spring Harbor 
Perspectives in Biology. 5(10),pp.a012732–a012732. 
Clement, C., Tiwari, V., Scanlan, P.M., Valyi-Nagy, T., Yue, B.Y.J.T. and Shukla, D. 2006. 
A novel role for phagocytosis-like uptake in herpes simplex virus entry. The 
Journal of Cell Biology. 174(7),pp.1009–1021. 
Cliffe, A.R., Garber, D.A. and Knipe, D.M. 2009. Transcription of the Herpes Simplex 
Virus Latency-Associated Transcript Promotes the Formation of Facultative 
Heterochromatin on Lytic Promoters. Journal of Virology. 83(16),pp.8182–8190. 
Cohrs, R.J. and Gilden, D.H. 2001. Human herpesvirus latency. Brain Pathology (Zurich, 
Switzerland). 11(4),pp.465–474. 
Coppola, J.A., Field, A.S. and Luse, D.S. 1983. Promoter-proximal pausing by RNA 
polymerase II in vitro: transcripts shorter than 20 nucleotides are not capped. 
Proceedings of the National Academy of Sciences of the United States of 
America. 80(5),pp.1251–1255. 
Coscoy, L. 2007. Immune evasion by Kaposi’s sarcoma-associated herpesvirus. Nature 
Reviews Immunology. 7(5),pp.391–401. 
Cote, J.-F. 2002. Identification of an evolutionarily conserved superfamily of DOCK180-
related proteins with guanine nucleotide exchange activity. Journal of Cell 
Science. 115(24),pp.4901–4913. 
Cotter, M.A. and Robertson, E.S. 1999. The latency-associated nuclear antigen tethers 
the Kaposi’s sarcoma-associated herpesvirus genome to host chromosomes in 
body cavity-based lymphoma cells. Virology. 264(2),pp.254–264. 
Covarrubias, S., Gaglia, M.M., Kumar, G.R., Wong, W., Jackson, A.O. and Glaunsinger, 
B.A. 2011. Coordinated Destruction of Cellular Messages in Translation 
Complexes by the Gammaherpesvirus Host Shutoff Factor and the Mammalian 
Exonuclease Xrn1 R. Renne, ed. PLoS Pathogens. 7(10),p.e1002339. 
Damania, B. 2004. Oncogenic gamma-herpesviruses: comparison of viral proteins 
involved in tumorigenesis. Nature Reviews. Microbiology. 2(8),pp.656–668. 
Damania, B. and Pipas, J.M. (eds.). 2009. DNA Tumor Viruses [Online]. New York, NY: 
Springer US. [Accessed 25 June 2015]. Available from: 
http://link.springer.com/10.1007/978-0-387-68945-6. 
Davis, A.J. and Chen, D.J. 2013. DNA double strand break repair via non-homologous 
end-joining. Translational Cancer Research. 2(3),pp.130–143. 
Davis, D.A. 2001. Hypoxia induces lytic replication of Kaposi sarcoma-associated 
herpesvirus. Blood. 97(10),pp.3244–3250. 
IX 
 
Davison, A.J. 2007a. Comparative analysis of the genomes In: A. Arvin, G. Campadelli-
Fiume, E. Mocarski, P. S. Moore, B. Roizman, R. Whitley and K. Yamanishi, eds. 
Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis [Online]. 
Cambridge: Cambridge University Press. [Accessed 25 June 2015]. Available 
from: http://www.ncbi.nlm.nih.gov/books/NBK47439/. 
Davison, A.J. 2010. Herpesvirus systematics. Veterinary Microbiology. 143(1),pp.52–69. 
Davison, A.J. 2007b. Overview of classification In: A. Arvin, G. Campadelli-Fiume, E. 
Mocarski, P. S. Moore, B. Roizman, R. Whitley and K. Yamanishi, eds. Human 
Herpesviruses: Biology, Therapy, and Immunoprophylaxis [Online]. Cambridge: 
Cambridge University Press. [Accessed 25 June 2015]. Available from: 
http://www.ncbi.nlm.nih.gov/books/NBK47406/. 
Davison, A.J., Eberle, R., Ehlers, B., Hayward, G.S., McGeoch, D.J., Minson, A.C., Pellett, 
P.E., Roizman, B., Studdert, M.J. and Thiry, E. 2009. The order Herpesvirales. 
Archives of Virology. 154(1),pp.171–177. 
Davison, A.J., Trus, B.L., Cheng, N., Steven, A.C., Watson, M.S., Cunningham, C., Le 
Deuff, R.-M. and Renault, T. 2005. A novel class of herpesvirus with bivalve 
hosts. The Journal of General Virology. 86(Pt 1),pp.41–53. 
DeCaprio, J.A., Ludlow, J.W., Figge, J., Shew, J.Y., Huang, C.M., Lee, W.H., Marsilio, E., 
Paucha, E. and Livingston, D.M. 1988. SV40 large tumor antigen forms a specific 
complex with the product of the retinoblastoma susceptibility gene. Cell. 
54(2),pp.275–283. 
Decroly, E., Ferron, F., Lescar, J. and Canard, B. 2011. Conventional and unconventional 
mechanisms for capping viral mRNA. Nature Reviews Microbiology. [Online]. 
[Accessed 13 July 2015]. Available from: 
http://www.nature.com/doifinder/10.1038/nrmicro2675. 
Delorme-Axford, E. and Coyne, C.B. 2011. The Actin Cytoskeleton as a Barrier to Virus 
Infection of Polarized Epithelial Cells. Viruses. 3(12),pp.2462–2477. 
Denli, A.M., Tops, B.B.J., Plasterk, R.H.A., Ketting, R.F. and Hannon, G.J. 2004. 
Processing of primary microRNAs by the Microprocessor complex. Nature. 
432(7014),pp.231–235. 
Desselberger, U., Racaniello, V.R., Zazra, J.J. and Palese, P. 1980. The 3’ and 5’-terminal 
sequences of influenza A, B and C virus RNA segments are highly conserved and 
show partial inverted complementarity. Gene. 8(3),pp.315–328. 
Dictor, M. and Andersson, C. 1988. Lymphaticovenous differentiation in Kaposi’s 
sarcoma. Cellular phenotypes by stage. The American Journal of Pathology. 
130(2),pp.411–417. 
Direkze, S. and Laman, H. 2004. Regulation of growth signalling and cell cycle by 
Kaposi’s sarcoma-associated herpesvirus genes: KSHV regulation of growth 
X 
 
signalling and cell cycle. International Journal of Experimental Pathology. 
85(6),pp.305–319. 
Domingo, E., Parrish, C. and Holland, J.J. (eds.). 2008. Origin and evolution of viruses 
2nd ed. Amsterdam: Elsevier, Acad. Press. 
Douglas, M.W., Diefenbach, R.J., Homa, F.L., Miranda-Saksena, M., Rixon, F.J., Vittone, 
V., Byth, K. and Cunningham, A.L. 2004. Herpes Simplex Virus Type 1 Capsid 
Protein VP26 Interacts with Dynein Light Chains RP3 and Tctex1 and Plays a 
Role in Retrograde Cellular Transport. Journal of Biological Chemistry. 
279(27),pp.28522–28530. 
Dourmishev, L.A., Dourmishev, A.L., Palmeri, D., Schwartz, R.A. and Lukac, D.M. 2003. 
Molecular Genetics of Kaposi’s Sarcoma-Associated Herpesvirus (Human 
Herpesvirus 8) Epidemiology and Pathogenesis. Microbiology and Molecular 
Biology Reviews. 67(2),pp.175–212. 
Dubois, J., Terrier, O. and Rosa-Calatrava, M. 2014. Influenza Viruses and mRNA 
Splicing: Doing More with Less. mBio. 5(3),pp.e00070–14–e00070–14. 
Duman, S., Töz, H., Aşçi, G., Alper, S., Ozkahya, M., Unal, I., Celik, A., Ok, E. and Başçi, A. 
2002. Successful treatment of post-transplant Kaposi’s sarcoma by reduction of 
immunosuppression. Nephrology, Dialysis, Transplantation: Official Publication 
of the European Dialysis and Transplant Association - European Renal 
Association. 17(5),pp.892–896. 
Durocher, D. and Jackson, S.P. 2001. DNA-PK, ATM and ATR as sensors of DNA damage: 
variations on a theme? Current Opinion in Cell Biology. 13(2),pp.225–231. 
Dynan, W.S. and Tjian, R. 1983. The promoter-specific transcription factor Sp1 binds to 
upstream sequences in the SV40 early promoter. Cell. 35(1),pp.79–87. 
Edmonds, M., Vaughan, M.H. and Nakazato, H. 1971. Polyadenylic acid sequences in 
the heterogeneous nuclear RNA and rapidly-labeled polyribosomal RNA of HeLa 
cells: possible evidence for a precursor relationship. Proceedings of the 
National Academy of Sciences of the United States of America. 68(6),pp.1336–
1340. 
Eiring, A.M., Harb, J.G., Neviani, P., Garton, C., Oaks, J.J., Spizzo, R., Liu, S., Schwind, S., 
Santhanam, R., Hickey, C.J., Becker, H., Chandler, J.C., Andino, R., Cortes, J., 
Hokland, P., Huettner, C.S., Bhatia, R., Roy, D.C., Liebhaber, S.A., Caligiuri, M.A., 
Marcucci, G., Garzon, R., Croce, C.M., Calin, G.A. and Perrotti, D. 2010. miR-328 
functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA 
translation in leukemic blasts. Cell. 140(5),pp.652–665. 
Emmott, E., Dove, B.K., Howell, G., Chappell, L.A., Reed, M.L., Boyne, J.R., You, J.-H., 
Brooks, G., Whitehouse, A. and Hiscox, J.A. 2008. Viral nucleolar localisation 
signals determine dynamic trafficking within the nucleolus. Virology. 
380(2),pp.191–202. 
XI 
 
Epstein, M.A., Achong, B.G. and Barr, Y.M. 1964. Virus particles in cultured 
lymphoblasts from Burkitt’s lymphoma. Lancet (London, England). 
1(7335),pp.702–703. 
Evans, V.C., Barker, G., Heesom, K.J., Fan, J., Bessant, C. and Matthews, D.A. 2012. De 
novo derivation of proteomes from transcriptomes for transcript and protein 
identification. Nature Methods. 9(12),pp.1207–1211. 
Everett, R.D. 2006. Interactions between DNA viruses, ND10 and the DNA damage 
response. Cellular Microbiology. 8(3),pp.365–374. 
Everett, R.D., Rechter, S., Papior, P., Tavalai, N., Stamminger, T. and Orr, A. 2006. PML 
contributes to a cellular mechanism of repression of herpes simplex virus type 
1 infection that is inactivated by ICP0. Journal of Virology. 80(16),pp.7995–
8005. 
E, X., Pickering, M.T., Debatis, M., Castillo, J., Lagadinos, A., Wang, S., Lu, S. and 
Kowalik, T.F. 2011. An E2F1-mediated DNA damage response contributes to the 
replication of human cytomegalovirus. PLoS pathogens. 7(5),p.e1001342. 
Fabian, M.R., Sonenberg, N. and Filipowicz, W. 2010. Regulation of mRNA Translation 
and Stability by microRNAs. Annual Review of Biochemistry. 79(1),pp.351–379. 
Fakhari, F.D. and Dittmer, D.P. 2002. Charting latency transcripts in Kaposi’s sarcoma-
associated herpesvirus by whole-genome real-time quantitative PCR. Journal of 
Virology. 76(12),pp.6213–6223. 
Faraoni, I., Antonetti, F.R., Cardone, J. and Bonmassar, E. 2009. miR-155 gene: A typical 
multifunctional microRNA. Biochimica et Biophysica Acta (BBA) - Molecular 
Basis of Disease. 1792(6),pp.497–505. 
Fire, A., Xu, S., Montgomery, M.K., Kostas, S.A., Driver, S.E. and Mello, C.C. 1998. 
Potent and specific genetic interference by double-stranded RNA in 
Caenorhabditis elegans. Nature. 391(6669),pp.806–811. 
Fletcher, D.A. and Mullins, R.D. 2010. Cell mechanics and the cytoskeleton. Nature. 
463(7280),pp.485–492. 
Forest, T., Barnard, S. and Baines, J.D. 2005. Active intranuclear movement of 
herpesvirus capsids. Nature Cell Biology. 7(4),pp.429–431. 
Fromm, M. and Berg, P. 1983. Simian virus 40 early- and late-region promoter 
functions are enhanced by the 72-base-pair repeat inserted at distant locations 
and inverted orientations. Molecular and Cellular Biology. 3(6),pp.991–999. 
Fu, Y., Dominissini, D., Rechavi, G. and He, C. 2014. Gene expression regulation 
mediated through reversible m6A RNA methylation. Nature Reviews Genetics. 
15(5),pp.293–306. 
XII 
 
Ganem, D. 2007. Kaposi’s sarcoma-associated herpesvirus In: Fields Virology. 
Philadelphia, PA: Lippincott, Williams & Wilkins, pp. 2487–2888. 
Ganem, D. 2010. KSHV and the pathogenesis of Kaposi sarcoma: listening to human 
biology and medicine. The Journal of Clinical Investigation. 120(4),pp.939–949. 
Gan, W., Guan, Z., Liu, J., Gui, T., Shen, K., Manley, J.L. and Li, X. 2011. R-loop-mediated 
genomic instability is caused by impairment of replication fork progression. 
Genes & Development. 25(19),pp.2041–2056. 
Gao, L. and Qi, J. 2007. Whole genome molecular phylogeny of large dsDNA viruses 
using composition vector method. BMC Evolutionary Biology. 7(1),p.41. 
Garber, A.C., Hu, J. and Renne, R. 2002. Latency-associated nuclear antigen (LANA) 
cooperatively binds to two sites within the terminal repeat, and both sites 
contribute to the ability of LANA to suppress transcription and to facilitate DNA 
replication. The Journal of Biological Chemistry. 277(30),pp.27401–27411. 
Garneau, N.L., Wilusz, J. and Wilusz, C.J. 2007. The highways and byways of mRNA 
decay. Nature Reviews Molecular Cell Biology. 8(2),pp.113–126. 
Garriga, J. and Graña, X. 2004. Cellular control of gene expression by T-type 
cyclin/CDK9 complexes. Gene. 337,pp.15–23. 
Gershburg, E. and Pagano, J.S. 2008. Conserved herpesvirus protein kinases. 
Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics. 1784(1),pp.203–
212. 
Giacinti, C. and Giordano, A. 2006. RB and cell cycle progression. Oncogene. 
25(38),pp.5220–5227. 
Gilmartin, G.M. and Nevins, J.R. 1989. An ordered pathway of assembly of components 
required for polyadenylation site recognition and processing. Genes & 
Development. 3(12B),pp.2180–2190. 
Glass, M. and Everett, R.D. 2013. Components of promyelocytic leukemia nuclear 
bodies (ND10) act cooperatively to repress herpesvirus infection. Journal of 
Virology. 87(4),pp.2174–2185. 
Goodsell, D.S. 2001. The Molecular Perspective: Ultraviolet Light and Pyrimidine 
Dimers. The Oncologist. 6(3),pp.298–299. 
Görg, A., Weiss, W. and Dunn, M.J. 2004. Current two-dimensional electrophoresis 
technology for proteomics. Proteomics. 4(12),pp.3665–3685. 
Gottlieb, T.M. and Jackson, S.P. 1993. The DNA-dependent protein kinase: requirement 
for DNA ends and association with Ku antigen. Cell. 72(1),pp.131–142. 
Gottwein, E., Corcoran, D.L., Mukherjee, N., Skalsky, R.L., Hafner, M., Nusbaum, J.D., 
Shamulailatpam, P., Love, C.L., Dave, S.S., Tuschl, T., Ohler, U. and Cullen, B.R. 
XIII 
 
2011. Viral MicroRNA Targetome of KSHV-Infected Primary Effusion Lymphoma 
Cell Lines. Cell Host & Microbe. 10(5),pp.515–526. 
Gottwein, E., Mukherjee, N., Sachse, C., Frenzel, C., Majoros, W.H., Chi, J.-T.A., Braich, 
R., Manoharan, M., Soutschek, J., Ohler, U. and Cullen, B.R. 2007. A viral 
microRNA functions as an orthologue of cellular miR-155. Nature. 
450(7172),pp.1096–1099. 
Gradoville, L., Gerlach, J., Grogan, E., Shedd, D., Nikiforow, S., Metroka, C. and Miller, 
G. 2000. Kaposi’s Sarcoma-Associated Herpesvirus Open Reading Frame 50/Rta 
Protein Activates the Entire Viral Lytic Cycle in the HH-B2 Primary Effusion 
Lymphoma Cell Line. Journal of Virology. 74(13),pp.6207–6212. 
Granzow, H., Klupp, B.G., Fuchs, W., Veits, J., Osterrieder, N. and Mettenleiter, T.C. 
2001. Egress of alphaherpesviruses: comparative ultrastructural study. Journal 
of Virology. 75(8),pp.3675–3684. 
Greninger, A.L., Naccache, S.N., Federman, S., Yu, G., Mbala, P., Bres, V., Bouquet, J., 
Stryke, D., Somasekar, S., Linnen, J., Dodd, R., Mulembakani, P., Schneider, B., 
Muyembe, J.-J., Stramer, S. and Chiu, C.Y. 2015. Rapid metagenomic 
identification of viral pathogens in clinical samples by real-time nanopore 
sequencing analysis [Online]. [Accessed 6 July 2015]. Available from: 
http://biorxiv.org/lookup/doi/10.1101/020420. 
Griffin, N.M., Yu, J., Long, F., Oh, P., Shore, S., Li, Y., Koziol, J.A. and Schnitzer, J.E. 2010. 
Label-free, normalized quantification of complex mass spectrometry data for 
proteomic analysis. Nature Biotechnology. 28(1),pp.83–89. 
Grote, M., Wolf, E., Will, C.L., Lemm, I., Agafonov, D.E., Schomburg, A., Fischle, W., 
Urlaub, H. and Lührmann, R. 2010. Molecular architecture of the human 
Prp19/CDC5L complex. Molecular and Cellular Biology. 30(9),pp.2105–2119. 
Grundhoff, A. and Ganem, D. 2004. Inefficient establishment of KSHV latency suggests 
an additional role for continued lytic replication in Kaposi sarcoma 
pathogenesis. Journal of Clinical Investigation. 113(1),pp.124–136. 
Guasparri, I. 2004. KSHV vFLIP Is Essential for the Survival of Infected Lymphoma Cells. 
Journal of Experimental Medicine. 199(7),pp.993–1003. 
Guilligay, D., Kadlec, J., Crépin, T., Lunardi, T., Bouvier, D., Kochs, G., Ruigrok, R.W.H. 
and Cusack, S. 2014. Comparative Structural and Functional Analysis of 
Orthomyxovirus Polymerase Cap-Snatching Domains P. Digard, ed. PLoS ONE. 
9(1),p.e84973. 
Guo, Y.E., Riley, K.J., Iwasaki, A. and Steitz, J.A. 2014. Alternative Capture of Noncoding 
RNAs or Protein-Coding Genes by Herpesviruses to Alter Host T Cell Function. 
Molecular Cell. 54(1),pp.67–79. 
XIV 
 
Gurtan, A.M. and Sharp, P.A. 2013. The Role of miRNAs in Regulating Gene Expression 
Networks. Journal of Molecular Biology. 425(19),pp.3582–3600. 
Gwack, Y., Baek, H.J., Nakamura, H., Lee, S.H., Meisterernst, M., Roeder, R.G. and Jung, 
J.U. 2003. Principal Role of TRAP/Mediator and SWI/SNF Complexes in Kaposi’s 
Sarcoma-Associated Herpesvirus RTA-Mediated Lytic Reactivation. Molecular 
and Cellular Biology. 23(6),pp.2055–2067. 
Gygi, S.P., Rist, B., Gerber, S.A., Turecek, F., Gelb, M.H. and Aebersold, R. 1999. 
Quantitative analysis of complex protein mixtures using isotope-coded affinity 
tags. Nature Biotechnology. 17(10),pp.994–999. 
Ha, M. and Kim, V.N. 2014. Regulation of microRNA biogenesis. Nature Reviews 
Molecular Cell Biology. 15(8),pp.509–524. 
Han, J. 2004. The Drosha-DGCR8 complex in primary microRNA processing. Genes & 
Development. 18(24),pp.3016–3027. 
Harris, J.L., Richards, R.S., Chow, C.W.K., Lee, S., Kim, M., Buck, M., Teng, L., Clarke, R., 
Gardiner, R.A. and Lavin, M.F. 2013. BMCC1 is an AP-2 associated endosomal 
protein in prostate cancer cells. PloS One. 8(9),p.e73880. 
Helleday, T., Eshtad, S. and Nik-Zainal, S. 2014. Mechanisms underlying mutational 
signatures in human cancers. Nature Reviews Genetics. 15(9),pp.585–598. 
Henle, W., Diehl, V., Kohn, G., Hausen, H. Zur and Henle, G. 1967. Herpes-type virus 
and chromosome marker in normal leukocytes after growth with irradiated 
Burkitt cells. Science (New York, N.Y.). 157(3792),pp.1064–1065. 
Le Hir, H. 2001. The exon-exon junction complex provides a binding platform for 
factors involved in mRNA export and nonsense-mediated mRNA decay. The 
EMBO Journal. 20(17),pp.4987–4997. 
Hiscox, J.A. 2007. RNA viruses: hijacking the dynamic nucleolus. Nature Reviews. 
Microbiology. 5(2),pp.119–127. 
Hiscox, J.A. 2002. The nucleolus--a gateway to viral infection? Archives of Virology. 
147(6),pp.1077–1089. 
Ho, B.-C., Yu, S.-L., Chen, J.J.W., Chang, S.-Y., Yan, B.-S., Hong, Q.-S., Singh, S., Kao, C.-L., 
Chen, H.-Y., Su, K.-Y., Li, K.-C., Cheng, C.-L., Cheng, H.-W., Lee, J.-Y., Lee, C.-N. 
and Yang, P.-C. 2011. Enterovirus-induced miR-141 contributes to shutoff of 
host protein translation by targeting the translation initiation factor eIF4E. Cell 
Host & Microbe. 9(1),pp.58–69. 
Hofmann, T.G., Glas, C. and Bitomsky, N. 2013. HIPK2: A tumour suppressor that 
controls DNA damage-induced cell fate and cytokinesis. BioEssays. 35(1),pp.55–
64. 
XV 
 
Hollingworth, R., Skalka, G., Stewart, G., Hislop, A., Blackbourn, D. and Grand, R. 2015. 
Activation of DNA Damage Response Pathways during Lytic Replication of 
KSHV. Viruses. 7(6),pp.2908–2927. 
Hollinshead, M., Johns, H.L., Sayers, C.L., Gonzalez-Lopez, C., Smith, G.L. and Elliott, G. 
2012. Endocytic tubules regulated by Rab GTPases 5 and 11 are used for 
envelopment of herpes simplex virus: HSV1 envelopment by endocytic 
membranes. The EMBO Journal. 31(21),pp.4204–4220. 
Holmes, E.C. 2010. The comparative genomics of viral emergence. Proceedings of the 
National Academy of Sciences. 107(suppl_1),pp.1742–1746. 
Hricová, M. and Mistríková, J. 2007. Murine gammaherpesvirus 68 serum antibodies in 
general human population. Acta Virologica. 51(4),pp.283–287. 
Hsu, M.T., Parvin, J.D., Gupta, S., Krystal, M. and Palese, P. 1987. Genomic RNAs of 
influenza viruses are held in a circular conformation in virions and in infected 
cells by a terminal panhandle. Proceedings of the National Academy of Sciences 
of the United States of America. 84(22),pp.8140–8144. 
Huang, D.W., Sherman, B.T., Tan, Q., Kir, J., Liu, D., Bryant, D., Guo, Y., Stephens, R., 
Baseler, M.W., Lane, H.C. and Lempicki, R.A. 2007. DAVID Bioinformatics 
Resources: expanded annotation database and novel algorithms to better 
extract biology from large gene lists. Nucleic Acids Research. 35(Web 
Server),pp.W169–W175. 
Huang, T., Xu, D. and Zhang, X. 2012. Characterization of host microRNAs that respond 
to DNA virus infection in a crustacean. BMC Genomics. 13(1),p.159. 
Huang, Y. and Carmichael, G.G. 1996. Role of polyadenylation in nucleocytoplasmic 
transport of mRNA. Molecular and Cellular Biology. 16(4),pp.1534–1542. 
Huff, J.L. and Barry, P.A. 2003. B-Virus ( Cercopithecine herpesvirus 1) Infection in 
Humans and Macaques: Potential for Zoonotic Disease. Emerging Infectious 
Diseases. 9(2),pp.246–250. 
Hu, J., Garber, A.C. and Renne, R. 2002. The latency-associated nuclear antigen of 
Kaposi’s sarcoma-associated herpesvirus supports latent DNA replication in 
dividing cells. Journal of Virology. 76(22),pp.11677–11687. 
Hussain, M., Taft, R.J. and Asgari, S. 2008. An insect virus-encoded microRNA regulates 
viral replication. Journal of Virology. 82(18),pp.9164–9170. 
Hwang, L.N., Englund, N. and Pattnaik, A.K. 1998. Polyadenylation of vesicular 
stomatitis virus mRNA dictates efficient transcription termination at the 
intercistronic gene junctions. Journal of Virology. 72(3),pp.1805–1813. 
XVI 
 
Ikeda, J.E., Longiaru, M., Horwitz, M.S. and Hurwitz, J. 1980. Elongation of primed DNA 
templates by eukaryotic DNA polymerases. Proceedings of the National 
Academy of Sciences of the United States of America. 77(10),pp.5827–5831. 
Ikeda, M.A. and Nevins, J.R. 1993. Identification of distinct roles for separate E1A 
domains in disruption of E2F complexes. Molecular and Cellular Biology. 
13(11),pp.7029–7035. 
Jackson, B.R., Boyne, J.R., Noerenberg, M., Taylor, A., Hautbergue, G.M., Walsh, M.J., 
Wheat, R., Blackbourn, D.J., Wilson, S.A. and Whitehouse, A. 2011. An 
Interaction between KSHV ORF57 and UIF Provides mRNA-Adaptor Redundancy 
in Herpesvirus Intronless mRNA Export B. A. Glaunsinger, ed. PLoS Pathogens. 
7(7),p.e1002138. 
Jackson, B.R., Noerenberg, M. and Whitehouse, A. 2014. A novel mechanism inducing 
genome instability in Kaposi’s sarcoma-associated herpesvirus infected cells. 
PLoS pathogens. 10(5),p.e1004098. 
Jackson, B.R., Noerenberg, M. and Whitehouse, A. 2012. The Kaposi’s Sarcoma-
Associated Herpesvirus ORF57 Protein and Its Multiple Roles in mRNA 
Biogenesis. Frontiers in Microbiology. 3,p.59. 
Jacquenet, S., Méreau, A., Bilodeau, P.S., Damier, L., Stoltzfus, C.M. and Branlant, C. 
2001. A second exon splicing silencer within human immunodeficiency virus 
type 1 tat exon 2 represses splicing of Tat mRNA and binds protein hnRNP H. 
The Journal of Biological Chemistry. 276(44),pp.40464–40475. 
Jerabek, H. and Heermann, D.W. 2014. How chromatin looping and nuclear envelope 
attachment affect genome organization in eukaryotic cell nuclei. International 
Review of Cell and Molecular Biology. 307,pp.351–381. 
Jiricny, J. 2013. Postreplicative Mismatch Repair. Cold Spring Harbor Perspectives in 
Biology. 5(4),pp.a012633–a012633. 
Joaquin, A. and Fernandez-Capetillo, O. 2012. Signalling DNA Damage In: C. Huang, ed. 
Protein Phosphorylation in Human Health [Online]. InTech. [Accessed 23 June 
2015]. Available from: http://www.intechopen.com/books/protein-
phosphorylation-in-human-health/signalling-dna-damage. 
Johns, H.L., Gonzalez-Lopez, C., Sayers, C.L., Hollinshead, M. and Elliott, G. 2014. Rab6 
Dependent Post-Golgi Trafficking of HSV1 Envelope Proteins to Sites of Virus 
Envelopment: Rab6 Specific Exocytosis of Virus Glycoproteins. Traffic. 
15(2),pp.157–178. 
Johnson, A.S., Maronian, N. and Vieira, J. 2005. Activation of Kaposi’s Sarcoma-
Associated Herpesvirus Lytic Gene Expression during Epithelial Differentiation. 
Journal of Virology. 79(21),pp.13769–13777. 
XVII 
 
Johnson, D.C. and Baines, J.D. 2011. Herpesviruses remodel host membranes for virus 
egress. Nature Reviews Microbiology. 9(5),pp.382–394. 
Johnson, D.C. and Huber, M.T. 2002. Directed Egress of Animal Viruses Promotes Cell-
to-Cell Spread. Journal of Virology. 76(1),pp.1–8. 
Jones, J.F., Shurin, S., Abramowsky, C., Tubbs, R.R., Sciotto, C.G., Wahl, R., Sands, J., 
Gottman, D., Katz, B.Z. and Sklar, J. 1988. T-Cell Lymphomas Containing 
Epstein–Barr Viral DNA in Patients with Chronic Epstein–Barr Virus Infections. 
New England Journal of Medicine. 318(12),pp.733–741. 
Jopling, C.L., Yi, M., Lancaster, A.M., Lemon, S.M. and Sarnow, P. 2005. Modulation of 
hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science (New 
York, N.Y.). 309(5740),pp.1577–1581. 
Jurica, M.S. and Moore, M.J. 2003. Pre-mRNA splicing: awash in a sea of proteins. 
Molecular Cell. 12(1),pp.5–14. 
Kaipa, B.R., Shao, H., Schäfer, G., Trinkewitz, T., Groth, V., Liu, J., Beck, L., Bogdan, S., 
Abmayr, S.M. and Önel, S.-F. 2013. Dock mediates Scar- and WASp-dependent 
actin polymerization through interaction with cell adhesion molecules in 
founder cells and fusion-competent myoblasts. Journal of Cell Science. 126(Pt 
1),pp.360–372. 
Kaposi 1872. Idiopathisches multiples Pigmentsarkom der Haut. Archiv für 
Dermatologie und Syphilis. 4(2),pp.265–273. 
Kaschka-Dierich, C., Werner, F.J., Bauer, I. and Fleckenstein, B. 1982. Structure of 
nonintegrated, circular Herpesvirus saimiri and Herpesvirus ateles genomes in 
tumor cell lines and in vitro-transformed cells. Journal of Virology. 
44(1),pp.295–310. 
Katahira, J. 2012. mRNA export and the TREX complex. Biochimica Et Biophysica Acta. 
1819(6),pp.507–513. 
Katahira, J., Inoue, H., Hurt, E. and Yoneda, Y. 2009. Adaptor Aly and co-adaptor Thoc5 
function in the Tap-p15-mediated nuclear export of HSP70 mRNA. The EMBO 
Journal. 28(5),pp.556–567. 
Kati, S., Tsao, E.H., Gunther, T., Weidner-Glunde, M., Rothamel, T., Grundhoff, A., 
Kellam, P. and Schulz, T.F. 2013. Activation of the B Cell Antigen Receptor 
Triggers Reactivation of Latent Kaposi’s Sarcoma-Associated Herpesvirus in B 
Cells. Journal of Virology. 87(14),pp.8004–8016. 
Kawaji, H. and Hayashizaki, Y. 2008. Exploration of small RNAs. PLoS genetics. 
4(1),p.e22. 
Kawamata, T. and Tomari, Y. 2010. Making RISC. Trends in Biochemical Sciences. 
35(7),pp.368–376. 
XVIII 
 
Keller, S.A., Schattner, E.J. and Cesarman, E. 2000. Inhibition of NF-kappaB induces 
apoptosis of KSHV-infected primary effusion lymphoma cells. Blood. 
96(7),pp.2537–2542. 
Kelly, B.J., Fraefel, C., Cunningham, A.L. and Diefenbach, R.J. 2009. Functional roles of 
the tegument proteins of herpes simplex virus type 1. Virus Research. 
145(2),pp.173–186. 
Khvorova, A., Reynolds, A. and Jayasena, S.D. 2003. Functional siRNAs and miRNAs 
exhibit strand bias. Cell. 115(2),pp.209–216. 
Klose, J. and Kobalz, U. 1995. Two-dimensional electrophoresis of proteins: an updated 
protocol and implications for a functional analysis of the genome. 
Electrophoresis. 16(6),pp.1034–1059. 
Knight, L.M., Stakaityte, G., Wood, J., J., Abdul-Sada, H., Griffiths, D.A., Howell, G.J., 
Wheat, R., Blair, G.E., Steven, N.M., Macdonald, A., Blackbourn, D.J. and 
Whitehouse, A. 2015. Merkel Cell Polyomavirus Small T Antigen Mediates 
Microtubule Destabilization To Promote Cell Motility and Migration M. J. 
Imperiale, ed. Journal of Virology. 89(1),pp.35–47. 
Köhler, A. and Hurt, E. 2007. Exporting RNA from the nucleus to the cytoplasm. Nature 
Reviews. Molecular Cell Biology. 8(10),pp.761–773. 
Komarnitsky, P., Cho, E.J. and Buratowski, S. 2000. Different phosphorylated forms of 
RNA polymerase II and associated mRNA processing factors during 
transcription. Genes & Development. 14(19),pp.2452–2460. 
Koretzky, G.A. 2007. The legacy of the Philadelphia chromosome. Journal of Clinical 
Investigation. 117(8),pp.2030–2032. 
Kornberg, R.D. 2001. The eukaryotic gene transcription machinery. Biological 
Chemistry. 382(8),pp.1103–1107. 
Kosior, K., Lewandowska-Grygiel, M. and Giannopoulos, K. 2011. Tyrosine kinase 
inhibitors in hematological malignancies. Postȩpy Higieny I Medycyny 
Doświadczalnej (Online). 65,pp.819–828. 
Krijgsveld, J., Ketting, R.F., Mahmoudi, T., Johansen, J., Artal-Sanz, M., Verrijzer, C.P., 
Plasterk, R.H.A. and Heck, A.J.R. 2003. Metabolic labeling of C. elegans and D. 
melanogaster for quantitative proteomics. Nature Biotechnology. 
21(8),pp.927–931. 
Krokan, H.E., Drabløs, F. and Slupphaug, G. 2002. Uracil in DNA – occurrence, 
consequences and repair. Oncogene. 21(58),pp.8935–8948. 
Krokan, H.E., Standal, R. and Slupphaug, G. 1997. DNA glycosylases in the base excision 
repair of DNA. The Biochemical Journal. 325 ( Pt 1),pp.1–16. 
XIX 
 
Krüger, M., Moser, M., Ussar, S., Thievessen, I., Luber, C.A., Forner, F., Schmidt, S., 
Zanivan, S., Fässler, R. and Mann, M. 2008. SILAC mouse for quantitative 
proteomics uncovers kindlin-3 as an essential factor for red blood cell function. 
Cell. 134(2),pp.353–364. 
Kusumoto-Matsuo, R., Ghosh, D., Karmakar, P., May, A., Ramsden, D. and Bohr, V.A. 
2014. Serines 440 and 467 in the Werner syndrome protein are phosphorylated 
by DNA-PK and affects its dynamics in response to DNA double strand breaks. 
Aging. 6(1),pp.70–81. 
Labokha, A. and Fassati, A. 2013. Viruses Challenge Selectivity Barrier of Nuclear Pores. 
Viruses. 5(10),pp.2410–2423. 
Laemmli, U.K. 1970. Cleavage of structural proteins during the assembly of the head of 
bacteriophage T4. Nature. 227(5259),pp.680–685. 
Lakin, N.D. and Jackson, S.P. 1999. Regulation of p53 in response to DNA damage. 
Oncogene. 18(53),pp.7644–7655. 
Lam, Y.W., Evans, V.C., Heesom, K.J., Lamond, A.I. and Matthews, D.A. 2010. 
Proteomics Analysis of the Nucleolus in Adenovirus-infected Cells. Molecular & 
Cellular Proteomics. 9(1),pp.117–130. 
Lander, E.S., Linton, L.M., Birren, B., Nusbaum, C., Zody, M.C., Baldwin, J., Devon, K., 
Dewar, K., Doyle, M., FitzHugh, W., Funke, R., Gage, D., Harris, K., Heaford, A., 
Howland, J., Kann, L., Lehoczky, J., LeVine, R., McEwan, P., McKernan, K., 
Meldrim, J., Mesirov, J.P., Miranda, C., Morris, W., Naylor, J., Raymond, C., 
Rosetti, M., Santos, R., Sheridan, A., Sougnez, C., Stange-Thomann, N., 
Stojanovic, N., Subramanian, A., Wyman, D., Rogers, J., Sulston, J., Ainscough, 
R., Beck, S., Bentley, D., Burton, J., Clee, C., Carter, N., Coulson, A., Deadman, 
R., Deloukas, P., Dunham, A., Dunham, I., Durbin, R., French, L., Grafham, D., 
Gregory, S., Hubbard, T., Humphray, S., Hunt, A., Jones, M., Lloyd, C., 
McMurray, A., Matthews, L., Mercer, S., Milne, S., Mullikin, J.C., Mungall, A., 
Plumb, R., Ross, M., Shownkeen, R., Sims, S., Waterston, R.H., Wilson, R.K., 
Hillier, L.W., McPherson, J.D., Marra, M.A., Mardis, E.R., Fulton, L.A., Chinwalla, 
A.T., Pepin, K.H., Gish, W.R., Chissoe, S.L., Wendl, M.C., Delehaunty, K.D., 
Miner, T.L., Delehaunty, A., Kramer, J.B., Cook, L.L., Fulton, R.S., Johnson, D.L., 
Minx, P.J., Clifton, S.W., Hawkins, T., Branscomb, E., Predki, P., Richardson, P., 
Wenning, S., Slezak, T., Doggett, N., Cheng, J.F., Olsen, A., Lucas, S., Elkin, C., 
Uberbacher, E., Frazier, M., Gibbs, R.A., Muzny, D.M., Scherer, S.E., Bouck, J.B., 
Sodergren, E.J., Worley, K.C., Rives, C.M., Gorrell, J.H., Metzker, M.L., Naylor, 
S.L., Kucherlapati, R.S., Nelson, D.L., Weinstock, G.M., Sakaki, Y., Fujiyama, A., 
Hattori, M., Yada, T., Toyoda, A., Itoh, T., Kawagoe, C., Watanabe, H., Totoki, Y., 
Taylor, T., Weissenbach, J., Heilig, R., Saurin, W., Artiguenave, F., Brottier, P., 
Bruls, T., Pelletier, E., Robert, C., Wincker, P., Smith, D.R., Doucette-Stamm, L., 
Rubenfield, M., Weinstock, K., Lee, H.M., Dubois, J., Rosenthal, A., Platzer, M., 
Nyakatura, G., Taudien, S., Rump, A., Yang, H., Yu, J., Wang, J., Huang, G., Gu, J., 
Hood, L., Rowen, L., Madan, A., Qin, S., Davis, R.W., Federspiel, N.A., Abola, 
XX 
 
A.P., Proctor, M.J., Myers, R.M., Schmutz, J., Dickson, M., Grimwood, J., Cox, 
D.R., Olson, M.V., Kaul, R., Raymond, C., Shimizu, N., Kawasaki, K., Minoshima, 
S., Evans, G.A., Athanasiou, M., Schultz, R., Roe, B.A., Chen, F., Pan, H., Ramser, 
J., Lehrach, H., Reinhardt, R., McCombie, W.R., de la Bastide, M., Dedhia, N., 
Blöcker, H., Hornischer, K., Nordsiek, G., Agarwala, R., Aravind, L., Bailey, J.A., 
Bateman, A., Batzoglou, S., Birney, E., Bork, P., Brown, D.G., Burge, C.B., Cerutti, 
L., Chen, H.C., Church, D., Clamp, M., Copley, R.R., Doerks, T., Eddy, S.R., 
Eichler, E.E., Furey, T.S., Galagan, J., Gilbert, J.G., Harmon, C., Hayashizaki, Y., 
Haussler, D., Hermjakob, H., Hokamp, K., Jang, W., Johnson, L.S., Jones, T.A., 
Kasif, S., Kaspryzk, A., Kennedy, S., Kent, W.J., Kitts, P., Koonin, E.V., Korf, I., 
Kulp, D., Lancet, D., Lowe, T.M., McLysaght, A., Mikkelsen, T., Moran, J.V., 
Mulder, N., Pollara, V.J., Ponting, C.P., Schuler, G., Schultz, J., Slater, G., Smit, 
A.F., Stupka, E., Szustakowski, J., Thierry-Mieg, D., Thierry-Mieg, J., Wagner, L., 
Wallis, J., Wheeler, R., Williams, A., Wolf, Y.I., Wolfe, K.H., Yang, S.P., Yeh, R.F., 
Collins, F., Guyer, M.S., Peterson, J., Felsenfeld, A., Wetterstrand, K.A., Patrinos, 
A., Morgan, M.J., de Jong, P., Catanese, J.J., Osoegawa, K., Shizuya, H., Choi, S., 
Chen, Y.J., Szustakowki, J. and International Human Genome Sequencing 
Consortium 2001. Initial sequencing and analysis of the human genome. 
Nature. 409(6822),pp.860–921. 
Lane, D.P. and Crawford, L.V. 1979. T antigen is bound to a host protein in SV40-
transformed cells. Nature. 278(5701),pp.261–263. 
Lassmann, T., Maida, Y., Tomaru, Y., Yasukawa, M., Ando, Y., Kojima, M., Kasim, V., 
Simon, C., Daub, C., Carninci, P., Hayashizaki, Y. and Masutomi, K. 2015. 
Telomerase Reverse Transcriptase Regulates microRNAs. International Journal 
of Molecular Sciences. 16(1),pp.1192–1208. 
Laurin, M. and Cote, J.-F. 2014. Insights into the biological functions of Dock family 
guanine nucleotide exchange factors. Genes & Development. 28(6),pp.533–547. 
Law, G.L., Korth, M.J., Benecke, A.G. and Katze, M.G. 2013. Systems virology: host-
directed approaches to viral pathogenesis and drug targeting. Nature Reviews 
Microbiology. 11(7),pp.455–466. 
Lee, G.E., Murray, J.W., Wolkoff, A.W. and Wilson, D.W. 2006. Reconstitution of herpes 
simplex virus microtubule-dependent trafficking in vitro. Journal of Virology. 
80(9),pp.4264–4275. 
Lee, L.W., Zhang, S., Etheridge, A., Ma, L., Martin, D., Galas, D. and Wang, K. 2010. 
Complexity of the microRNA repertoire revealed by next-generation 
sequencing. RNA. 16(11),pp.2170–2180. 
Lee, Y., Jeon, K., Lee, J.-T., Kim, S. and Kim, V.N. 2002. MicroRNA maturation: stepwise 
processing and subcellular localization. The EMBO journal. 21(17),pp.4663–
4670. 
XXI 
 
Lee, Y.J. and Glaunsinger, B.A. 2009. Aberrant Herpesvirus-Induced Polyadenylation 
Correlates With Cellular Messenger RNA Destruction B. Sugden, ed. PLoS 
Biology. 7(5),p.e1000107. 
Lee, Y., Kim, M., Han, J., Yeom, K.-H., Lee, S., Baek, S.H. and Kim, V.N. 2004. MicroRNA 
genes are transcribed by RNA polymerase II. The EMBO Journal. 
23(20),pp.4051–4060. 
Lei, H., Dias, A.P. and Reed, R. 2011. Export and stability of naturally intronless mRNAs 
require specific coding region sequences and the TREX mRNA export complex. 
Proceedings of the National Academy of Sciences. 108(44),pp.17985–17990. 
Lei, X., Bai, Z., Ye, F., Xie, J., Kim, C.-G., Huang, Y. and Gao, S.-J. 2010. Regulation of NF-
kappaB inhibitor IkappaBalpha and viral replication by a KSHV microRNA. 
Nature Cell Biology. 12(2),pp.193–199. 
Lei, X., Ye, F., Bai, Z., Huang, Y. and Gao, S.-J. 2010. Regulation of herpes virus lifecycle 
by viral microRNAs. Virulence. 1(5),pp.433–435. 
Levine, P.H., Ablashi, D.V., Berard, C.W., Carbone, P.P., Waggoner, D.E. and Malan, L. 
1971. Elevated antibody titers to epstein-barr virus in Hodgkin’s disease. 
Cancer. 27(2),pp.416–421. 
Lewis, B.P., Burge, C.B. and Bartel, D.P. 2005. Conserved seed pairing, often flanked by 
adenosines, indicates that thousands of human genes are microRNA targets. 
Cell. 120(1),pp.15–20. 
Lewis, B.P., Shih, I. -hun., Jones-Rhoades, M.W., Bartel, D.P. and Burge, C.B. 2003. 
Prediction of mammalian microRNA targets. Cell. 115(7),pp.787–798. 
Lewis, J.D., Gunderson, S.I. and Mattaj, I.W. 1995. The influence of 5’ and 3’ end 
structures on pre-mRNA metabolism. Journal of Cell Science. 1995(Supplement 
19),pp.13–19. 
Liang, X., Pickering, M.T., Cho, N.-H., Chang, H., Volkert, M.R., Kowalik, T.F. and Jung, 
J.U. 2006. Deregulation of DNA damage signal transduction by herpesvirus 
latency-associated M2. Journal of Virology. 80(12),pp.5862–5874. 
Liang, Y. 2002. The lytic switch protein of KSHV activates gene expression via functional 
interaction with RBP-Jkappa (CSL), the target of the Notch signaling pathway. 
Genes & Development. 16(15),pp.1977–1989. 
Lieberman, P.M., Hu, J. and Renne, R. 2007. Maintenance and replication during 
latency In: A. Arvin, G. Campadelli-Fiume, E. Mocarski, P. S. Moore, B. Roizman, 
R. Whitley and K. Yamanishi, eds. Human Herpesviruses: Biology, Therapy, and 
Immunoprophylaxis [Online]. Cambridge: Cambridge University Press. 
[Accessed 25 June 2015]. Available from: 
http://www.ncbi.nlm.nih.gov/books/NBK47400/. 
XXII 
 
Li, J.Z., Chapman, B., Charlebois, P., Hofmann, O., Weiner, B., Porter, A.J., Samuel, R., 
Vardhanabhuti, S., Zheng, L., Eron, J., Taiwo, B., Zody, M.C., Henn, M.R., 
Kuritzkes, D.R. and Hide, W. 2014. Comparison of Illumina and 454 Deep 
Sequencing in Participants Failing Raltegravir-Based Antiretroviral Therapy L. 
Kaderali, ed. PLoS ONE. 9(3),p.e90485. 
Lim, E.L., Trinh, D.L., Scott, D.W., Chu, A., Krzywinski, M., Zhao, Y., Robertson, A.G., 
Mungall, A.J., Schein, J., Boyle, M., Mottok, A., Ennishi, D., Johnson, N.A., Steidl, 
C., Connors, J.M., Morin, R.D., Gascoyne, R.D. and Marra, M.A. 2015. 
Comprehensive miRNA sequence analysis reveals survival differences in diffuse 
large B-cell lymphoma patients. Genome Biology. [Online]. 16(1). [Accessed 29 
April 2015]. Available from: http://genomebiology.com/2015/16/1/18. 
Li, M., Lee, H., Yoon, D.W., Albrecht, J.C., Fleckenstein, B., Neipel, F. and Jung, J.U. 
1997. Kaposi’s sarcoma-associated herpesvirus encodes a functional cyclin. 
Journal of Virology. 71(3),pp.1984–1991. 
Ling, H., Fabbri, M. and Calin, G.A. 2013. MicroRNAs and other non-coding RNAs as 
targets for anticancer drug development. Nature Reviews Drug Discovery. 
12(11),pp.847–865. 
Linsen, S.E.V., de Wit, E., Janssens, G., Heater, S., Chapman, L., Parkin, R.K., Fritz, B., 
Wyman, S.K., de Bruijn, E., Voest, E.E., Kuersten, S., Tewari, M. and Cuppen, E. 
2009. Limitations and possibilities of small RNA digital gene expression 
profiling. Nature Methods. 6(7),pp.474–476. 
Lin, X., Liang, D., He, Z., Deng, Q., Robertson, E.S. and Lan, K. 2011. miR-K12-7-5p 
Encoded by Kaposi’s Sarcoma-Associated Herpesvirus Stabilizes the Latent 
State by Targeting Viral ORF50/RTA T. F. Schulz, ed. PLoS ONE. 6(1),p.e16224. 
Linzer, D.I. and Levine, A.J. 1979. Characterization of a 54K dalton cellular SV40 tumor 
antigen present in SV40-transformed cells and uninfected embryonal 
carcinoma cells. Cell. 17(1),pp.43–52. 
Li, R., Zhu, J., Xie, Z., Liao, G., Liu, J., Chen, M.-R., Hu, S., Woodard, C., Lin, J., Taverna, 
S.D., Desai, P., Ambinder, R.F., Hayward, G.S., Qian, J., Zhu, H. and Hayward, 
S.D. 2011. Conserved Herpesvirus Kinases Target the DNA Damage Response 
Pathway and TIP60 Histone Acetyltransferase to Promote Virus Replication. Cell 
Host & Microbe. 10(4),pp.390–400. 
Liu, H., Sadygov, R.G. and Yates, J.R. 2004. A model for random sampling and 
estimation of relative protein abundance in shotgun proteomics. Analytical 
Chemistry. 76(14),pp.4193–4201. 
Liu, L.F., Desai, S.D., Li, T.K., Mao, Y., Sun, M. and Sim, S.P. 2000. Mechanism of action 
of camptothecin. Annals of the New York Academy of Sciences. 922,pp.1–10. 
XXIII 
 
Liu, S., Shiotani, B., Lahiri, M., Maréchal, A., Tse, A., Leung, C.C.Y., Glover, J.N.M., Yang, 
X.H. and Zou, L. 2011. ATR Autophosphorylation as a Molecular Switch for 
Checkpoint Activation. Molecular Cell. 43(2),pp.192–202. 
Li, W., Fan, J. and Woodley, D.T. 2001. Nck/Dock: an adapter between cell surface 
receptors and the actin cytoskeleton. Oncogene. 20(44),pp.6403–6417. 
Li, X. and Heyer, W.-D. 2008. Homologous recombination in DNA repair and DNA 
damage tolerance. Cell Research. 18(1),pp.99–113. 
Li, Y., Masaki, T., Yamane, D., McGivern, D.R. and Lemon, S.M. 2013. Competing and 
noncompeting activities of miR-122 and the 5’ exonuclease Xrn1 in regulation 
of hepatitis C virus replication. Proceedings of the National Academy of Sciences 
of the United States of America. 110(5),pp.1881–1886. 
Li, Y., Zhang, Z., Liu, F., Vongsangnak, W., Jing, Q. and Shen, B. 2012. Performance 
comparison and evaluation of software tools for microRNA deep-sequencing 
data analysis. Nucleic Acids Research. 40(10),pp.4298–4305. 
Li, Z., Cui, X., Li, F., Li, P., Ni, M., Wang, S. and Bo, X. 2013. Exploring the role of human 
miRNAs in virus-host interactions using systematic overlap analysis. 
Bioinformatics. 29(19),pp.2375–2379. 
Lodish, H.F. (ed.). 2000. Molecular cell biology 4th ed. New York: W.H. Freeman. 
Loeb, L.A. and Preston, B.D. 1986. Mutagenesis by apurinic/apyrimidinic sites. Annual 
Review of Genetics. 20,pp.201–230. 
Longnecker, R. and Neipel, F. 2007. Introduction to the human γ-herpesviruses In: A. 
Arvin, G. Campadelli-Fiume, E. Mocarski, P. S. Moore, B. Roizman, R. Whitley 
and K. Yamanishi, eds. Human Herpesviruses: Biology, Therapy, and 
Immunoprophylaxis [Online]. Cambridge: Cambridge University Press. 
[Accessed 25 June 2015]. Available from: 
http://www.ncbi.nlm.nih.gov/books/NBK47397/. 
Lu, F., Stedman, W., Yousef, M., Renne, R. and Lieberman, P.M. 2010. Epigenetic 
Regulation of Kaposi’s Sarcoma-Associated Herpesvirus Latency by Virus-
Encoded MicroRNAs That Target Rta and the Cellular Rbl2-DNMT Pathway. 
Journal of Virology. 84(6),pp.2697–2706. 
Luftig, M.A. 2014. Viruses and the DNA Damage Response: Activation and Antagonism. 
Annual Review of Virology. 1(1),pp.605–625. 
Lu, F., Weidmer, A., Liu, C.-G., Volinia, S., Croce, C.M. and Lieberman, P.M. 2008. 
Epstein-Barr Virus-Induced miR-155 Attenuates NF- B Signaling and Stabilizes 
Latent Virus Persistence. Journal of Virology. 82(21),pp.10436–10443. 
Luitweiler, E.M., Henson, B.W., Pryce, E.N., Patel, V., Coombs, G., McCaffery, J.M., 
Desai, P.J. 2013. Interactions of the Kaposi's Sarcoma-associated herpesvirus 
XXIV 
 
nuclear egress complex: ORF69 is a potent factor for remodeling cellular 
membranes. Journal of Virology. 87(7), pp.3915-3929. 
Lukac, D.M., Renne, R., Kirshner, J.R. and Ganem, D. 1998. Reactivation of Kaposi’s 
sarcoma-associated herpesvirus infection from latency by expression of the 
ORF 50 transactivator, a homolog of the EBV R protein. Virology. 
252(2),pp.304–312. 
Luna, J.M., Scheel, T.K.H., Danino, T., Shaw, K.S., Mele, A., Fak, J.J., Nishiuchi, E., 
Takacs, C.N., Catanese, M.T., de Jong, Y.P., Jacobson, I.M., Rice, C.M. and 
Darnell, R.B. 2015. Hepatitis C Virus RNA Functionally Sequesters miR-122. Cell. 
160(6),pp.1099–1110. 
Luo, C., Tsementzi, D., Kyrpides, N., Read, T. and Konstantinidis, K.T. 2012. Direct 
Comparisons of Illumina vs. Roche 454 Sequencing Technologies on the Same 
Microbial Community DNA Sample F. Rodriguez-Valera, ed. PLoS ONE. 
7(2),p.e30087. 
Lu, X. and Legerski, R.J. 2007. The Prp19/Pso4 core complex undergoes ubiquitylation 
and structural alterations in response to DNA damage. Biochemical and 
Biophysical Research Communications. 354(4),pp.968–974. 
Lyman, M.G. and Enquist, L.W. 2009. Herpesvirus interactions with the host 
cytoskeleton. Journal of Virology. 83(5),pp.2058–2066. 
Lytle, J.R., Yario, T.A. and Steitz, J.A. 2007. Target mRNAs are repressed as efficiently by 
microRNA-binding sites in the 5’ UTR as in the 3’ UTR. Proceedings of the 
National Academy of Sciences of the United States of America. 
104(23),pp.9667–9672. 
Mabit, H., Nakano, M.Y., Prank, U., Saam, B., Dohner, K., Sodeik, B. and Greber, U.F. 
2002. Intact Microtubules Support Adenovirus and Herpes Simplex Virus 
Infections. Journal of Virology. 76(19),pp.9962–9971. 
Machida, T., Fujita, T., Ooo, M.L., Ohira, M., Isogai, E., Mihara, M., Hirato, J., 
Tomotsune, D., Hirata, T., Fujimori, M., Adachi, W. and Nakagawara, A. 2006. 
Increased expression of proapoptotic BMCC1, a novel gene with the BNIP2 and 
Cdc42GAP homology (BCH) domain, is associated with favorable prognosis in 
human neuroblastomas. Oncogene. 25(13),pp.1931–1942. 
Majerciak, V., Ni, T., Yang, W., Meng, B., Zhu, J. and Zheng, Z.-M. 2013. A Viral Genome 
Landscape of RNA Polyadenylation from KSHV Latent to Lytic Infection B. A. 
Glaunsinger, ed. PLoS Pathogens. 9(11),p.e1003749. 
Majerciak, V., Yamanegi, K., Allemand, E., Kruhlak, M., Krainer, A.R. and Zheng, Z.-M. 
2008. Kaposi’s sarcoma-associated herpesvirus ORF57 functions as a viral 
splicing factor and promotes expression of intron-containing viral lytic genes in 
spliceosome-mediated RNA splicing. Journal of Virology. 82(6),pp.2792–2801. 
XXV 
 
Majerciak, V. and Zheng, Z.-M. 2015. KSHV ORF57, a protein of many faces. Viruses. 
7(2),pp.604–633. 
Makarova, O.V., Makarov, E.M., Urlaub, H., Will, C.L., Gentzel, M., Wilm, M. and 
Lührmann, R. 2004. A subset of human 35S U5 proteins, including Prp19, 
function prior to catalytic step 1 of splicing. The EMBO journal. 23(12),pp.2381–
2391. 
Malik, P., Blackbourn, D.J. and Clements, J.B. 2004. The evolutionarily conserved 
Kaposi’s sarcoma-associated herpesvirus ORF57 protein interacts with REF 
protein and acts as an RNA export factor. The Journal of Biological Chemistry. 
279(31),pp.33001–33011. 
Malone, J.H. and Oliver, B. 2011. Microarrays, deep sequencing and the true measure 
of the transcriptome. BMC Biology. 9(1),p.34. 
Manley, J.L. 1995. A complex protein assembly catalyzes polyadenylation of mRNA 
precursors. Current Opinion in Genetics & Development. 5(2),pp.222–228. 
Mardis, E.R. 2008. Next-Generation DNA Sequencing Methods. Annual Review of 
Genomics and Human Genetics. 9(1),pp.387–402. 
Maréchal, A., Li, J.-M., Ji, X.Y., Wu, C.-S., Yazinski, S.A., Nguyen, H.D., Liu, S., Jiménez, 
A.E., Jin, J. and Zou, L. 2014. PRP19 transforms into a sensor of RPA-ssDNA after 
DNA damage and drives ATR activation via a ubiquitin-mediated circuitry. 
Molecular Cell. 53(2),pp.235–246. 
Marquitz, A.R., Mathur, A., Nam, C.S. and Raab-Traub, N. 2011. The Epstein-Barr Virus 
BART microRNAs target the pro-apoptotic protein Bim. Virology. 
412(2),pp.392–400. 
Marteijn, J.A., Lans, H., Vermeulen, W. and Hoeijmakers, J.H.J. 2014. Understanding 
nucleotide excision repair and its roles in cancer and ageing. Nature Reviews 
Molecular Cell Biology. 15(7),pp.465–481. 
Martin, E.R., Kinnamon, D.D., Schmidt, M.A., Powell, E.H., Zuchner, S. and Morris, R.W. 
2010. SeqEM: an adaptive genotype-calling approach for next-generation 
sequencing studies. Bioinformatics. 26(22),pp.2803–2810. 
Masuda, S., Das, R., Cheng, H., Hurt, E., Dorman, N. and Reed, R. 2005. Recruitment of 
the human TREX complex to mRNA during splicing. Genes & Development. 
19(13),pp.1512–1517. 
Matthews, R.E. 1979. Third report of the International Committee on Taxonomy of 
Viruses. Classification and nomenclature of viruses. Intervirology. 12(3-
5),pp.129–296. 
McCracken, S., Fong, N., Yankulov, K., Ballantyne, S., Pan, G., Greenblatt, J., Patterson, 
S.D., Wickens, M. and Bentley, D.L. 1997. The C-terminal domain of RNA 
XXVI 
 
polymerase II couples mRNA processing to transcription. Nature. 
385(6614),pp.357–361. 
McGeoch, D.J., Rixon, F.J. and Davison, A.J. 2006. Topics in herpesvirus genomics and 
evolution. Virus Research. 117(1),pp.90–104. 
McKendrick, L., Thompson, E., Ferreira, J., Morley, S.J. and Lewis, J.D. 2001. Interaction 
of Eukaryotic Translation Initiation Factor 4G with the Nuclear Cap-Binding 
Complex Provides a Link between Nuclear and Cytoplasmic Functions of the m7 
Guanosine Cap. Molecular and Cellular Biology. 21(11),pp.3632–3641. 
Megger, D.A., Bracht, T., Meyer, H.E. and Sitek, B. 2013. Label-free quantification in 
clinical proteomics. Biochimica et Biophysica Acta (BBA) - Proteins and 
Proteomics. 1834(8),pp.1581–1590. 
Melamed, Z., Levy, A., Ashwal-Fluss, R., Lev-Maor, G., Mekahel, K., Atias, N., Gilad, S., 
Sharan, R., Levy, C., Kadener, S. and Ast, G. 2013. Alternative Splicing Regulates 
Biogenesis of miRNAs Located across Exon-Intron Junctions. Molecular Cell. 
50(6),pp.869–881. 
Meller, N., Irani-Tehrani, M., Kiosses, W.B., Del Pozo, M.A. and Schwartz, M.A. 2002. 
Zizimin1, a novel Cdc42 activator, reveals a new GEF domain for Rho proteins. 
Nature Cell Biology. 4(9),pp.639–647. 
Menon, V. and Povirk, L. 2014. Involvement of p53 in the Repair of DNA Double Strand 
Breaks: Multifaceted Roles of p53 in Homologous Recombination Repair (HRR) 
and Non-Homologous End Joining (NHEJ) In: S. P. Deb and S. Deb, eds. Mutant 
p53 and MDM2 in Cancer [Online]. Dordrecht: Springer Netherlands, pp. 321–
336. [Accessed 29 June 2015]. Available from: 
http://link.springer.com/10.1007/978-94-017-9211-0_17. 
Mercader, M., Taddeo, B., Panella, J.R., Chandran, B., Nickoloff, B.J. and Foreman, K.E. 
2000. Induction of HHV-8 lytic cycle replication by inflammatory cytokines 
produced by HIV-1-infected T cells. The American Journal of Pathology. 
156(6),pp.1961–1971. 
Mesri, E.A., Cesarman, E. and Boshoff, C. 2010. Kaposi’s sarcoma and its associated 
herpesvirus. Nature Reviews Cancer. 10(10),pp.707–719. 
Metpally, R.P.R., Nasser, S., Malenica, I., Courtright, A., Carlson, E., Ghaffari, L., Villa, S., 
Tembe, W. and Van Keuren-Jensen, K. 2013. Comparison of Analysis Tools for 
miRNA High Throughput Sequencing Using Nerve Crush as a Model. Frontiers in 
Genetics. [Online]. 4. [Accessed 29 April 2015]. Available from: 
http://journal.frontiersin.org/article/10.3389/fgene.2013.00020/abstract. 
Mettenleiter, T.C. 2004. Budding events in herpesvirus morphogenesis. Virus Research. 
106(2),pp.167–180. 
XXVII 
 
Mettenleiter, T.C., Klupp, B.G. and Granzow, H. 2009. Herpesvirus assembly: An 
update. Virus Research. 143(2),pp.222–234. 
Michalski, A., Cox, J. and Mann, M. 2011. More than 100,000 detectable peptide 
species elute in single shotgun proteomics runs but the majority is inaccessible 
to data-dependent LC-MS/MS. Journal of Proteome Research. 10(4),pp.1785–
1793. 
Mizumoto, K. and Kaziro, Y. 1987. Messenger RNA capping enzymes from eukaryotic 
cells. Progress in Nucleic Acid Research and Molecular Biology. 34,pp.1–28. 
Mocarski Jr., E.S. 2007. Comparative analysis of herpesvirus-common proteins In: A. 
Arvin, G. Campadelli-Fiume, E. Mocarski, P. S. Moore, B. Roizman, R. Whitley 
and K. Yamanishi, eds. Human Herpesviruses: Biology, Therapy, and 
Immunoprophylaxis [Online]. Cambridge: Cambridge University Press. 
[Accessed 25 June 2015]. Available from: 
http://www.ncbi.nlm.nih.gov/books/NBK47403/. 
Mochan, T.A., Venere, M., DiTullio, R.A. and Halazonetis, T.D. 2003. 53BP1 and 
NFBD1/MDC1-Nbs1 function in parallel interacting pathways activating ataxia-
telangiectasia mutated (ATM) in response to DNA damage. Cancer Research. 
63(24),pp.8586–8591. 
Monteys, A.M., Spengler, R.M., Dufour, B.D., Wilson, M.S., Oakley, C.K., Sowada, M.J., 
McBride, J.L. and Davidson, B.L. 2014. Single nucleotide seed modification 
restores in vivo tolerability of a toxic artificial miRNA sequence in the mouse 
brain. Nucleic Acids Research. 42(21),pp.13315–13327. 
Moody, C.A. and Laimins, L.A. 2009. Human Papillomaviruses Activate the ATM DNA 
Damage Pathway for Viral Genome Amplification upon Differentiation D. 
Galloway, ed. PLoS Pathogens. 5(10),p.e1000605. 
Moore, P.S. 2007. KSHV manipulation of the cell cycle and apoptosis In: A. Arvin, G. 
Campadelli-Fiume, E. Mocarski, P. S. Moore, B. Roizman, R. Whitley and K. 
Yamanishi, eds. Human Herpesviruses: Biology, Therapy, and 
Immunoprophylaxis [Online]. Cambridge: Cambridge University Press. 
[Accessed 26 June 2015]. Available from: 
http://www.ncbi.nlm.nih.gov/books/NBK47432/. 
Mortazavi, A., Williams, B.A., McCue, K., Schaeffer, L. and Wold, B. 2008. Mapping and 
quantifying mammalian transcriptomes by RNA-Seq. Nature Methods. 
5(7),pp.621–628. 
Moteki, S. and Price, D. 2002. Functional coupling of capping and transcription of 
mRNA. Molecular Cell. 10(3),pp.599–609. 
Mothes, W., Sherer, N.M., Jin, J. and Zhong, P. 2010. Virus Cell-to-Cell Transmission. 
Journal of Virology. 84(17),pp.8360–8368. 
XXVIII 
 
Münger, K., Werness, B.A., Dyson, N., Phelps, W.C., Harlow, E. and Howley, P.M. 1989. 
Complex formation of human papillomavirus E7 proteins with the 
retinoblastoma tumor suppressor gene product. The EMBO journal. 
8(13),pp.4099–4105. 
Muthukrishnan, S., Both, G.W., Furuichi, Y. and Shatkin, A.J. 1975. 5’-Terminal 7-
methylguanosine in eukaryotic mRNA is required for translation. Nature. 
255(5503),pp.33–37. 
Myoung, J. and Ganem, D. 2011. Generation of a doxycycline-inducible KSHV producer 
cell line of endothelial origin: Maintenance of tight latency with efficient 
reactivation upon induction. Journal of Virological Methods. 174(1-2),pp.12–21. 
Nakamura, H., Lu, M., Gwack, Y., Souvlis, J., Zeichner, S.L. and Jung, J.U. 2003. Global 
Changes in Kaposi’s Sarcoma-Associated Virus Gene Expression Patterns 
following Expression of a Tetracycline-Inducible Rta Transactivator. Journal of 
Virology. 77(7),pp.4205–4220. 
Napoli, C. 1990. Introduction of a Chimeric Chalcone Synthase Gene into Petunia 
Results in Reversible Co-Suppression of Homologous Genes in trans. THE PLANT 
CELL ONLINE. 2(4),pp.279–289. 
Naranatt, P.P., Krishnan, H.H., Smith, M.S. and Chandran, B. 2005. Kaposi’s sarcoma-
associated herpesvirus modulates microtubule dynamics via RhoA-GTP-
diaphanous 2 signaling and utilizes the dynein motors to deliver its DNA to the 
nucleus. Journal of Virology. 79(2),pp.1191–1206. 
Odumade, O.A., Hogquist, K.A. and Balfour, H.H. 2011. Progress and Problems in 
Understanding and Managing Primary Epstein-Barr Virus Infections. Clinical 
Microbiology Reviews. 24(1),pp.193–209. 
O’Farrell, P.H. 1975. High resolution two-dimensional electrophoresis of proteins. The 
Journal of Biological Chemistry. 250(10),pp.4007–4021. 
Ogawa, K., Tanaka, Y., Uruno, T., Duan, X., Harada, Y., Sanematsu, F., Yamamura, K., 
Terasawa, M., Nishikimi, A., Cote, J.-F. and Fukui, Y. 2014. DOCK5 functions as a 
key signaling adaptor that links Fc RI signals to microtubule dynamics during 
mast cell degranulation. Journal of Experimental Medicine. 211(7),pp.1407–
1419. 
Ong, S.-E., Blagoev, B., Kratchmarova, I., Kristensen, D.B., Steen, H., Pandey, A. and 
Mann, M. 2002. Stable isotope labeling by amino acids in cell culture, SILAC, as 
a simple and accurate approach to expression proteomics. Molecular & cellular 
proteomics: MCP. 1(5),pp.376–386. 
Ong, S.-E. and Mann, M. 2007. A practical recipe for stable isotope labeling by amino 
acids in cell culture (SILAC). Nature Protocols. 1(6),pp.2650–2660. 
XXIX 
 
O’Reilly, M.M., McNally, M.T. and Beemon, K.L. 1995. Two strong 5’ splice sites and 
competing, suboptimal 3’ splice sites involved in alternative splicing of human 
immunodeficiency virus type 1 RNA. Virology. 213(2),pp.373–385. 
Owen, C., Hughes, D., Baquero-Perez, B., Berndt, A., Schumann, S., Jackson, B. and 
Whitehouse, A. 2014. Utilising proteomic approaches to understand oncogenic 
human herpesviruses (Review). Molecular and Clinical Oncology. [Online]. 
[Accessed 24 April 2015]. Available from: http://www.spandidos-
publications.com/10.3892/mco.2014.341. 
Ozsolak, F. and Milos, P.M. 2011. RNA sequencing: advances, challenges and 
opportunities. Nature Reviews Genetics. 12(2),pp.87–98. 
Paludan, S.R., Bowie, A.G., Horan, K.A. and Fitzgerald, K.A. 2011. Recognition of 
herpesviruses by the innate immune system. Nature Reviews Immunology. 
11(2),pp.143–154. 
Paniagua, R., Nistal, M., Amat, P. and Rodríguez, M.C. 1986. Ultrastructural 
observations on nucleoli and related structures during human 
spermatogenesis. Anatomy and Embryology. 174(3),pp.301–306. 
Parkin, D.M., Sitas, F., Chirenje, M., Stein, L., Abratt, R. and Wabinga, H. 2008. Part I: 
Cancer in Indigenous Africans--burden, distribution, and trends. The Lancet. 
Oncology. 9(7),pp.683–692. 
Park, J.-E., Heo, I., Tian, Y., Simanshu, D.K., Chang, H., Jee, D., Patel, D.J. and Kim, V.N. 
2011. Dicer recognizes the 5’ end of RNA for efficient and accurate processing. 
Nature. 475(7355),pp.201–205. 
Pathmanathan, R., Prasad, U., Sadler, R., Flynn, K. and Raab-Traub, N. 1995. Clonal 
proliferations of cells infected with Epstein-Barr virus in preinvasive lesions 
related to nasopharyngeal carcinoma. The New England Journal of Medicine. 
333(11),pp.693–698. 
Patton, W.F. 2002. Detection technologies in proteome analysis. Journal of 
Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 
771(1-2),pp.3–31. 
Payvar, F., DeFranco, D., Firestone, G.L., Edgar, B., Wrange, O., Okret, S., Gustafsson, 
J.A. and Yamamoto, K.R. 1983. Sequence-specific binding of glucocorticoid 
receptor to MTV DNA at sites within and upstream of the transcribed region. 
Cell. 35(2 Pt 1),pp.381–392. 
Pedro Simas, J. and Efstathiou, S. 1998. Murine gammaherpesvirus 68: a model for the 
study of gammaherpesvirus pathogenesis. Trends in Microbiology. 6(7),pp.276–
282. 
Penkert, R.R. and Kalejta, R.F. 2011. Tegument protein control of latent herpesvirus 
establishment and animation. Herpesviridae. 2(1),p.3. 
XXX 
 
Pfeffer, S., Zavolan, M., Grässer, F.A., Chien, M., Russo, J.J., Ju, J., John, B., Enright, A.J., 
Marks, D., Sander, C. and Tuschl, T. 2004. Identification of virus-encoded 
microRNAs. Science (New York, N.Y.). 304(5671),pp.734–736. 
Plotch, S.J., Bouloy, M., Ulmanen, I. and Krug, R.M. 1981. A unique cap(m7GpppXm)-
dependent influenza virion endonuclease cleaves capped RNAs to generate the 
primers that initiate viral RNA transcription. Cell. 23(3),pp.847–858. 
Plotch, S.J. and Krug, R.M. 1977. Influenza virion transcriptase: synthesis in vitro of 
large, polyadenylic acid-containing complementary RNA. Journal of Virology. 
21(1),pp.24–34. 
Podhorecka, M., Skladanowski, A. and Bozko, P. 2010. H2AX Phosphorylation: Its Role 
in DNA Damage Response and Cancer Therapy. Journal of Nucleic Acids. 
2010,pp.1–9. 
Poirier, M.C. 2012. Chemical-induced DNA damage and human cancer risk. Discovery 
Medicine. 14(77),pp.283–288. 
Polizzotto, M.N., Uldrick, T.S. and Yarchoan, R. 2013. Multicentric Castleman Disease 
In: T. J. Hope, M. Stevenson and D. Richman, eds. Encyclopedia of AIDS [Online]. 
New York, NY: Springer New York, pp. 1–11. [Accessed 26 June 2015]. Available 
from: http://link.springer.com/10.1007/978-1-4614-9610-6_6-1. 
Polson, A.G., Wang, D., DeRisi, J. and Ganem, D. 2002. Modulation of host gene 
expression by the constitutively active G protein-coupled receptor of Kaposi’s 
sarcoma-associated herpesvirus. Cancer Research. 62(15),pp.4525–4530. 
Pratt, Z.L., Kuzembayeva, M., Sengupta, S. and Sugden, B. 2009. The microRNAs of 
Epstein–Barr Virus are expressed at dramatically differing levels among cell 
lines. Virology. 386(2),pp.387–397. 
Pritchard, C.C., Cheng, H.H. and Tewari, M. 2012. MicroRNA profiling: approaches and 
considerations. Nature Reviews Genetics. 13(5),pp.358–369. 
Pritlove, D.C., Poon, L.L., Fodor, E., Sharps, J. and Brownlee, G.G. 1998. Polyadenylation 
of influenza virus mRNA transcribed in vitro from model virion RNA templates: 
requirement for 5’ conserved sequences. Journal of Virology. 72(2),pp.1280–
1286. 
Proudfoot, N. 1991. Poly(A) signals. Cell. 64(4),pp.671–674. 
Punj, V., Matta, H., Schamus, S., Tamewitz, A., Anyang, B. and Chaudhary, P.M. 2010. 
Kaposi’s sarcoma-associated herpesvirus-encoded viral FLICE inhibitory protein 
(vFLIP) K13 suppresses CXCR4 expression by upregulating miR-146a. Oncogene. 
29(12),pp.1835–1844. 
XXXI 
 
Purcell, D.F. and Martin, M.A. 1993. Alternative splicing of human immunodeficiency 
virus type 1 mRNA modulates viral protein expression, replication, and 
infectivity. Journal of Virology. 67(11),pp.6365–6378. 
Qin, Z., Jakymiw, A., Findlay, V. and Parsons, C. 2012. KSHV-Encoded MicroRNAs: 
Lessons for Viral Cancer Pathogenesis and Emerging Concepts. International 
Journal of Cell Biology. 2012,pp.1–9. 
Quinlan, M.P., Chen, L.B. and Knipe, D.M. 1984. The intranuclear location of a herpes 
simplex virus DNA-binding protein is determined by the status of viral DNA 
replication. Cell. 36(4),pp.857–868. 
Qunibi, W., Al-Furayh, O., Almeshari, K., Lin, S.F., Sun, R., Heston, L., Ross, D., Rigsby, 
M. and Miller, G. 1998. Serologic association of human herpesvirus eight with 
posttransplant Kaposi’s sarcoma in Saudi Arabia. Transplantation. 
65(4),pp.583–585. 
Radtke, K., Dohner, K. and Sodeik, B. 2006. Viral interactions with the cytoskeleton: a 
hitchhiker’s guide to the cell. Cellular Microbiology. 8(3),pp.387–400. 
Rajagopalan, R., Vaucheret, H., Trejo, J. and Bartel, D.P. 2006. A diverse and 
evolutionarily fluid set of microRNAs in Arabidopsis thaliana. Genes & 
Development. 20(24),pp.3407–3425. 
Rass, U., Compton, S.A., Matos, J., Singleton, M.R., Ip, S.C.Y., Blanco, M.G., Griffith, J.D. 
and West, S.C. 2010. Mechanism of Holliday junction resolution by the human 
GEN1 protein. Genes & Development. 24(14),pp.1559–1569. 
Reed, R. and Maniatis, T. 1985. Intron sequences involved in lariat formation during 
pre-mRNA splicing. Cell. 41(1),pp.95–105. 
Rivera-Calzada, A., Spagnolo, L., Pearl, L.H. and Llorca, O. 2007. Structural model of 
full-length human Ku70–Ku80 heterodimer and its recognition of DNA and 
DNA-PKcs. EMBO reports. 8(1),pp.56–62. 
Roberts, K.L. and Baines, J.D. 2010. Myosin Va Enhances Secretion of Herpes Simplex 
Virus 1 Virions and Cell Surface Expression of Viral Glycoproteins. Journal of 
Virology. 84(19),pp.9889–9896. 
Robertson, B., Dalby, A.B., Karpilow, J., Khvorova, A., Leake, D. and Vermeulen, A. 
2010. Specificity and functionality of microRNA inhibitors. Silence. 1(1),p.10. 
Robey, R.C., Mletzko, S. and Gotch, F.M. 2010. The T-Cell Immune Response against 
Kaposi’s Sarcoma-Associated Herpesvirus. Advances in Virology. 2010,pp.1–9. 
Robinson, M.D., McCarthy, D.J. and Smyth, G.K. 2010. edgeR: a Bioconductor package 
for differential expression analysis of digital gene expression data. 
Bioinformatics. 26(1),pp.139–140. 
XXXII 
 
Rochat, R.H., Liu, X., Murata, K., Nagayama, K., Rixon, F.J. and Chiu, W. 2011. Seeing 
the Portal in Herpes Simplex Virus Type 1 B Capsids. Journal of Virology. 
85(4),pp.1871–1874. 
Rode, K., Dohner, K., Binz, A., Glass, M., Strive, T., Bauerfeind, R. and Sodeik, B. 2011. 
Uncoupling Uncoating of Herpes Simplex Virus Genomes from Their Nuclear 
Import and Gene Expression. Journal of Virology. 85(9),pp.4271–4283. 
Rodríguez-Navarro, S. and Hurt, E. 2011. Linking gene regulation to mRNA production 
and export. Current Opinion in Cell Biology. 23(3),pp.302–309. 
Roizmann, B., Desrosiers, R.C., Fleckenstein, B., Lopez, C., Minson, A.C. and Studdert, 
M.J. 1992. The family Herpesviridae: an update. The Herpesvirus Study Group 
of the International Committee on Taxonomy of Viruses. Archives of Virology. 
123(3-4),pp.425–449. 
Roos, W.P. and Kaina, B. 2006. DNA damage-induced cell death by apoptosis. Trends in 
Molecular Medicine. 12(9),pp.440–450. 
Ross, P.L., Huang, Y.N., Marchese, J.N., Williamson, B., Parker, K., Hattan, S., 
Khainovski, N., Pillai, S., Dey, S., Daniels, S., Purkayastha, S., Juhasz, P., Martin, 
S., Bartlet-Jones, M., He, F., Jacobson, A. and Pappin, D.J. 2004. Multiplexed 
protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric 
tagging reagents. Molecular & cellular proteomics: MCP. 3(12),pp.1154–1169. 
Roukos, V. and Misteli, T. 2014. The biogenesis of chromosome translocations. Nature 
Cell Biology. 16(4),pp.293–300. 
Ruby, J.G., Jan, C., Player, C., Axtell, M.J., Lee, W., Nusbaum, C., Ge, H. and Bartel, D.P. 
2006. Large-Scale Sequencing Reveals 21U-RNAs and Additional MicroRNAs and 
Endogenous siRNAs in C. elegans. Cell. 127(6),pp.1193–1207. 
Ruiz-Lafuente, N., Alcaraz-Garcia, M.-J., Garcia-Serna, A.-M., Sebastian-Ruiz, S., Moya-
Quiles, M.-R., Garcia-Alonso, A.-M. and Parrado, A. 2015. Dock10, a Cdc42 and 
Rac1 GEF, induces loss of elongation, filopodia, and ruffles in cervical cancer 
epithelial HeLa cells. Biology Open. 4(5),pp.627–635. 
Russo, J.J., Bohenzky, R.A., Chien, M.C., Chen, J., Yan, M., Maddalena, D., Parry, J.P., 
Peruzzi, D., Edelman, I.S., Chang, Y. and Moore, P.S. 1996. Nucleotide sequence 
of the Kaposi sarcoma-associated herpesvirus (HHV8). Proceedings of the 
National Academy of Sciences of the United States of America. 
93(25),pp.14862–14867. 
Ryu, S., Gallis, B., Goo, Y.A., Shaffer, S.A., Radulovic, D. and Goodlett, D.R. 2008. 
Comparison of a label-free quantitative proteomic method based on peptide 
ion current area to the isotope coded affinity tag method. Cancer Informatics. 
6,pp.243–255. 
XXXIII 
 
Sahin, B.B., Patel, D. and Conrad, N.K. 2010. Kaposi’s sarcoma-associated herpesvirus 
ORF57 protein binds and protects a nuclear noncoding RNA from cellular RNA 
decay pathways. PLoS pathogens. 6(3),p.e1000799. 
Salvetti, A. and Greco, A. 2014. Viruses and the nucleolus: the fatal attraction. 
Biochimica Et Biophysica Acta. 1842(6),pp.840–847. 
Sanders, M.A., Ampasala, D. and Basson, M.D. 2009. DOCK5 and DOCK1 Regulate Caco-
2 Intestinal Epithelial Cell Spreading and Migration on Collagen IV. Journal of 
Biological Chemistry. 284(1),pp.27–35. 
Sanford, J.R. 2004. Pre-mRNA splicing: life at the centre of the central dogma. Journal 
of Cell Science. 117(26),pp.6261–6263. 
Sanui, T. 2003. DOCK2 regulates Rac activation and cytoskeletal reorganization through 
interaction with ELMO1. Blood. 102(8),pp.2948–2950. 
Savin, K.W., Cocks, B.G., Wong, F., Sawbridge, T., Cogan, N., Savage, D. and Warner, S. 
2010. A neurotropic herpesvirus infecting the gastropod, abalone, shares 
ancestry with oyster herpesvirus and a herpesvirus associated with the 
amphioxus genome. Virology Journal. 7(1),p.308. 
Schena, M., Shalon, D., Davis, R.W. and Brown, P.O. 1995. Quantitative monitoring of 
gene expression patterns with a complementary DNA microarray. Science (New 
York, N.Y.). 270(5235),pp.467–470. 
Schmidt, A., Kellermann, J. and Lottspeich, F. 2005. A novel strategy for quantitative 
proteomics using isotope-coded protein labels. Proteomics. 5(1),pp.4–15. 
Schroeder, S.C., Schwer, B., Shuman, S. and Bentley, D. 2000. Dynamic association of 
capping enzymes with transcribing RNA polymerase II. Genes & Development. 
14(19),pp.2435–2440. 
Schubert, M., Keene, J.D., Herman, R.C. and Lazzarini, R.A. 1980. Site on the vesicular 
stomatitis virus genome specifying polyadenylation and the end of the L gene 
mRNA. Journal of Virology. 34(2),pp.550–559. 
Schulz, T.F. and Chang, Y. 2007. KSHV gene expression and regulation In: A. Arvin, G. 
Campadelli-Fiume, E. Mocarski, P. S. Moore, B. Roizman, R. Whitley and K. 
Yamanishi, eds. Human Herpesviruses: Biology, Therapy, and 
Immunoprophylaxis [Online]. Cambridge: Cambridge University Press. 
[Accessed 26 June 2015]. Available from: 
http://www.ncbi.nlm.nih.gov/books/NBK47415/. 
Schumann, S., Jackson, B., Baquero-Perez, B. and Whitehouse, A. 2013. Kaposi’s 
Sarcoma-Associated Herpesvirus ORF57 Protein: Exploiting All Stages of Viral 
mRNA Processing. Viruses. 5(8),pp.1901–1923. 
XXXIV 
 
Seo, G.J., Fink, L.H.L., O’Hara, B., Atwood, W.J. and Sullivan, C.S. 2008. Evolutionarily 
Conserved Function of a Viral MicroRNA. Journal of Virology. 82(20),pp.9823–
9828. 
Shahin, V. 2006. The genome of HSV-1 translocates through the nuclear pore as a 
condensed rod-like structure. Journal of Cell Science. 119(1),pp.23–30. 
Shatkin, A.J. 1976. Capping of eucaryotic mRNAs. Cell. 9(4 PT 2),pp.645–653. 
Shen, Z.-Z., Pan, X., Miao, L.-F., Ye, H.-Q., Chavanas, S., Davrinche, C., McVoy, M. and 
Luo, M.-H. 2014. Comprehensive Analysis of Human Cytomegalovirus 
MicroRNA Expression during Lytic and Quiescent Infection W. Ho, ed. PLoS 
ONE. 9(2),p.e88531. 
Shih, S.R. and Krug, R.M. 1996. Novel exploitation of a nuclear function by influenza 
virus: the cellular SF2/ASF splicing factor controls the amount of the essential 
viral M2 ion channel protein in infected cells. The EMBO journal. 
15(19),pp.5415–5427. 
Shih, S.R., Nemeroff, M.E. and Krug, R.M. 1995. The choice of alternative 5’ splice sites 
in influenza virus M1 mRNA is regulated by the viral polymerase complex. 
Proceedings of the National Academy of Sciences of the United States of 
America. 92(14),pp.6324–6328. 
Shiio, Y. and Aebersold, R. 2006. Quantitative proteome analysis using isotope-coded 
affinity tags and mass spectrometry. Nature Protocols. 1(1),pp.139–145. 
Shiloh, Y. 2001. ATM and ATR: networking cellular responses to DNA damage. Current 
Opinion in Genetics & Development. 11(1),pp.71–77. 
Shiloh, Y. and Ziv, Y. 2013. The ATM protein kinase: regulating the cellular response to 
genotoxic stress, and more. Nature Reviews Molecular Cell Biology. 
14(4),pp.197–210. 
Shrinet, J., Jain, S., Jain, J., Bhatnagar, R.K. and Sunil, S. 2014. Next Generation 
Sequencing Reveals Regulation of Distinct Aedes microRNAs during 
Chikungunya Virus Development J. M. C. Ribeiro, ed. PLoS Neglected Tropical 
Diseases. 8(1),p.e2616. 
da Silva, L.F. and Jones, C. 2013. Small non-coding RNAs encoded within the herpes 
simplex virus type 1 latency associated transcript (LAT) cooperate with the 
retinoic acid inducible gene I (RIG-I) to induce beta-interferon promoter activity 
and promote cell survival. Virus Research. 175(2),pp.101–109. 
Skalsky, R.L. and Cullen, B.R. 2010. Viruses, microRNAs, and host interactions. Annual 
Review of Microbiology. 64,pp.123–141. 
Smith, G.L. and McFadden, G. 2002. Science and society: Smallpox: anything to 
declare? Nature Reviews Immunology. 2(7),pp.521–527. 
XXXV 
 
Smith, J., Tho, L.M., Xu, N. and Gillespie, D.A. 2010. The ATM-Chk2 and ATR-Chk1 
pathways in DNA damage signaling and cancer. Advances in Cancer Research. 
108,pp.73–112. 
Sodeik, B., Ebersold, M.W. and Helenius, A. 1997. Microtubule-mediated transport of 
incoming herpes simplex virus 1 capsids to the nucleus. The Journal of Cell 
Biology. 136(5),pp.1007–1021. 
Sokoloski, K.J., Chaskey, E.L. and Wilusz, J. 2009. Virus-mediated mRNA decay by 
hyperadenylation. Genome Biology. 10(8),p.234. 
Song, M.J., Li, X., Brown, H.J. and Sun, R. 2002. Characterization of interactions 
between RTA and the promoter of polyadenylated nuclear RNA in Kaposi’s 
sarcoma-associated herpesvirus/human herpesvirus 8. Journal of Virology. 
76(10),pp.5000–5013. 
Sood, P., Krek, A., Zavolan, M., Macino, G. and Rajewsky, N. 2006. Cell-type-specific 
signatures of microRNAs on target mRNA expression. Proceedings of the 
National Academy of Sciences. 103(8),pp.2746–2751. 
Soulier, J., Grollet, L., Oksenhendler, E., Cacoub, P., Cazals-Hatem, D., Babinet, P., 
d’Agay, M.F., Clauvel, J.P., Raphael, M. and Degos, L. 1995. Kaposi’s sarcoma-
associated herpesvirus-like DNA sequences in multicentric Castleman’s disease. 
Blood. 86(4),pp.1276–1280. 
Spear, P.G. and Longnecker, R. 2003. Herpesvirus entry: an update. Journal of Virology. 
77(19),pp.10179–10185. 
Speck, S.H. and Ganem, D. 2010. Viral Latency and Its Regulation: Lessons from the γ-
Herpesviruses. Cell Host & Microbe. 8(1),pp.100–115. 
Squatrito, M., Gorrini, C. and Amati, B. 2006. Tip60 in DNA damage response and 
growth control: many tricks in one HAT. Trends in Cell Biology. 16(9),pp.433–
442. 
Staffa, A. and Cochrane, A. 1994. The tat/rev intron of human immunodeficiency virus 
type 1 is inefficiently spliced because of suboptimal signals in the 3’ splice site. 
Journal of Virology. 68(5),pp.3071–3079. 
Stoltzfus, C.M. and Madsen, J.M. 2006. Role of viral splicing elements and cellular RNA 
binding proteins in regulation of HIV-1 alternative RNA splicing. Current HIV 
research. 4(1),pp.43–55. 
Sultan, M., Schulz, M.H., Richard, H., Magen, A., Klingenhoff, A., Scherf, M., Seifert, M., 
Borodina, T., Soldatov, A., Parkhomchuk, D., Schmidt, D., O’Keeffe, S., Haas, S., 
Vingron, M., Lehrach, H. and Yaspo, M.-L. 2008. A Global View of Gene Activity 
and Alternative Splicing by Deep Sequencing of the Human Transcriptome. 
Science. 321(5891),pp.956–960. 
XXXVI 
 
Sun, R., Lin, S.F., Gradoville, L. and Miller, G. 1996. Polyadenylylated nuclear RNA 
encoded by Kaposi sarcoma-associated herpesvirus. Proceedings of the 
National Academy of Sciences of the United States of America. 
93(21),pp.11883–11888. 
Sun, R., Lin, S.-F., Gradoville, L., Yuan, Y., Zhu, F. and Miller, G. 1998. A viral gene that 
activates lytic cycle expression of Kaposi’s sarcoma-associated herpesvirus. 
Proceedings of the National Academy of Sciences. 95(18),pp.10866–10871. 
Sun, R., Lin, S.-F., Staskus, K., Gradoville, L., Grogan, E., Haase, A. and Miller, G. 1999. 
Kinetics of Kaposi’s Sarcoma-Associated Herpesvirus Gene Expression. Journal 
of Virology. 73(3),pp.2232–2242. 
Szeto, C.Y.-Y., Lin, C.H., Choi, S.C., Yip, T.T.C., Ngan, R.K.-C., Tsao, G.S.-W. and Lung, M. 
2014. Integrated mRNA and microRNA transcriptome sequencing characterizes 
sequence variants and mRNA–microRNA regulatory network in nasopharyngeal 
carcinoma model systems. FEBS Open Bio. 4,pp.128–140. 
Tang, S., Bertke, A.S., Patel, A., Margolis, T.P. and Krause, P.R. 2011. Herpes Simplex 
Virus 2 MicroRNA miR-H6 Is a Novel Latency-Associated Transcript-Associated 
MicroRNA, but Reduction of Its Expression Does Not Influence the 
Establishment of Viral Latency or the Recurrence Phenotype. Journal of 
Virology. 85(9),pp.4501–4509. 
Tatsumi, Y., Takano, R., Islam, M.S., Yokochi, T., Itami, M., Nakamura, Y. and 
Nakagawara, A. 2015. BMCC1, which is an interacting partner of BCL2, 
attenuates AKT activity, accompanied by apoptosis. Cell Death and Disease. 
6(1),p.e1607. 
Taylor, M.P., Koyuncu, O.O. and Enquist, L.W. 2011. Subversion of the actin 
cytoskeleton during viral infection. Nature Reviews Microbiology. 9(6),pp.427–
439. 
Tay, Y., Zhang, J., Thomson, A.M., Lim, B. and Rigoutsos, I. 2008. MicroRNAs to Nanog, 
Oct4 and Sox2 coding regions modulate embryonic stem cell differentiation. 
Nature. 455(7216),pp.1124–1128. 
Thermo Scientific 2009. Thermo Scientific Dharmacon miRIDIAN microRNA Mimics & 
Hairpin Inhibitors. [Accessed 30 April 2015]. Available from: 
http://www.thermo.com.cn/Resources/200907/1711741370.pdf. 
Thompson, A., Schäfer, J., Kuhn, K., Kienle, S., Schwarz, J., Schmidt, G., Neumann, T., 
Johnstone, R., Mohammed, A.K.A. and Hamon, C. 2003. Tandem mass tags: a 
novel quantification strategy for comparative analysis of complex protein 
mixtures by MS/MS. Analytical Chemistry. 75(8),pp.1895–1904. 
Thompson, S.R. and Sarnow, P. 2003. Enterovirus 71 contains a type I IRES element 
that functions when eukaryotic initiation factor eIF4G is cleaved. Virology. 
315(1),pp.259–266. 
XXXVII 
 
Tischer, B.K. and Osterrieder, N. 2010. Herpesviruses—A zoonotic threat? Veterinary 
Microbiology. 140(3-4),pp.266–270. 
Tortora, G.J., Funke, B.R. and Case, C.L. 2013. Microbiology: an introduction 11th ed. 
Boston: Pearson. 
Trigon, S., Serizawa, H., Conaway, J.W., Conaway, R.C., Jackson, S.P. and Morange, M. 
1998. Characterization of the residues phosphorylated in vitro by different C-
terminal domain kinases. The Journal of Biological Chemistry. 273(12),pp.6769–
6775. 
Tsai, P.-L., Chiou, N.-T., Kuss, S., García-Sastre, A., Lynch, K.W. and Fontoura, B.M.A. 
2013. Cellular RNA binding proteins NS1-BP and hnRNP K regulate influenza A 
virus RNA splicing. PLoS pathogens. 9(6),p.e1003460. 
Tsai, Y.-H., Wu, M.-F., Wu, Y.-H., Chang, S.-J., Lin, S.-F., Sharp, T.V. and Wang, H.-W. 
2009. The M type K15 protein of Kaposi’s sarcoma-associated herpesvirus 
regulates microRNA expression via its SH2-binding motif to induce cell 
migration and invasion. Journal of Virology. 83(2),pp.622–632. 
Uldrick, T.S. and Whitby, D. 2011. Update on KSHV epidemiology, Kaposi Sarcoma 
pathogenesis, and treatment of Kaposi Sarcoma. Cancer Letters. 305(2),pp.150–
162. 
Umbach, J.L., Kramer, M.F., Jurak, I., Karnowski, H.W., Coen, D.M. and Cullen, B.R. 
2008. MicroRNAs expressed by herpes simplex virus 1 during latent infection 
regulate viral mRNAs. Nature. [Online]. [Accessed 25 June 2015]. Available 
from: http://www.nature.com/doifinder/10.1038/nature07103. 
Uziel, T. 2003. Requirement of the MRN complex for ATM activation by DNA damage. 
The EMBO Journal. 22(20),pp.5612–5621. 
Valencia-Sanchez, M.A. 2006. Control of translation and mRNA degradation by miRNAs 
and siRNAs. Genes & Development. 20(5),pp.515–524. 
Valinezhad Orang, A., Safaralizadeh, R. and Kazemzadeh-Bavili, M. 2014. Mechanisms 
of miRNA-Mediated Gene Regulation from Common Downregulation to mRNA-
Specific Upregulation. International Journal of Genomics. 2014,pp.1–15. 
Varthakavi, V., Browning, P.J. and Spearman, P. 1999. Human immunodeficiency virus 
replication in a primary effusion lymphoma cell line stimulates lytic-phase 
replication of Kaposi’s sarcoma-associated herpesvirus. Journal of Virology. 
73(12),pp.10329–10338. 
Vassalli, J.D., Huarte, J., Belin, D., Gubler, P., Vassalli, A., O’Connell, M.L., Parton, L.A., 
Rickles, R.J. and Strickland, S. 1989. Regulated polyadenylation controls mRNA 
translation during meiotic maturation of mouse oocytes. Genes & 
Development. 3(12B),pp.2163–2171. 
XXXVIII 
 
Vasudevan, S., Tong, Y. and Steitz, J.A. 2007. Switching from repression to activation: 
microRNAs can up-regulate translation. Science (New York, N.Y.). 
318(5858),pp.1931–1934. 
Verma, S.C., Borah, S. and Robertson, E.S. 2004. Latency-Associated Nuclear Antigen of 
Kaposi’s Sarcoma-Associated Herpesvirus Up-Regulates Transcription of Human 
Telomerase Reverse Transcriptase Promoter through Interaction with 
Transcription Factor Sp1. Journal of Virology. 78(19),pp.10348–10359. 
Verma, S.C., Lan, K. and Robertson, E. 2007. Structure and function of latency-
associated nuclear antigen. Current Topics in Microbiology and Immunology. 
312,pp.101–136. 
Verschuren, E.W. 2004. The cell cycle and how it is steered by Kaposi’s sarcoma-
associated herpesvirus cyclin. Journal of General Virology. 85(6),pp.1347–1361. 
Vieira, J. and O’Hearn, P.M. 2004. Use of the red fluorescent protein as a marker of 
Kaposi’s sarcoma-associated herpesvirus lytic gene expression. Virology. 
325(2),pp.225–240. 
Vousden, K.H. and Prives, C. 2009. Blinded by the Light: The Growing Complexity of 
p53. Cell. 137(3),pp.413–431. 
Wachtler, F., Hopman, A.H., Wiegant, J. and Schwarzacher, H.G. 1986. On the position 
of nucleolus organizer regions (NORs) in interphase nuclei. Studies with a new, 
non-autoradiographic in situ hybridization method. Experimental Cell Research. 
167(1),pp.227–240. 
Wahle, E., Lustig, A., Jenö, P. and Maurer, P. 1993. Mammalian poly(A)-binding protein 
II. Physical properties and binding to polynucleotides. The Journal of Biological 
Chemistry. 268(4),pp.2937–2945. 
Wang, F.-Z., Weber, F., Croce, C., Liu, C.-G., Liao, X. and Pellett, P.E. 2008. Human 
cytomegalovirus infection alters the expression of cellular microRNA species 
that affect its replication. Journal of Virology. 82(18),pp.9065–9074. 
Wang, J., Han, X. and Zhang, Y. 2012. Autoregulatory Mechanisms of Phosphorylation 
of Checkpoint Kinase 1. Cancer Research. 72(15),pp.3786–3794. 
Wang, Q.-Y., Zhou, C., Johnson, K.E., Colgrove, R.C., Coen, D.M. and Knipe, D.M. 2005. 
Herpesviral latency-associated transcript gene promotes assembly of 
heterochromatin on viral lytic-gene promoters in latent infection. Proceedings 
of the National Academy of Sciences of the United States of America. 
102(44),pp.16055–16059. 
Wang, S.E., Wu, F.Y., Chen, H., Shamay, M., Zheng, Q. and Hayward, G.S. 2004. Early 
activation of the Kaposi’s sarcoma-associated herpesvirus RTA, RAP, and MTA 
promoters by the tetradecanoyl phorbol acetate-induced AP1 pathway. Journal 
of Virology. 78(8),pp.4248–4267. 
XXXIX 
 
Wang, S.E., Wu, F.Y., Fujimuro, M., Zong, J., Hayward, S.D. and Hayward, G.S. 2003. 
Role of CCAAT/enhancer-binding protein alpha (C/EBPalpha) in activation of the 
Kaposi’s sarcoma-associated herpesvirus (KSHV) lytic-cycle replication-
associated protein (RAP) promoter in cooperation with the KSHV replication 
and transcription activator (RTA) and RAP. Journal of Virology. 77(1),pp.600–
623. 
Wang, Y., Li, H., Tang, Q., Maul, G.G. and Yuan, Y. 2008. Kaposi’s Sarcoma-Associated 
Herpesvirus ori-Lyt-Dependent DNA Replication: Involvement of Host Cellular 
Factors. Journal of Virology. 82(6),pp.2867–2882. 
Wang, Z., Gerstein, M. and Snyder, M. 2009. RNA-Seq: a revolutionary tool for 
transcriptomics. Nature Reviews Genetics. 10(1),pp.57–63. 
Ward, B.M. 2011. The taking of the cytoskeleton one two three: How viruses utilize the 
cytoskeleton during egress. Virology. 411(2),pp.244–250. 
Washburn, M.P., Wolters, D. and Yates, J.R. 2001. Large-scale analysis of the yeast 
proteome by multidimensional protein identification technology. Nature 
Biotechnology. 19(3),pp.242–247. 
Wei, C.M. and Moss, B. 1975. Methylated nucleotides block 5’-terminus of vaccinia 
virus messenger RNA. Proceedings of the National Academy of Sciences of the 
United States of America. 72(1),pp.318–322. 
Wells, S.E., Hillner, P.E., Vale, R.D. and Sachs, A.B. 1998. Circularization of mRNA by 
eukaryotic translation initiation factors. Molecular Cell. 2(1),pp.135–140. 
Wen, H.-J., Minhas, V. and Wood, C. 2009. Identification and characterization of a new 
Kaposi’s sarcoma-associated herpesvirus replication and transcription activator 
(RTA)-responsive element involved in RTA-mediated transactivation. Journal of 
General Virology. 90(4),pp.944–953. 
Werner, F.J., Bornkamm, G.W., Fleckenstein, B. and Mulder, C. 1978. Episomal viral 
DNA in herpesvirus saimiri-transformed lymphoid cell lines. IARC scientific 
publications. (24 Pt 1),pp.125–130. 
Westover, K.D. 2004. Structural Basis of Transcription: Separation of RNA from DNA by 
RNA Polymerase II. Science. 303(5660),pp.1014–1016. 
White, C.A., Stow, N.D., Patel, A.H., Hughes, M. and Preston, V.G. 2003. Herpes simplex 
virus type 1 portal protein UL6 interacts with the putative terminase subunits 
UL15 and UL28. Journal of Virology. 77(11),pp.6351–6358. 
Wiese, S., Reidegeld, K.A., Meyer, H.E. and Warscheid, B. 2007. Protein labeling by 
iTRAQ: a new tool for quantitative mass spectrometry in proteome research. 
Proteomics. 7(3),pp.340–350. 
XL 
 
Wilhelm, B.T., Marguerat, S., Watt, S., Schubert, F., Wood, V., Goodhead, I., Penkett, 
C.J., Rogers, J. and Bähler, J. 2008. Dynamic repertoire of a eukaryotic 
transcriptome surveyed at single-nucleotide resolution. Nature. 
453(7199),pp.1239–1243. 
Wilson, D.M., Takeshita, M. and Demple, B. 1997. Abasic Site Binding by the Human 
Apurinic Endonuclease, Ape, and Determination of the DNA Contact Sites. 
Nucleic Acids Research. 25(5),pp.933–939. 
Wong, J.W.H. and Cagney, G. 2010. An Overview of Label-Free Quantitation Methods 
in Proteomics by Mass Spectrometry In: S. J. Hubbard and A. R. Jones, eds. 
Proteome Bioinformatics [Online]. Totowa, NJ: Humana Press, pp. 273–283. 
[Accessed 8 July 2015]. Available from: http://link.springer.com/10.1007/978-
1-60761-444-9_18. 
Wong, N. and Wang, X. 2015. miRDB: an online resource for microRNA target 
prediction and functional annotations. Nucleic Acids Research. 43(D1),pp.D146–
D152. 
Wu, R. 1972. Nucleotide Sequence Analysis of DNA. Nature New Biology. 
236(68),pp.198–200. 
Wu, X. and Brewer, G. 2012. The regulation of mRNA stability in mammalian cells: 2.0. 
Gene. 500(1),pp.10–21. 
Wu, X., Yang, Z., Liu, Y. and Zou, Y. 2005. Preferential localization of 
hyperphosphorylated replication protein A to double-strand break repair and 
checkpoint complexes upon DNA damage. The Biochemical Journal. 391(Pt 
3),pp.473–480. 
Wu, Y.-H., Hu, T.-F., Chen, Y.-C., Tsai, Y.-N., Tsai, Y.-H., Cheng, C.-C. and Wang, H.-W. 
2011. The manipulation of miRNA-gene regulatory networks by KSHV induces 
endothelial cell motility. Blood. 118(10),pp.2896–2905. 
Xiao, C. and Rajewsky, K. 2009. MicroRNA control in the immune system: basic 
principles. Cell. 136(1),pp.26–36. 
Xie, A. and Scully, R. 2007. Hijacking the DNA Damage Response to Enhance Viral 
Replication: γ-Herpesvirus 68 orf36 Phosphorylates Histone H2AX. Molecular 
Cell. 27(2),pp.178–179. 
Xu, N., Lao, Y., Zhang, Y. and Gillespie, D.A. 2012. Akt: a double-edged sword in cell 
proliferation and genome stability. Journal of Oncology. 2012,p.951724. 
Xu, N., Wang, J., Zhang, Z.-F., Pang, D.-W., Wang, H.-Z. and Zhang, Z.-L. 2014. 
Anisotropic cell-to-cell spread of vaccinia virus on microgrooved substrate. 
Biomaterials. 35(19),pp.5049–5055. 
XLI 
 
Xu, X. and Jin, T. 2012. A shortcut from GPCR signaling to Rac-mediated actin 
cytoskeleton through an ELMO/DOCK complex. Small GTPases. 3(3),pp.183–
185. 
Xu, Z., Xiao, S.-B., Xu, P., Xie, Q., Cao, L., Wang, D., Luo, R., Zhong, Y., Chen, H.-C. and 
Fang, L.-R. 2011. miR-365, a Novel Negative Regulator of Interleukin-6 Gene 
Expression, Is Cooperatively Regulated by Sp1 and NF- B. Journal of Biological 
Chemistry. 286(24),pp.21401–21412. 
Yamauchi, T., Yoshida, A. and Ueda, T. 2011. Camptothecin induces DNA strand breaks 
and is cytotoxic in stimulated normal lymphocytes. Oncology Reports. 
25(2),pp.347–352. 
Yang, J. 2003. ATM, ATR and DNA-PK: initiators of the cellular genotoxic stress 
responses. Carcinogenesis. 24(10),pp.1571–1580. 
Yang, J.-S. and Lai, E.C. 2011. Alternative miRNA biogenesis pathways and the 
interpretation of core miRNA pathway mutants. Molecular Cell. 43(6),pp.892–
903. 
Yang, J., Yu, Y. and Duerksen-Hughes, P.J. 2003. Protein kinases and their involvement 
in the cellular responses to genotoxic stress. Mutation Research. 543(1),pp.31–
58. 
Yates, J.R., Eng, J.K., McCormack, A.L. and Schieltz, D. 1995. Method to correlate 
tandem mass spectra of modified peptides to amino acid sequences in the 
protein database. Analytical Chemistry. 67(8),pp.1426–1436. 
Yi, R., Qin, Y., Macara, I.G. and Cullen, B.R. 2003. Exportin-5 mediates the nuclear 
export of pre-microRNAs and short hairpin RNAs. Genes & Development. 
17(24),pp.3011–3016. 
Yoo, S. 1999. Geometry of a complex formed by double strand break repair proteins at 
a single DNA end: recruitment of DNA-PKcs induces inward translocation of Ku 
protein. Nucleic Acids Research. 27(24),pp.4679–4686. 
Yoshizaki, K., Matsuda, T., Nishimoto, N., Kuritani, T., Taeho, L., Aozasa, K., Nakahata, 
T., Kawai, H., Tagoh, H. and Komori, T. 1989. Pathogenic significance of 
interleukin-6 (IL-6/BSF-2) in Castleman’s disease. Blood. 74(4),pp.1360–1367. 
Young, L.S., Arrand, J.R. and Murray, P.G. 2007. EBV gene expression and regulation In: 
A. Arvin, G. Campadelli-Fiume, E. Mocarski, P. S. Moore, B. Roizman, R. Whitley 
and K. Yamanishi, eds. Human Herpesviruses: Biology, Therapy, and 
Immunoprophylaxis [Online]. Cambridge: Cambridge University Press. 
[Accessed 25 June 2015]. Available from: 
http://www.ncbi.nlm.nih.gov/books/NBK47431/. 
Young, L.S. and Rickinson, A.B. 2004. Epstein–Barr virus: 40 years on. Nature Reviews 
Cancer. 4(10),pp.757–768. 
XLII 
 
Yu, F., Feng, J., Harada, J.N., Chanda, S.K., Kenney, S.C. and Sun, R. 2007. B cell terminal 
differentiation factor XBP-1 induces reactivation of Kaposi’s sarcoma-
associated herpesvirus. FEBS letters. 581(18),pp.3485–3488. 
Yu, M.C. and Yuan, J.-M. 2002. Epidemiology of nasopharyngeal carcinoma. Seminars 
in Cancer Biology. 12(6),pp.421–429. 
Zahler, A.M., Damgaard, C.K., Kjems, J. and Caputi, M. 2004. SC35 and heterogeneous 
nuclear ribonucleoprotein A/B proteins bind to a juxtaposed exonic splicing 
enhancer/exonic splicing silencer element to regulate HIV-1 tat exon 2 splicing. 
The Journal of Biological Chemistry. 279(11),pp.10077–10084. 
Zeng, Y., Yi, R. and Cullen, B.R. 2005. Recognition and cleavage of primary microRNA 
precursors by the nuclear processing enzyme Drosha. The EMBO journal. 
24(1),pp.138–148. 
Zhao, S., Fung-Leung, W.-P., Bittner, A., Ngo, K. and Liu, X. 2014. Comparison of RNA-
Seq and Microarray in Transcriptome Profiling of Activated T Cells S.-D. Zhang, 
ed. PLoS ONE. 9(1),p.e78644. 
Zhong, W., Wang, H., Herndier, B. and Ganem, D. 1996. Restricted expression of Kaposi 
sarcoma-associated herpesvirus (human herpesvirus 8) genes in Kaposi 
sarcoma. Proceedings of the National Academy of Sciences of the United States 
of America. 93(13),pp.6641–6646. 
Zhou, Z., Luo, M.J., Straesser, K., Katahira, J., Hurt, E. and Reed, R. 2000. The protein 
Aly links pre-messenger-RNA splicing to nuclear export in metazoans. Nature. 
407(6802),pp.401–405. 
Ziegler, J.L. and Katongole-Mbidde, E. 1996. Kaposi’s sarcoma in childhood: an analysis 
of 100 cases from Uganda and relationship to HIV infection. International 
Journal of Cancer. Journal International Du Cancer. 65(2),pp.200–203. 
Zisoulis, D.G., Lovci, M.T., Wilbert, M.L., Hutt, K.R., Liang, T.Y., Pasquinelli, A.E. and Yeo, 
G.W. 2010. Comprehensive discovery of endogenous Argonaute binding sites in 
Caenorhabditis elegans. Nature Structural &#38; Molecular Biology. 
17(2),pp.173–179. 
Zorio, D. 2004. The link between mRNA processing and transcription: communication 
works both ways. Experimental Cell Research. 296(1),pp.91–97. 
Zou, L. 2007. Single- and double-stranded DNA: building a trigger of ATR-mediated 
DNA damage response. Genes & Development. 21(8),pp.879–885. 
Zou, L. and Elledge, S.J. 2003. Sensing DNA damage through ATRIP recognition of RPA-
ssDNA complexes. Science (New York, N.Y.). 300(5625),pp.1542–1548. 
 
